

FISH & RICHARDSON P.C., P.A.

3300 Dain Bosworth Plaza
60 South Sixth Street
Minneapolis, Minnesota
55402

Telephone
612 335-5070

Facsimile
612 288-9696

December 4, 1997

Attorney Docket No.: 06868/005002

Box Patent Application

Assistant Commissioner of Patents
Washington, DC 20231

Presented for filing is a new continuation patent application of:

Applicant: ANTHONY J.F. D'APICE, MARTIN J. PEARSE, ALLAN J. ROBINS, ROBERT J. CRAWFORD
Title: MATERIALS AND METHODS FOR MANAGEMENT OF HYPERACUTE REJECTION IN HUMAN XENOTRANSPLANTATION

Enclosed are the following papers, including those required to receive a filing date under 37 CFR §1.53(b):

	<u>Pages</u>
Specification	133
Claims	8
Abstract	1
Declaration	4
Drawing(s)	39

Enclosures:

- Rule 63 declaration, copy from a previous application under rule 63(d) for continuation or divisional only.
- Preliminary amendment, 1 page.
- Postcard.

"EXPRESS MAIL" Mailing Label Number EM 295179364 US

Date of Deposit December 4, 1997
I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Donna R. Taylor
Donna R. Taylor

12/04/97
Jc530 U.S. PRO
Frederick P. Fish
1855-1930

W.K. Richardson
1859-1951

BOSTON
HOUSTON
NEW YORK
SOUTHERN CALIFORNIA
SILICON VALLEY
TWIN CITIES
WASHINGTON, DC

068684900-160497

FISH & RICHARDSON P.C., P.A.

December 4, 1997

Page 2

This application is a continuation (and claims the benefit of priority under 35 USC 120) of U.S. application serial no. 08/378,617, filed 01/26/95. The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application.

Preliminarily, on page 1 of the specification, before line 1, insert --This is a continuation of U.S. application serial no. 08/378,617, filed 01/26/95, (pending).--

Under 35 USC §120, this application claims the benefit of prior U.S. application 08/378,617, filed 01/26/95.

Please delete Peter D. Rathjen as a named inventor in this new continuation patent application pursuant to §1.53(d)(4).

Basic filing fee	790.00
Total claims in excess of 20 times \$22.00	22.00
Independent claims in excess of 3 times \$82.00	164.00
Fee for multiple dependent claims	0.00
Total filing fee:	\$ 976.00

A check for the filing fee is enclosed. Please apply any other required fees or any credits to deposit account 06-1050, referencing the attorney docket number shown above.


If this application is found to be incomplete, or if a telephone conference would otherwise be helpful, please call the undersigned at 612/335-5070.

Kindly acknowledge receipt of this application by returning the enclosed postcard.

Please send all correspondence to:

Mark S. Ellinger
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402

Respectfully submitted,



Mark S. Ellinger, Ph.D.
Reg. No. 34,812
Enclosures

0898490.120497

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : D'Apice et al. Art Unit: Unknown
Serial No.: Unknown Examiner: Unknown
Filed : December 4, 1997
Title : MATERIALS AND METHODS FOR MANAGEMENT OF HYPERACUTE
REJECTION IN HUMAN XENOTRANSPLANTATION

Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the Claims

Please cancel claims 8-11, 13-14, 19-20, 27, 30, 32-45.


REMARKS

Claims 8-11, 13-14, 19-20, 27, 30, 32-45 have been canceled. Claims 1-7, 12, 15-18, 21-26, 28-29 and 31 remain for consideration.

Please apply any charges not covered, or any credits, to Deposit Account 06-1050.

Respectfully submitted,

Date: December 4, 1997


Mark S. Ellinger, Ph.D.
Reg. No. 34,812


Fish & Richardson P.C., P.A.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402

Telephone: 612/335-5070
Facsimile: 612/288-9696
11981.M11

"EXPRESS MAIL" Mailing Label Number EM295 179 364US

Date of Deposit December 4, 1997

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Donna R. Taylor

APPLICATION
FOR
UNITED STATES LETTERS PATENT

TITLE: MATERIALS AND METHODS FOR MANAGEMENT OF
HYPERACUTE REJECTION IN HUMAN
XENOTRANSPLANTATION

APPLICANT: ANTHONY J.F. D'APICE, MARTIN J. PEARSE, ALLAN J.
ROBINS, ROBERT J. CRAWFORD AND PETER D. RATHJEN

"EXPRESS MAIL" Mailing Label Number TB426403945US

Date of Deposit January 26, 1995

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Kathleen Bowen

Kathleen Bowen

MATERIALS AND METHODS FOR MANAGEMENT OF HYPERACUTE
REJECTION IN HUMAN XENOTRANSPLANTATION

Cross Reference to Related Applications

5 The present application is a continuation-in-part
of U.S. Application Serial No. 08/188,607, filed January
27, 1994.

Field of the Invention

2640001.169
10 This invention relates generally to the field of
xenotransplantation. In particular this invention
relates to methods and materials for reduction or
elimination of the hyperacute rejection response in
humans. More particularly, this invention relates to
methods for treating human serum to reduce or eliminate
15 hyperacute rejection. This invention also relates to
methods and materials for generating non-human organs
lacking or having reduced α 1,3 galactosyl transferase
activity.

Background of the Invention

20 It is widely acknowledged that there is an acute,
worldwide shortage of human organs for transplantation.
This is in spite of legislative changes and education
programs to increase public awareness of the problem. In
the United States, for example, there is an estimated
25 annual shortfall of approximately 18,000 kidneys/year.
Similarly, in Australia in 1992, only 41% of renal
patients awaiting transplantation received transplants.

In Japan the imbalance between supply and demand is even greater due to religious prohibitions on the use of organs from cadaveric donors.

The benefits of transplantation can be seen by comparing the rehabilitation rates of transplant patients with those of dialysis patients. In Australia and New Zealand, the majority of transplant patients (60%) are capable of full time work or school with a further 10% in part time work, while only 7% are unfit for work. In contrast, 23% of dialysis patients are capable of full time work or school, with 15% involved in part time work and 20% unfit for work. The remainder are "retired." Fifteenth Report of the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), Queen Elizabeth Hospital, Woodville, S.A., APS Disney, ed. (1992).

The direct financial cost of dialysis in Australia and New Zealand is approximately \$A45,000/patient/year. In addition, indirect costs due to unemployment and sickness are higher in dialysis patients and the social costs are considerable. Transplantation engenders an expense of approximately \$A30,000/patient in the first year and \$A14,000/patient/year thereafter. These statistics indicate that a) transplantation is the optimal therapy for end stage renal failure; b) there is an undersupply of donor kidneys; and c) present strategies aimed at increasing the transplant rate have

been less than successful. There are, in addition, serious shortages of other transplantable organs including hearts, livers, lungs and pancreases.

The use of xenografts (transplants between
5 species) is one option for overcoming the short supply of human organs for transplantation. Non-viable, non-antigenic xenografts are commonly used in vascular reconstruction (bovine arteries) and in cardiac surgery (porcine cardiac valves). However, despite their
10 occasional use in the past, immunological barriers have prevented the common use of viable xenografts. Between 1964 and 1991 a total of 27 non-human primate to human organ xenografts was reported; the longest reported patient survival was 9 months. Two liver transplants
15 from baboon to human were recently performed in anticipation that modern immunosuppressive therapies could cope with the severe rejection problems likely to occur in xenotransplantation. To date, the course of one of these patients has been reported, and in this case
20 rejection was not the direct cause of death. Starzl et al., Baboon-to-Human Liver Transplantation. Lancet 341: 65-71 (1993). This clinical experience indicates that a) non-human organs can function and support human life; b) rejection episodes can be reversed by conventional anti-
25 rejection therapy; and c) the mechanisms of rejection are similar, in principle, to those in allograft rejection.

It is unlikely that primates will be a satisfactory source of organs for xenotransplantation. Most are endangered species, breed slowly in the wild and poorly in captivity. The baboon is an exception to these 5 generalizations, but other disadvantages limit the usefulness of this species. Baboons have single pregnancies, long gestation times, are difficult and expensive to maintain and may be infected with or carry organisms, particularly viruses, that are pathogenic in 10 humans. For hearts and kidneys where organ size may be a consideration, the smaller primates are unsatisfactory as donors to human adults. Finally, the use of primates is likely to arouse considerable opposition from the public.

These difficulties have led to renewed interest in 15 the use of non-primate species as organ donors for human patients. The pig is a widely acknowledged choice for xenotransplantation into humans. The pig erythrocyte diameter ($6.5\mu\text{m}$) and, by implication, its capillary size, are similar to humans, facilitating connection of 20 xenografts to the human circulatory system. The pig breeds well in captivity, has a short gestation time and produces large litters. In addition, pigs can be bred and maintained in low pathogen facilities, can be reared to any size and do not arouse the level of public 25 reaction associated with primates.

The immunological barriers to use of pig organs in human patients include a) an immediate severe

("hyperacute") rejection phenomenon that develops in minutes to hours after transplantation, and b) a proposed acute rejection that develops in days to weeks. Once the hyperacute rejection phenomenon has been overcome, it is expected that normal acute rejection would ensue. This form of rejection is thought to be similar to that experienced with allografts (transplants between individuals of the same species) and should be amenable to normal immunosuppressive therapies.

10 Both preformed "natural antibodies" (xenoantibodies) and complement regulating factors in human serum are thought to be involved in the process of hyperacute rejection. Hyperacute rejection is thought to be initiated when xenoantibodies bind to epitopes on the
15 endothelium of a donor organ, activating the classical complement pathway.

Summary of the Invention

A purified and isolated nucleic acid molecule of the present invention comprises the porcine nucleic acid
20 sequence depicted in Figure 4 (SEQ ID NO: 7), which encodes a porcine polypeptide having α -1,3 galactosyltransferase activity. Variations on this sequence that may be routinely generated by the skilled artisan include those sequences corresponding to Figure 4
25 but varying within the scope of the degeneracy of the genetic code. That is, the present invention includes

variants of the sequence set out in Figure 4, readily determined by the skilled artisan, that code for the same amino acid sequence encoded by the sequence set out in Figure 4. The present invention also includes a

5 purified and isolated nucleic acid molecule that encodes a porcine α -1,3 galactosyltransferase and that hybridizes under standard high stringency conditions with a sequence complementary to the sequence set out in Figure 4, or with a sequence complementary to a variation of the
10 sequence set out in Figure 4 within the scope of the degeneracy of the genetic code. The complementary strands to the above-described nucleic acid sequences are readily determined by standard methods, and are also within the scope of the present invention.

15 Within the parameters set out in the preceding paragraph, the present invention includes variants of the porcine α -1,3 galactosyltransferase coding sequence that preserve the functional characteristics of the native gene product. Such variants include, for example, minor
20 nucleotide variations in the 5' untranslated region or in various coding regions of the disclosed sequence. Minor amino acid variations deriving from changes in the coding regions, that leave a functional α -1,3 galactosyltransferase catalytic site, membrane anchor
25 domain and stem region as described below, are within the scope of the present invention. Such routine variations in nucleic acid and amino acid sequences can be

identified by those having ordinary skill in the art based on the sequence and structural information provided herein.

As used herein, "high stringency conditions" are those hybridization conditions generally understood by the skilled artisan to reflect standard conditions of high stringency as set out in widely recognized protocols for nucleic acid hybridization. See, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual (2nd Edition), Cold Spring Harbor Laboratory Press (1989), pp. 1.101 - 1.104; 9.47 - 9.58 and 11.45 - 11.57. Generally, these conditions reflect at least one wash of the hybridization membrane in 0.05x to 0.5x SSC with 0.1% SDS at 65°C, or washing conditions of equivalent stringency.

The present invention also includes a host cell transformed with any of the above-described purified and isolated nucleic acid molecules, as well as a porcine α -1,3 galactosyltransferase encoded by such transforming nucleic acid molecules and expressed from the host cell. Methods for transforming appropriate host cells and for expressing polypeptides from such host cells are known in the art and are described, for example, in Sambrook et al., (1984), pp. 12.2-12.44; 16.3-17.44.

The invention further includes a DNA construct useful for inactivating the porcine α -1,3 galactosyltransferase gene by insertion of a desired DNA sequence into an insertion site of the gene. As used

herein, the term " α -1,3 galactosyltransferase gene" includes the exons encoding or potentially encoding α -1,3 galactosyltransferase, introns contiguous with such exons, and regulatory elements associated with such exons and introns. The DNA construct includes the desired DNA sequence flanked by first and second homology sequences. These first and second homology sequences are sufficiently homologous, respectively, to first and second genomic sequences flanking the insertion site to allow for homologous recombination of the DNA construct with the porcine α -1,3 galactosyltransferase gene when the DNA construct is introduced into a target cell containing the porcine α -1,3 galactosyltransferase gene. Preferably the insertion site is within exon 4, exon 7, exon 8 or exon 9 of the porcine α -1,3 galactosyltransferase gene. The desired DNA sequence is preferably a selectable marker, including but not limited to the neo^R gene, the hydromycin resistance (hyg^R) gene and the thymidine kinase gene. The desired DNA sequence may be bordered at both ends by FRT DNA elements, with stop codons for each of the three reading frames being inserted 3' to the desired DNA sequence. Presence of the FRT elements allows the selectable marker to be deleted from the targeted cell, and the stop codons ensure that the α -1,3 galactosyltransferase gene remains inactivated following deletion of the selectable marker.

The invention further includes a DNA construct useful for inactivating the murine α -1,3 galactosyltransferase gene by insertion of a desired DNA sequence into an insertion site of the gene. The DNA construct includes the desired DNA sequence flanked by first and second homology sequences. These first and second homology sequences are sufficiently homologous, respectively, to first and second genomic sequences flanking the insertion site to allow for homologous recombination of the DNA construct with the murine α -1,3 galactosyltransferase gene when the DNA construct is introduced into a cell containing the murine α -1,3 galactosyltransferase gene. Preferably the insertion site is within exon 4, exon 7, exon 8 or exon 9 of the murine α -1,3 galactosyltransferase gene. The desired DNA sequence is preferably a selectable marker, including but not limited to the neo^R gene, the hyg^R gene and the thymidine kinase gene. The desired DNA sequence may be bordered at both ends by FRT DNA elements, with stop codons for each of the three reading frames being inserted 3' to the desired DNA sequence. Presence of the FRT elements allows the selectable marker to be deleted from the targeted cell, and the stop codons ensure that the α -1,3 galactosyltransferase gene remains inactivated following deletion of the selectable marker.

The invention also includes methods for generating a mammalian totipotent cell having at least one

inactivated (non-functional) α -1,3 galactosyltransferase alleles, where the totipotent cell is derived from a mammalian species in which alleles for the α -1,3 galactosyltransferase gene normally are present and functional. A "functional" allele is capable of being transcribed and translated to produce a polypeptide having an activity the same as or substantially similar to the native α -1,3 galactosyltransferase. The methods include providing a plurality of cells characterized as totipotent cells of the aforementioned mammalian species, introducing into the totipotent cells a nucleic acid construct effective for inactivating the α -1,3 galactosyltransferase gene by insertion of a desired DNA sequence into an insertion site of the gene through homologous recombination, and then identifying a totipotent cell having at least one inactivated α -1,3 galactosyltransferase allele.

The totipotent cells can include, without limitation, embryonic stem (ES) cells, primordial germ cells (PGC's) and eggs. The cells can be taken from a variety of mammalian species in which alleles for the α -1,3 galactosyltransferase gene are present and functional, including without limitation murine and porcine species.

The invention further includes methods for generating a mammal lacking a functional α -1,3 galactosyltransferase gene, where the mammal belongs to a

species having a functional α -1,3 galactosyltransferase gene. The methods include providing a mammalian totipotent cell having at least one inactivated α -1,3 galactosyltransferase allele, where the totipotent cell
5 is derived from the aforementioned mammalian species having a functional α -1,3 galactosyltransferase gene, manipulating the totipotent cell such that mitotic descendants of the cell constitute all or part of a developing embryo, allowing the embryo to develop to
10 term, recovering a neonate individual derived from the embryo, and raising and breeding the neonate to obtain a mammal homozygous for an inactivated α -1,3 galactosyltransferase allele, i.e., a mammal in which both α -1,3 galactosyltransferase allele are inactivated.

15 The totipotent cells can include, without limitation, ES cells, PGC's and eggs. The cells can be taken from a variety of mammalian species in which alleles for the α -1,3 galactosyltransferase gene are present and functional, including without limitation
20 murine and porcine species. ES cells and PGC's are manipulated in various ways such that their mitotic descendants are found in a developing embryo. These manipulations can include, without limitation, injection into a blastocyst or morula, co-culture with a zona
25 pellucida-disrupted morula, and fusion with an enucleated zygote. Cells injected into a blastocyst- or morula-stage embryo become incorporated into the inner cell mass

of the blastocyst embryo, giving rise to various differentiated cell types of the resulting embryo, including in some cases germ cells. The embryo derived from such manipulations is a chimera composed of normal embryonic cells as well as mitotic descendants of the introduced ES cells or PGC's. Alternatively, chimeric embryos can be obtained by co-culturing at least one ES cell or PGC with a morula embryo in which the zona pellucida is sufficiently disrupted to allow direct contact between the ES cell/PGC and at least one cell of the morula. The zona pellucida-disrupted embryo may be an embryo that is completely free of the zona pellucida. Finally, the genome of an ES cell or PGC can be incorporated into an embryo by fusing the ES cell/PGC with an enucleated zygote. Such a procedure is capable of generating a non-chimeric embryo, i.e., an embryo in which all nuclei are mitotic descendants of the fused ES cell/PGC nucleus. The resulting embryos are implanted in a recipient female, or surrogate mother, and allowed to develop to term.

When eggs, as opposed to ES cells or PGC's, are directly injected with a nucleic acid construct effective for inactivating the α -1,3 galactosyltransferase gene, the eggs can be manipulated to form an embryo by implanting into a recipient female.

The invention also includes a mammal, produced through human intervention, that lacks a functional α -1,3

galactosyltransferase gene. The mammal belongs to a species in which the α -1,3 galactosyltransferase gene is normally present and functional. The mammal can be, without limitation, a mouse or a pig.

5 The invention further includes a purified and isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of (1) the nucleic acid sequence depicted in Figure 26 (SEQ ID NO: 25), (2) a sequence corresponding to the sequence of (1)
10 within the scope of the degeneracy of the genetic code, and (3) a sequence that encodes murine T-LIF and that hybridizes under standard high stringency conditions with a sequence complementary to the sequence of (1) or (2). The complementary strands to the above-described nucleic
15 acid sequences are readily determined by standard methods, and are also within the scope of the present invention.

 The present invention also includes a host cell transformed with any of the purified and isolated nucleic
20 acid molecules described in the preceding paragraph, as well as a T-LIF polypeptide encoded by such transforming nucleic acid molecules and expressed from the host cell.

 The invention further includes a purified and isolated nucleic acid molecule comprising a nucleic acid
25 sequence selected from the group consisting of (1) the nucleic acid sequence depicted in Figure 27 (SEQ ID NO: 31), (2) a sequence corresponding to the sequence of (1)

059400-1697

within the scope of the degeneracy of the genetic code,
and (3) a sequence that encodes human T-LIF and that
hybridizes under standard high stringency conditions with
a sequence complementary to the sequence of (1) or (2).

5 The complementary strands to the above-described nucleic
acid sequences are readily determined by standard
methods, and are also within the scope of the present
invention.

The present invention also includes a host cell
10 transformed with any of the purified and isolated nucleic
acid molecules described in the preceding paragraph, as
well as a T-LIF polypeptide encoded by such transforming
nucleic acid molecules and expressed from the host cell.

The invention further includes a method for
15 eliminating or reducing hyperacute rejection of non-
primate mammalian cells by human serum, comprising
adding, to the human serum, a physiologically acceptable
amount of galactose or a saccharide in which the terminal
carbohydrate is an α galactose linked at position 1,
20 prior to exposure of the human serum to the non-primate
cells. The amount of galactose or saccharide added is
sufficient to reduce or eliminate the hyperacute
rejection response. The saccharide can be, without
limitation, melibiose, galactose α 1-3 galactose or
25 stachyose. Alternatively, the human serum can be treated
so as to be substantially depleted of immunoglobulin, IgM
antibodies, anti-GAL IgM and IgG antibodies, or anti-GAL

IgM antibodies. The invention further includes affinity-treated human serum substantially free of anti-GAL antibodies or of anti-GAL IgM antibodies.

BRIEF DESCRIPTION OF THE DRAWINGS

5 FIGURE 1 is a graphical representation of fluorescence intensity following immunofluorescent staining of porcine aortic endothelial cells with anti-GAL antibody alone or with anti-GAL antibody that was preincubated with selected saccharides.

10 FIGURE 2 shows the results of an experiment in which lysis of porcine aortic endothelial cells by human serum and by purified anti-GAL antibodies was determined using a ^{51}CR release assay.

15 FIGURE 3 depicts physiograph tracings of perfused rat heart contractions in the presence of human serum with or without selected saccharides.

20 FIGURE 4 is a comparison of the porcine α -1,3 galactosyltransferase cDNA sequence with the corresponding murine and bovine sequences. PGTCD = porcine sequence. BOVGSTA = bovine sequence. MUSGLYTNG = murine sequence.

25 FIGURE 5 is a comparison of the porcine α -1,3 galactosyltransferase amino acid sequence with the corresponding murine and bovine amino acid sequences. PGT = porcine sequence. BGT = bovine sequence. MGT = murine sequence.

FIGURE 6 depicts the Sall restriction sites in four overlapping phage clones spanning a portion of the murine α -1,3 galactosyltransferase genomic region.

FIGURE 7 is a detailed restriction map of murine
5 α -1,3 galactosyltransferase subclone p α GT-S5.5.

FIGURE 8 is a detailed restriction map of murine α -1,3 galactosyltransferase subclone p α GT-S4.0.

FIGURE 9 is a detailed restriction map of murine α -1,3 galactosyltransferase subclone p α GT-S11.

10 FIGURE 10 is a detailed restriction map of murine α -1,3 galactosyltransferase subclone p α GT-S13.

FIGURE 11 is an additional detailed restriction map of murine α -1,3 galactosyltransferase subclone p α GT-S5.5.

15 FIGURE 12 is an additional detailed restriction map of murine α -1,3 galactosyltransferase subclone p α GT-S4.0.

FIGURE 13 is a diagram of a knockout construct carrying the 4.0 and 5.5kb Sall fragments from p α GT-S5.5
20 and p α GT-S4.0, which flank the Exon 9 Sall site.

FIGURE 14 depicts the 8.3kb and 6.4kb BglIII fragments that are diagnostic for the uninterrupted α -1,3 galactosyltransferase gene and the targeted (inactivated) α -1,3 galactosyltransferase gene, respectively, using the
25 probes identified in the text.

FIGURE 15 is a schematic representation of the generation of a knockout construct using the vector p α GT-S5.5 as the starting vector.

FIGURE 16 sets out the nucleotide sequence of a neomycin resistance cassette used in the construction of a DNA construct for interrupting the α -1,3-GalT gene in mice.

FIGURE 17 is a diagram of one example of a final knockout construct that has been sequenced to confirm the identity, copy number and orientation of the various inserts.

FIGURE 18 is a Southern blot of genomic DNA from various murine ES cell lines transformed with the knockout construct of Figure 16, probed to reveal the diagnostic fragments depicted in Figure 14.

FIGURE 19 depicts the "long" PCR products derived from wild type and interrupted α -1,3-GalT genes using the designated primers.

FIGURE 20 is a Southern blot of long PCR products obtained from wild type and knockout mice.

FIGURE 21 depicts the PCR products used for identification of the interrupted (targeted) galT locus.

FIGURE 22 shows PCR products generated from mice carrying interrupted (inactivated) GalT alleles.

FIGURE 23 depicts the PCR products expected from PCR analysis of cDNA generated from α -1,3-GalT mRNA in normal and knockout mice. The ferrochelatase primers and

PCR fragment represent a control demonstrating that cDNA synthesis had occurred.

FIGURE 24 shows the PCR fragments generated from cDNA obtained from RNA isolated from kidney (K), heart (H) and liver (L) of a wild-type mouse (+/+), a mouse heterozygous for the interrupted α -1,3-GalT allele (+/-) and a mouse homozygous for the interrupted α -1,3-GalT allele (-/-).

FIGURE 25 is a graphical representation of the relative protection of spleen cells, derived from GalT knockout mice, from lysis by human serum.

FIGURE 26 is a representation of the nucleotide sequence and deduced amino acid sequence for murine T-LIF.

FIGURE 27 is a representation of the nucleotide sequence and deduced amino acid sequence for human T-LIF.

FIGURE 28 is a Western blot of LIF polypeptides expressed from transfected COS cells.

FIGURE 29 is a diagram of the expression plasmid used for transfection of the COS cells of Figure 27.

FIGURE 30 is a Southern blot of PCR-amplified cDNA from murine ES cells, using a LIF-specific probe.


DETAILED DESCRIPTION

Evidence presented herein establishes that a substantial portion of human pre-formed, anti-pig xenoantibodies recognize a specific terminal galactose

linkage on the surface of pig endothelial cells. As demonstrated in experiments carried out by the present inventors, it is possible to reduce the titers of preformed xenoantibodies by adsorption with immobilized
5 antigens containing the appropriate epitopes. This leads to reduction or elimination of cellular responses associated with the hyperacute rejection response. Conversely, it is demonstrated to be possible to neutralize such antibodies by addition of appropriate
10 carbohydrate antigens to human serum. In demonstrating the usefulness of these approaches, it was necessary to identify the relevant carbohydrate moieties and to demonstrate their efficacy in cultured cell systems and, importantly, in whole organs. As such, one approach to
15 reducing or eliminating the hyperacute rejection response is identified as treatment of the recipient by eliminating or neutralizing the relevant antibody populations.

An alternative approach to xenotransplantation
20 would be elimination of the relevant epitope(s) in the donor organ. This could be accomplished, for example, by reducing or eliminating expression of the gene(s) encoding the metabolic machinery responsible for formation of the epitopes. The epitope defined by the α -
25 1,3 galactose linkage (termed the GAL epitope) is generated by the enzyme UDP-galactose: β -D-galactosyl-1,4-N-acetyl-D-glucosaminide α -1,3 galactosyl- transferase

("α-1,3 galactosyltransferase" or "α-1,3-GalT"). This enzyme transfers galactose to the terminal galactose residue of N-acetyllactosamine-type carbohydrate chains and lactosaminoglycans. The reaction catalyzed by α-1,3-
5 GalT may be summarized as follows:



The α-1,3-Gal T enzyme is found in most mammals, but is not present in Old World monkeys and humans. For
10 purposes of xenotransplantation, it is significant that humans and Old World monkeys have naturally occurring xenoantibodies directed against the GAL epitope. The use of pig organs lacking the GAL epitope could reduce or eliminate the hyperacute rejection of such organs by
15 human recipients. The utility of such an approach is buttressed by the present inventors' demonstration that the GAL epitope is, in fact, central to the hyperacute rejection phenomenon in cells and whole organs. One approach to obtaining such organs would be to generate
20 pigs in which the gene encoding the α-1,3-GalT enzyme is "knocked out" by homologous recombination.

Role of the GAL Epitope in Hyperacute Rejection

The present inventors have affinity purified antibodies directed against the GAL epitope (anti-GAL
25 antibodies) from human serum. This was accomplished with affinity columns comprising the appropriate epitopes

(e.g., galactosyl-galactose or melibiose) attached to a solid phase. Total anti-GAL IgG and IgM were obtained in one set of experiments. In an alternative approach, anti-GAL IgG was obtained by passage of serum over an affinity column with specificity for all proteins except albumin and IgG. The wash-through from this column was then applied to a galactosyl-galactose affinity column and purified anti-GAL IgG was collected as the eluate. The obtained anti-GAL IgG can be further purified by passage over a protein G column, which specifically binds IgG but not other antibody isotypes. Conversely, the wash-through from the above-described columns can be used as sources of total anti-GAL (IgG + IgM)-depleted serum or of anti-GAL IgG-depleted serum in further experiments. Preferably, the anti-GAL antibody preparations are characterized for protein content, molecular weight and purity, and for antibody class and isotype.

To demonstrate the role of the GAL epitope in the hyperacute rejection response, it is necessary, first, to establish that IgG and IgM anti-GAL antibodies react with porcine cells and tissues. The present inventors investigated the binding of human anti-GAL antibodies to porcine cells and tissues using immunofluorescent staining. In this technique, selected human antibody preparations are reacted with intact porcine cells and then reacted with signal antibody comprising non-human anti-human IgG or IgM labeled with fluorescein

isothiocyanate (FITC). Stained cells may be detected and quantified with a fluorescence-activated cell sorter (FACS) or other appropriate detection means. Other methods for detecting the presence of a bound antibody on a cell surface, for example through use of enzyme-labeled signal antibody reagents, are known to the skilled artisan.

Total anti-GAL (IgM and IgG), as well as purified anti-GAL IgG, stained cells from a porcine epithelial cell line (PK₁) as well as cells from a porcine aortic endothelial cell line (PAE). Neither anti-GAL (total IgM + IgG) antibody-depleted serum nor anti-GAL IgG-depleted serum gave detectable staining. To further investigate the specificity of the response, it is desirable to determine whether or not reactivity of the antibodies with porcine cells can be diminished or eliminated by prior exposure to one or more molecules suspected of comprising the epitope(s) in question. In this regard, the present inventors have established that antibody binding is inhibited by galactose and by disaccharides having terminal galactose residues in the $\alpha 1$ configuration. Staining was not inhibited with sugars having a terminal galactose in a $\beta 1 \rightarrow 4$ configuration. These results demonstrate the specificity of the antibody binding and the ability of appropriate sugars to inhibit such binding.

Reactivity of anti-GAL antibodies with cultured pig cells was confirmed using tissue sections of pig organs. Again, using a fluorescent signal antibody system, staining was seen with total anti-GAL IgM + IgG and with purified anti-GAL IgG but not with the anti-GAL antibody-depleted sera. Staining was particularly strong with kidney, heart and liver endothelium, with heart endocardium and with bile duct epithelium. The tissue binding was inhibited with melibiose but was not inhibited by other disaccharides not representative of the GAL epitope.

These data clearly indicate that the GAL epitope is expressed at high levels on the endothelial cells of arteries, veins and capillaries of porcine kidney, heart and liver. In a xenograft situation, the endothelial cells of these vessels come into direct contact with the anti-GAL antibodies in human serum. The above results are consistent with evidence that binding of these antibodies (with attendant complement activation) is a key component of the hyperacute rejection response.

To further investigate the specificities of naturally occurring xenoantibodies in human serum directed against porcine antigens, the ability of human serum to cause agglutination of pig red blood cells was investigated. These studies revealed the presence of high levels of such antibodies in human serum. Moreover, sugars such as melibiose, stachyose, galactose and

fucose, having terminal residues in the $\alpha 1-6$ configuration, were found to inhibit agglutination in the μM to mM range. Sugars with other configurations were only inhibitory at very high doses, where the observed effects are likely due to simple changes in osmolarity or other non-specific mechanisms.

The above investigations establish a potential role for naturally occurring, human anti-GAL xenoantibodies in the complement-mediated destruction underlying hyperacute rejection. However, it is preferable to directly examine complement-mediated destruction of porcine cells in order to confirm the specificity of the GAL epitope and of anti-GAL antibodies in the process of lysis. To this end, the present inventors have examined the ability of human serum to cause lysis of porcine cells.

To investigate complement-mediated destruction of cells, it is necessary to employ one or more assays that provide quantitative data on cell lysis. Preferably, such assays measure a cell-sequestered component that is released into the medium upon complement-mediated cell lysis. Such experiments should control for involvement of complement in the induced lysis by employing both native complement proteins as well as heat-inactivated complement. The present inventors have used a ^{51}Cr -release assay and a lactate dehydrogenase (LDH)-release

assay to investigate the complement-mediated lysis of porcine epithelial and endothelial cells by human serum.

In the ^{51}Cr -release assay, porcine cells were pre-labeled with ^{51}Cr and then incubated in the presence of heat-inactivated human serum plus rabbit complement (PAE's) or human complement in non-heat-inactivated normal human serum (PK₁'s). Release of ^{51}Cr into the medium was measured with a gamma counter following addition of scintillation fluid. In the LDH-release assay, cells were labeled with LDH as per the manufacturer's instructions (Promega, USA). Release of LDH into the medium was measured using an ELISA format, with absorbance read at 492nm. For both assays, the ability of various sugars to inhibit the complement-induced lysis was also tested.

Similar results were obtained with the two unrelated porcine cell lines, PAE and PK₁, using both types of assays. The results clearly demonstrate that naturally occurring xenoantibodies (NXAb's) are responsible for initiating the complement-induced lysis of porcine cells. The present inventors have also established that IgM and not IgG antibodies are responsible for the lysis in this system. Moreover, heat inactivation of the complement preparations prevented lysis, providing further evidence that lysis of the porcine cells is a complement-dependent phenomenon. The present inventors have also shown that melibiose, but not

lactose, protects the porcine cells from lysis.

Importantly, the concentrations of sugar found to be effective in these studies covered the physiological range of blood sugar, i.e., about 10mM.

5 These results indicate that the anti-GAL NXAb's in normal human serum are primarily responsible for lysis of the porcine cells. As such, the binding of anti-GAL NXAb's to the endothelial cells lining the blood vessels of a porcine xenograft, with attendant activation of the
10 complement cascade, is likely to be a key component of the hyperacute rejection of porcine xenografts. This would also be the case with organs from other discordant species, such as rodents, sheep, cows and goats, all of which have active α -1,3-GalT genes in their genomes.

15 These conclusions are further supported in a whole-organ study performed by the present inventors. For this study, isolated and perfused rat hearts were used to further demonstrate the involvement of anti-GAL xenoantibodies in hyperacute rejection. Rat hearts were
20 connected to a Langendorf perfusion apparatus, as described in Doring and Dehnert, The Isolated Perfused Heart According to Langendorf, Bionestechnik-Verlag March GmbH, D7806, West Germany. The connected hearts were then stabilized by perfusion with a physiological
25 buffer system, and perfused with the same buffer containing either melibiose or lactose (10mM). Human plasma was then added to a final concentration of 13% and

the effect of the added sugar on heart rate, strength of contraction and output were measured.

These results demonstrate in a whole-organ system that:

5 1) Perfusion with unmodified human plasma causes rapid loss of function.

 2) Perfusion of a rat heart with human plasma in the presence of melibiose, which competes for binding with the anti-GAL antibodies, prolongs heart survival and
10 output. Lactose, however, which does not compete for binding with the anti-GAL antibodies, does not prolong heart survival.

 3) Perfusion of a rat heart with anti-GAL antibody-depleted plasma prolongs heart survival and
15 output.

 4) If purified anti-GAL antibodies are added back to anti-GAL antibody-depleted plasma, the heart rapidly loses function

The present inventors' experiments with cultured
20 cells, tissues and whole organs provide important confirmation that anti-GAL antibodies are a critical element in the hyperacute rejection response. Moreover, the disclosed results point to various approaches that can be employed to eliminate or reduce the hyperacute
25 rejection of xenogeneic mammalian organs by humans.

For example, the intravenous administration of the specific disaccharide galactose α 1-3 galactose will block the naturally occurring anti-GAL antibodies of all classes and prevent them binding to their specific epitopes on the surface of the endothelial cells of the xenograft, thus preventing them from initiating or participating in hyperacute rejection. The present inventors' results indicate that the concentration of galactose α 1-3 galactose required to achieve this effect is in a physiologically tolerated range. The experiments also indicate that various other carbohydrates can be substituted for the specific disaccharide. These include the monosaccharide galactose and various other di-, tri- or tetra-saccharides in which there is a terminal α galactose linked to the next sugar via position 1. These other sugars include, but are not limited to, melibiose and stachyose.

Likewise, prior to xenotransplantation, all or a substantial portion of total IgM (that is, IgM of all specificities) can be removed from the serum of the patient by extracorporeal immunoabsorption. Alternatively, anti-GAL antibodies of all classes can be removed by extracorporeal immunoabsorption. Most preferably, the patient's pre-formed natural anti-GAL IgM antibodies can be removed. In this way, many or most of the primary immunological agents of the hyperacute response are eliminated, resulting in reduction or

elimination of the response following
xenotransplantation.

The α -1,3-GalT Gene as a Target for Suppressing
the GAL Epitope

5 The present inventors have succeeded in cloning
the entire coding region of the porcine α -1,3-GalT gene.
This is desirable for full exploitation of the gene in
genetic engineering of pigs for purposes of human
xenotransplantation. Previous attempts to obtain the
10 entire coding region of the porcine gene have, to the
knowledge of the inventors, failed to generate the 5'
coding regions. See, e.g., Dabkowski et al., Transplant.
Proc. 25: 2921 (1993). The present inventors have
employed a PCR-based approach to generate the full
15 sequence. In designing the primers and experimental
conditions required to obtain the 5' and 3' regions of
the gene, the present inventors overcame significant
theoretical and practical obstacles to success.

Primers were selected on the basis of careful
20 analysis of published sequences for the murine, bovine
and human α -1,3-GalT genes, the only published sequences
available for this purpose. The present inventors'
analysis revealed that in the reported sequence of the
bovine cDNA, exon 3 (which is in the 5'-untranslated
25 region) is missing. This had not been reported in the
literature. Thus, in order to find appropriate regions

for deriving useful primer sequences, the mouse and bovine sequences had to be realigned. Even with the appropriate realignment, however, only one island of about 20 base pairs (bp) in the 5' untranslated region displayed the desired homology (19 out of 20 bp) for design of a PCR oligonucleotide. The fact that the 5' untranslated regions of the mouse and bovine genes do not seem substantially related even upon optimal alignment would not be considered unusual by the ordinary skilled artisan. This is because the 5' untranslated regions are often not well conserved between species. As such, the natural inclination would be to perform a less-than-exhaustive analysis and to conclude that design of PCR oligonucleotides based on homology from this region was unlikely to be successful.

In the downstream 3'-untranslated region, the homology is less than obvious again. Various insertions and deletions had to be made in order to obtain proper alignment of the mouse and bovine sequences. Moreover, to obtain a region of appropriate homology for design of PCR oligonucleotides, it was necessary to select a region approximately 200 bp downstream of the stop codon. Finally, to get the 5' and 3' primers to work properly, the present inventors found it necessary to drop the annealing temperature by 9°C. These technical and theoretical hurdles to successful use of a PCR-based

approach were overcome by the present inventors and allowed the entire coding sequence to be determined.

Analysis of the nucleotide sequence indicates that a counterpart to murine exon 3 in the 5' untranslated region is not found in the porcine gene. The porcine sequence is similar to the bovine sequence in this regard. Analysis of the amino acid sequence demonstrates that the structure of the porcine α -1,3-GalT is similar to that of other glycosyltransferases, and in particular is closely related to bovine and murine α -1,3-GalTs. In each of these enzymes a short cytoplasmic amino-terminal domain of about 6 residues precedes a hydrophobic membrane-anchoring domain (extending from residues 7 to 22). The stem region, which serves as a flexible tether, and the catalytic domain, which catalyses the synthesis of α -1,3-GAL linkages, are located in the lumen of the Golgi and extend from amino acid 23 to the carboxyl terminus at amino acid 371. The precise boundary between the stem and catalytic domains is not well-defined. Based on the suggested characteristics of the stem region, it appears to be the least conserved region and is rich in glycine and proline residues. Paulson and Colley, J. Biol. Chem. 264: 17615 (1989); Joziassse et al., J. Biol. Chem. 267: 5534 (1992). The stem/catalytic boundary may occur around amino acid 60.

To generate constructs for inactivating genes by homologous recombination, the gene is preferably

interrupted within an appropriate coding exon by
insertion of an additional DNA fragment. Upon analysis
of the full-length porcine nucleic acid sequence, the
present inventors have identified exons 4, 7, 8 and 9 as
5 preferred locations for disruption of the gene by
homologous recombination. However, identification of
these exons as preferred sites should not be construed as
limiting the scope of the present invention, as
interruptions in exons 5 and 6 may be useful in
10 particular cell types or in situations where less-than-
complete inhibition of α -1,3-GalT gene expression is
desired. Moreover, regulatory elements associated with
the coding sequence may also present useful targets for
inactivation.

15 In a preferred embodiment, a SalI site located
within exon 9 of the mouse α -1,3-GalT gene at codons 221-
222 is chosen as the site for disruption of the murine
coding sequence. For disruption of the porcine sequence,
it is noted that the amino acids encoded by the
20 corresponding porcine nucleotides are conserved, although
the SalI site is not. In a preferred embodiment for
inactivation of the porcine gene, a SalI site is
engineered into the corresponding location of the pig
sequence for convenient construction of a knockout
25 sequence. SalI cuts only rarely in genomic DNA. Since
multiple restriction sites can be a problem in
manipulating large fragments of DNA, the presence of a

Sall site in the exon is very useful since it is not likely that other Sall sites will be present at other locations in the knockout constructs.

A gene coding for a selectable marker is generally
5 used to interrupt the targeted exon site by homologous recombination. Preferably, the selectable marker is flanked by sequences homologous to the sequences flanking the desired insertion site. Thomas and Capecchi, Cell 51: 503-12 (1987); Capecchi, Trends in Genetics 5: 70-76
10 (1989). It is not necessary for the flanking sequences to be immediately adjacent to the desired insertion site. The gene imparting resistance to the antibiotic G418 (a neomycin derivative) frequently is used, although other antibiotic resistance markers (e.g., hygromycin) also may
15 be employed. Other selection systems include negative-selection markers such as the thymidine kinase (TK) gene from herpes simplex. Any selectable marker suitable for inclusion in a knockout vector is within the scope of the present invention.

20 However, it is possible that in some circumstances it will not be desirable to have an expressed antibiotic resistance gene incorporated into the cells of a transplanted organ. Therefore, in a preferred embodiment, one or more genetic elements are included in
25 the knockout construct that permit the antibiotic resistance gene to be excised once the construct has

undergone homologous recombination with the α -1,3-GalT gene.

The FLP/FRT recombinase system from yeast represents one such set of genetic elements. O'Gorman et al., Science 251, 1351-1355 (1991). FLP recombinase is a protein of approximately 45 kD molecular weight. It is encoded by the FLP gene of the 2 micron plasmid of the yeast *Saccharomyces cerevisiae*. The protein acts by binding to the FLP Recombinase Target site, or FRT; the core region of the FRT is a DNA sequence of approximately 34 bp. FLP can mediate several kinds of recombination reactions including excision, insertion and inversion, depending on the relative orientations of flanking FRT sites. If a region of DNA is flanked by direct repeats of the FRT, FLP will act to excise the intervening DNA, leaving only a single FRT. FLP has been shown to function in a wide range of systems, including in the cultured mammalian cell lines CV-1 and F9, O'Gorman et al., Science 251: 1351 (1991), and in mouse ES cells, Jung et al., Science 259: 984 (1993).

Targeted cells carrying a genomic copy of an antibiotic resistance gene flanked by direct repeats of the FRT are supplied with FLP recombinase by 1) introduction into cells of partially purified FLP protein by electroporation, or 2) transfection with expression plasmids containing the FLP gene. In this way, the antibiotic resistance gene is deleted by action of the

FLP recombinase, and cells are generated that contain the inactivated α -1,3-GalT gene and are free of the exogenous antibiotic resistance gene.

Due to the relative infrequency of homologous recombination in targeted cells, most such cells will carry only one inactivated allele of the target gene. That is, the great majority of cells taken through a single round of transformation with an appropriate knockout construct will be heterozygotes. As used herein, the term "transformed" is defined as introduction of exogenous DNA into the target cell by any means known to the skilled artisan. These methods of introduction can include, without limitation, transfection, microinjection, infection (with, for example, retroviral-based vectors), electroporation and microballistics. The term "transformed," unless otherwise indicated, is not intended herein to indicate alterations in cell behavior and growth patterns accompanying immortalization, density-independent growth, malignant transformation or similar acquired states in culture.

Although heterozygous cells can be used in the methods of the present invention, various manipulations can be employed to generate homozygous cells in culture. For example, homozygous cells can be generated by performing a second homologous recombination procedure on cells heterozygous for the inactivated allele. If the knockout construct used in the initial transformation

carried the neo^R gene, a second construct may be employed in a second round of transformation in which the neo^R gene is replaced with a gene conferring resistance to a separate antibiotic (e.g., hygromycin). Cells resistant to both G418 and hygromycin can be screened by Southern blots in order to detect any "double knockouts" (i.e., homozygotes). Both antibiotic resistance genes can be removed subsequently in a single procedure using FLP recombinase. By maintaining selection with G418, this approach ensures that the second construct does not simply replace the previously knocked-out allele, leaving the cells heterozygous.

Alternatively, the neo^R gene can be deleted from an original heterozygous cell using FLP recombinase and a second knockout procedure conducted using the original neo^R gene-containing construct. Double knockouts could be detected by Southern analysis. The newly introduced neo^R gene then could be deleted by FLP recombinase. This alternative approach does not allow one to direct the knockout construct specifically to the non-inactivated allele. Nevertheless, screening of appropriate numbers of targeted cells can lead to identification of cells homozygous for the inactivated locus.

Cellular Vehicles for Incorporation of Knockout Constructs

To create animals having a particular gene inactivated in all cells, it is necessary to introduce a

knockout construct into the germ cells (sperm or eggs, i.e., the "germ line") of the desired species. Genes or other DNA sequences can be introduced into the pronuclei of fertilized eggs by microinjection. Following
5 pronuclear fusion, the developing embryo may carry the introduced gene in all its somatic and germ cells since the zygote is the mitotic progenitor of all cells in the embryo. Since targeted insertion of a knockout construct is a relatively rare event, it is desirable to generate
10 and screen a large number of animals when employing such an approach. Because of this, it can be advantageous to work with the large cell populations and selection criteria that are characteristic of cultured cell systems. However, for production of knockout animals
15 from an initial population of cultured cells, it is necessary that a cultured cell containing the desired knockout construct be capable of generating a whole animal. This is generally accomplished by placing the cell into a developing embryo environment of some sort.

20 Cells capable of giving rise to at least several differentiated cell types are hereinafter termed "pluripotent" cells. Pluripotent cells capable of giving rise to all cell types of an embryo, including germ cells, are hereinafter termed "totipotent" cells.
25 Totipotent murine cell lines (embryonic stem, or "ES" cells) have been isolated by culture of cells derived from very young embryos (blastocysts). Such cells are

capable, upon incorporation into an embryo, of
differentiating into all cell types, including germ
cells, and can be employed to generate animals lacking a
functional α -1,3-GalT gene. That is, cultured ES cells
5 can be transformed with a knockout construct and cells
selected in which the α -1,3-GalT gene is inactivated
through insertion of the construct within, for example,
an appropriate exon. In fact, ES cell lines have been
derived for both mice and pigs. See, e.g., Robertson,
10 Embryo-Derived Stem Cell Lines. In: Teratocarcinomas and
Embryonic Stem Cells: A Practical Approach (E.J.
Robertson, ed.), IRL Press, Oxford (1987); PCT
Publication No. WO/90/03432; PCT Publication No.
94/26884. Generally these cells lines must be propagated
15 in a medium containing a differentiation-inhibiting
factor (DIF) to prevent spontaneous differentiation and
loss of mitotic capability. Leukemia Inhibitory Factor
(LIF) is particularly useful as a DIF. Other DIF's
useful for prevention of ES cell differentiation include,
20 without limitation, Oncostatin M (Gearing and Bruce, The
New Biologist 4: 61-65 (1992); personal communication
from A. Smith), interleukin 6 (IL-6) with soluble IL-6
receptor (sIL-6R) (Taga et al., Cell 58: 573-81 (1989);
personal communication from A. Smith), and ciliary
25 neurotropic factor (CNTF) (Conover et al., Development
19: 559-65 (1993). Other known cytokines may also

function as appropriate DIF's, alone or in combination with other DIF's.

As a useful advance in maintenance of ES cells in an undifferentiated state, the present inventors have
5 identified a novel variant of LIF. In contrast to the previously identified forms of LIF which are extracellular, this new form of LIF (hereinafter T-LIF) is intracellularly localized. The transcript was cloned from murine ES cells using the RACE technique, Frohman et
10 al., Proc. Natl. Acad. Sci. USA 85: 8998-9002 (1988), and subjected to sequence analysis. Analysis of the obtained nucleic acid sequence and deduced amino acid sequence indicates that T-LIF is a truncated form of the LIF sequence previously reported in the literature.
15 Expression of the T-LIF nucleic acid in an appropriate host cell yields a 17 kD protein that is unglycosylated. This protein is useful for inhibiting differentiation of murine ES cells in culture. The protein is expected to have a similar activity with porcine cells, since murine
20 D-LIF is effective at inhibiting both murine and porcine ES cell differentiation. The present inventors have also determined the sequence of the human form of T-LIF.

To generate a knockout animal, ES cells having at least one inactivated α -1,3-GalT allele are identified
25 and incorporated into a developing embryo. This can be accomplished through injection into the blastocyst cavity of a murine blastocyst-stage embryo, by injection into a

morula-stage embryo, by co-culture of ES cells with a morula-stage embryo, or through fusion of the ES cell with an enucleated zygote. The resulting embryo is raised to sexual maturity and bred in order to obtain
5 animals, all of whose cells (including germ cells) carry the inactivated α -1,3-GalT allele. If the original ES cell was heterozygous for the inactivated α -1,3-GalT allele, several of these animals must be bred with each other in order to generate animals homozygous for the
10 inactivated allele.

Although direct microinjection of DNA into eggs does not generate the large numbers of recombination events obtained through transfecting large numbers of cultured cells, nevertheless direct injection of eggs can
15 be a useful approach since this avoids the special manipulations (see above) required to turn a cultured cell into an animal. This is because fertilized eggs are, of course, quintessentially "totipotent" - i.e., capable of developing into an adult without further
20 substantive manipulation other than implantation into a surrogate mother. To enhance the probability of homologous recombination when eggs are directly injected with knockout constructs, it is useful to incorporate at least
25 about 8 kb of homologous DNA into the targeting construct. In addition, it is also useful to prepare the knockout constructs from isogenic DNA. For example, for

injection of porcine eggs, it is useful to prepare the constructs from DNA isolated from the boar whose sperm are employed to fertilize the eggs used for injection.

Embryos derived from microinjected eggs can be
5 screened for homologous recombination events in several ways. For example, if the GALT gene is interrupted by a coding region that produces a detectable (e.g., fluorescent) gene product, then the injected eggs are cultured to the blastocyst stage and analyzed for
10 presence of the indicator polypeptide. Embryos with fluorescing cells, for example, are then implanted into a surrogate mother and allowed to develop to term. Alternatively, injected eggs are allowed to develop and the resulting piglets analyzed by polymerase chain
15 reaction (PCR) or reverse transcription PCR (RT/PCR) for evidence of homologous recombination.

Characterization of Knockout Animals

Animals having either one (heterozygous) or two (homozygous) inactivated GALT genes are characterized to
20 confirm the expected alterations in gene expression and phenotypic effect. For example, GALT mRNA should be absent from homozygous knockout animals. This can be confirmed, for example, with reverse transcription PCR (RT-PCR) using appropriate GALT-specific primers. In
25 addition, various tests can be performed to evaluate expression of the GAL epitope in homozygous knockout animals. For example, anti-GAL antibodies and IB₄ Lectin

(which has an exclusive affinity for terminal α -D-galactosyl residues) can be used in various assay or immunohistological formats to test for the presence of the GAL epitope in an array of tissues. As another indication of GAL epitope status, lysis of cells by human serum can be tested through use of a 51 chromium release assay.

EXAMPLE 1

Affinity Purification of Human Anti-GAL Antibodies

10 Anti-GAL antibodies were purified from normal heat inactivated AB serum (from CS1, Parkville, Victoria, Australia) using the following sets of procedures.

A. Preparation of total anti-GAL (IgG+IgM) antibodies

The following procedures are performed at 4°C.

15 1. Desalt 15-30ml serum (in 3ml batches) by passage through a pre-equilibrated (20ml application buffer: 20mM K_2HPO_4 , 30mM NaCl, pH 8) Econo Pac 10DG (Bio-Rad, Richmond, USA) column. Alternatively, for large scale preparations, desalt by dialysis exhaustively against application buffer.

2. Wash column with 4ml aliquots of application buffer. Collect and pool column eluates.

3. Apply pooled desalted serum to a pre-equilibrated (20ml application buffer) Synsorb 115 (galactosyl-galactose; Chembiomed, Alberta, Canada) or D(+) Melibiose-Agarose (Sigma) affinity column (5ml-50 ml depending on the yield required).

4. Collect run-through (partially anti-GAL-depleted) and reapply to column. Repeat process 3 times to ensure complete removal of anti-GAL antibodies. The wash-through from the 3rd passage through the Synsorb column is collected and the volume adjusted to the original volume of the serum with phosphate-buffered saline (PBS)

pH 7 +0.05% azide. This is used as a source of anti-GAL antibody-depleted serum.

5. Wash column with PBS pH 8 until the eluate is protein free (O.D. 280nm=0).

5 6. Elute anti-GAL antibodies with 3.5M KSCN, pH 7.5. Collect 4ml fractions, determine the O.D. 280 and pool peak fractions (usually 1-6).

7. Concentrate anti-GAL antibodies using CF25 ultrafiltration cones (Amicon, Danvers, USA). Add 7ml of
10 the pooled fractions containing anti-GAL antibodies to spin cone and centrifuge (2,000 RPM, 10min, 4°C). Refill cone and recentrifuge until volume is reduced to 3-5ml.

8. To dilute the KSCN, adjust vol. to 7ml with PBS and centrifuge (2,000 RPM, 10min, 4°C). Repeat process a
15 further 10 times.

9. Remove sample containing anti-GAL antibodies from cone using plastic pipette; rinse cone with PBS pH7 +0.05% azide.

B. Preparation of IgG anti-GAL antibodies

20 The following procedures are performed at 4°C.

1. Desalt 15-30 ml serum (in 3ml batches) by passage through a pre-equilibrated (20ml application buffer) Econo Pac 10DG (Bio-Rad, Richmond, USA) column. Alternatively for large scale preparations desalt by
25 dialysis exhaustively against application buffer.

2. Wash column with 4ml aliquots of application buffer. Collect and pool column eluates.

3. Apply desalted serum to a pre-equilibrated (30ml application buffer) Affi-Blue column (Bio-Rad, Richmond,
30 USA) (Affi-Blue binds all proteins except albumin and IgG).

4. Wash column with 20ml application buffer to elute IgG enriched fraction.

5. Apply IgG enriched fraction to a pre-equilibrated
35 (20ml application buffer, pH 8.0) Synsorb 115

(galactosyl-galactose; Chembiomed, Alberta, Canada) affinity column (5ml).

6. Collect run-through and reapply to column. Repeat process 3 times to ensure complete removal of anti-GAL antibodies. The wash-through from the 3rd passage through the Synsorb column is collected and the volume adjusted to the original volume of the serum with PBS pH 7 +0.05% azide. This is used as a source of control anti-GAL-depleted IgG.

10 In some cases anti-GAL IgG was further purified using a protein G column, which efficiently binds IgG but not other antibody isotypes. IgG was then eluted from the protein G column using glycine pH 2.4.

15 All anti-GAL antibody preparations were analyzed for the following:

- a. Protein content was determined using the Bradford colorimetric method (Bradford, M.M 1976, Anal. Biochem. 72:248-254), using purified human IgG as the standard.
- b. Molecular weight and purity were determined using polyacrylamide gel electrophoresis according to method described by Laemli, Nature (London) 227: 680 (1970), and protein was detected in the gels by silver staining using standard kit reagents (Amersham, UK).
- c. Antibody class and isotype were determined by radial immunodiffusion using standard techniques as set out in Rose et al. (eds.), Manual of Clinical

Laboratory Immunology, American
Society for Microbiology,
Washington, D.C. IgG anti-GAL
preparations were found to
contain all subclasses, with
IgG2 predominating.

EXAMPLE 2

Reactivity of IgG and IgM Anti-GAL Antibodies and
Depleted Serum with Porcine Cells and Tissues

10 I. CELLS

Reactivity of IgG and IgM anti-GAL antibodies was
assessed using either porcine aortic endothelial cells
(prepared by the inventors as described below) or porcine
epithelial cell line LLC PK₁ (PK₁), obtained from the
15 American Type Culture Collection (ATCC), Accession No.
CRL1392.

A. Isolation and culture of porcine aortic
endothelial cells (PAE's)

Pigs were blood typed (using human typing
20 reagents) to identify "O-type" pigs, i.e, pigs unreactive
with antibodies to A or B human red blood cell antigens.
Aortas were excised from "O-type" pigs, then transported
from the abattoir to the laboratory on ice. PAE's were
isolated by collagenase treatment as described by
25 Gimbrone et al., J. Cell Biol. 60: 673-84 (1974). PAE's
were cultured in RPMI medium containing 10% fetal calf
serum (FCS), supplemented with 150µg/ml endothelial cell
supplement (Sigma) and 50µg/ml heparin (Sigma). The
cells were identified as endothelial cells by their
30 typical cobblestone morphology and by their
immunoreactivity with Factor VIII antibodies, as
identified using immunofluorescence. In all the assays

described below, the PAE's were used between the 8th and 12th passages.

B. Tissue Culture: Maintenance of PK-1 and PAE cell lines

5 All tissue culture was performed in a laminar flow hood, using appropriate tissue culture sterile technique. All tissue culture reagents, unless otherwise indicated, were purchased from CSL, Melbourne, Australia. Media were constituted as follows:

10 PK-1 Culture Medium:

	DMEM (Cytosystems, Castle Hill, Australia)	500ml
	FCS (CSL, Melbourne, Australia)	37.5ml
	Glutamine (200mM) (Cytosystems)	5ml
	Hepes (1M) (CSL)	7.5ml
15	Penicillin (CSL)	0.5ml (10^5 U/ml final)
	Streptomycin (CSL)	0.5ml (10^5 μg/ml final)

PAE - Culture Medium:

	RPMI (CSL)	90ml
	FCS (CSL)	10ml
20	Endothelial cell supplement (3mg/ml) (Sigma)	1.5ml
	Heparin (10mg/ml) (CSL)	0.5ml

Endothelial cell supplement was purchased from Sigma Chem. Co. (St. Louis, Missouri, USA) as a
25 lyophilized powder, resuspended in sterile HBBS, and 3ml aliquots stored at 4°C.

	Heparin (Sigma, Missouri, USA) (10mg/ml)	- dissolved in PBS
		- filter sterilized
30	(0.22μm) Hanks Buffer Cytosystems	- purchased from

The following general procedures were used in propagating the cell lines.

- 35
- 1) Pour off old medium
 - 2) Rinse cells twice with sterile PBS

- 3) Add 3ml of TED (0.05 M trypsin, 0.53 M EDTA, Gibco, NY, USA)
- 4) Incubate 10 min. in CO₂ incubator at 37°C
- 5) Add 7ml RPMI with 10% FCS
- 5 6) Resuspend cells and transfer to a sterile 10ml tube
- 7) Centrifuge for 5min at 1200 rpm, discard supernatant
- 8) Resuspend cells in RPMI with 10% Newborn Bovine Serum (NBS) and repeat centrifugation
- 10 9) Resuspend cells in 1ml DMEM (PK-1's) or RPMI (PAE's) (with additives, as described above).
- 10) Add 10ml medium and the appropriate volume of cell suspension to achieve the desired dilution for each 75cm² tissue culture flask, and return to humidified CO₂ incubator.
- 15
- C. Antibody staining and FACS analysis
- 20 1) Add 2ml TED to a 75cm² culture flask containing PK-1 or PAE's, and incubate at room temperature for 10 min.
- 2) Add RPMI plus 10% FCS (5ml) to neutralize trypsin.
- 25 3) Pellet cells by centrifugation (700g, 5 min, 4°C).
- 4) Wash cells by resuspension and centrifugation in Hanks Buffer (x2).
- 30 5) Pellet cells by centrifugation (700g, 5 min, 4°C).
- 6) Resuspend cell pellet in Hanks buffer containing purified anti-GAL antibodies, GAL-depleted serum or GAL-depleted IgG and incubate
- 35 at 4°C for 60 min. All

antibodies were used undiluted,
or diluted 1:2 or 1:4 in Hanks
buffer.

- 5 7) Add 1ml of Hanks Buffer, pellet cells by
centrifugation and aspirate off
supernatant.
- 8) Resuspend pellet in FITC-labelled sheep-anti-
human IgG Fab2 or IgM Fab2
 (Silenus, Hawthorn, Australia)
10 diluted 1:80 in Hanks buffer.
- 9) Incubate for 30 min. at 4°C.
- 10) Wash three times with Hanks buffer; resuspend
pellet from final wash in 0.5ml
Hanks buffer.
- 15 11) Analyze stained samples using a FACScan II
 (Becton Dickinson) according to
the manufacturer's instructions.

20 The specificity of the anti-GAL antibody binding
to porcine cells was determined by examining the ability
of sugars of various structures to inhibit antibody
binding. In these competition studies the anti-GAL
antibodies were pre-incubated with sugar (0.1M) at 37°C
for 30 min before adding to the cells.

D. Results

25 Using immunofluorescence it was found that total
anti-GAL (IgM & IgG) and purified anti-GAL IgG stained
both PK-1 and PAE's cells. On the other hand, neither
the total anti-GAL antibody-depleted serum nor the anti-
GAL IgG-depleted serum gave detectable staining over
30 background. The staining with anti-GAL IgM and/or IgG
was inhibited with purified galactose and with
disaccharides having terminal galactose residues in the
 α 1-configuration such as melibiose (6-O- α -D-
galactopyranosyl- D-glucose) and stachyose (α -D-Gal-[1-

>6]- α -D-Glc-[1->2]- β -D-Fru). Staining was not inhibited with sugars such as lactose (4-O- β -D-galatopyranosyl- α -D-glucose), which has a terminal galactose residue, but in a β 1->4 configuration. The results of one such
5 experiment are represented in Figure 1. PAE's were stained with anti-GAL antibody alone (GAL:PBS) or with anti-GAL antibody that had been pre-incubated with either melibiose (GAL:MELIBIOSE), galactose (GAL:GALACTOSE) or lactose (GAL:LACTOSE). Anti-GAL antibody staining was
10 approximately 10 fold less in the samples containing melibiose and galactose, but was not affected significantly by lactose.

II. TISSUES

A. Methods

15 Pig kidney was fixed in formalin and dehydrated before embedding in Paraplast. Pig heart and liver were fixed in paraformaldehyde-lysine-periodate fixative and snap frozen in O.C.T. embedding compound (10.24% w/w polyvinyl alcohol, 4.26% w/w polyethylene glycol, 85.50%
20 w/w nonreactive ingredients; Tissue Tek®, Miles, Inc., Elkhart, Indiana, USA). Four μ m-thick sections of pig heart and liver and 2 μ m-thick sections of kidney were incubated with purified anti-GAL antibodies (undiluted, 1:2 and 1:4) for 60 min. and then incubated with a
25 fluorescein isothiocyanate (FITC)-conjugated sheep anti-human immunoglobulin F(ab') fragment (Silenus Laboratories, Hawthorn, Australia) (1:100) for 30 min. or a peroxidase-conjugated rabbit anti-human IgG (Dakopatts, Glostrup, Denmark) (1:50) for 60 min. Control sections
30 were analyzed for autofluorescence, with the secondary antibody alone, or with the anti-GAL-depleted IgG or normal pig serum as the primary antibody. No staining was detected. The specificity of the anti-GAL antibodies was tested by pre-incubating sections of pig renal cortex

with a variety of sugars, including melibiose, lactose, sucrose and glucose at 0.1M.

B. Results

As with the analyses performed on the pig cells using immunofluorescence, total anti-GAL IgM + IgG, purified anti-GAL IgG, but not the anti-GAL IgM and/or IgG-depleted sera, stained all pig tissues examined. The individual staining parameters varied from organ to organ as set out below:

10 Immunostaining of Pig Tissues with Anti-GAL Antibodies:

<u>Tissue</u>	<u>Anti-GAL Reactivity</u>	<u>Staining Intensity</u>
15 Kidney	Proximal and distal convoluted tubules	Variable
	Endothelium: Intertubular sinusoids	Variable
	Endothelium: Arteries and veins	Strong
	Glomerular capillaries	Variable
Heart	Endothelium: Arteries, veins, capillaries	Strong
	Endocardium	Strong
	Myocardium	Perinuclear
20 Liver	Small Bile Ducts (lining cells)	Strong
	Endothelium: Arteries, veins	Strong
	Intertubular sinusoids	Negative

The specificity of the binding of anti-GAL antibodies was tested on sections of pig renal cortex by inhibition with 0.1 M melibiose, lactose, sucrose and glucose. Reactivity of the anti-GAL antibodies with proximal tubule brush borders was reduced to near background by preincubation of antibody with melibiose, but was not inhibited by the other saccharides.

EXAMPLE 3

30 Hemagglutination of Pig RBC by Human Serum:

Sugar Inhibition Studies

The methods used to investigate the hemagglutination of pig red blood cells (RBC's) by human serum was adapted from the methods described by Galili,

J.Exp. Med. 160: 1579-81 (1984) and Severson, Immunol.
96: 785-789 (1966).

I. METHODS

A. Media/Solution Preparation

5 1. Human Serum Albumin (HSA) (CSL,
Melbourne, Australia) (5mg/ml) was dissolved in PBS,
filter sterilized, and stored at 4°C.

2. Preparation of sugars:

10 - 1M stock solutions of sugar were
prepared by dissolving the amount
indicated in 100ml of PBS. Sodium azide
was added (0.02%) and solutions stored at
4°C.

15	α -Lactose (4-O- β -D-galactopyranosyl- α -D-glucose)	36.0g
	D-(+)galactose	18.0g
	Stachyose (α -D-gal-[1->6]- α -D-Glc-[1->2]- β -D-Fru)	66.6g
	Melibiose (6-O- α -D-galactopyranosyl- D-glucose)	34.2 g
	Sucrose (α -D-Glucopyranosyl β -D-fructofuranoside)	34.2 g
20	D-(+)-Glucose	18.0 g
	α -D-(+)-Fucose (6-Deoxy-D-galactopyranose)	16.4 g

All sugars were purchased from Sigma (St. Louis,
Missouri, USA). Sugar solutions were diluted in PBS to
the appropriate concentration as required.

B. Preparation of pig RBC's

25 1. Heparinised pig blood
(Animal Resources, Clayton,
Australia) is centrifuged at 800
RPM for 10min to pellet the RBC.
2. The RBC pellet is washed by
30 resuspension in PBS (10ml) and
recentrifugation (repeated 3
times). After the final wash,
the RBC pellet is resuspended in
10ml PBS.

3. A 0.5% solution of RBC's is prepared by adding 50ul RBC solution (from step 2, above) to 10 ml PBS containing 0.5g/100 ml of HSA.

5

C. Preparation of 96-well microtitre plates
(Titretek, USA)

1. Add 25ul of PBS to each well.

10

2. Add 25ul of pooled human AB serum (CSL, Melbourne, Australia) to column 1 and serially dilute by removing 25ul from column 1 and adding to column 2, then repeating by sequentially removing and adding 25ul from and to each well across the plate, finally discarding 25ul from column 11 and adding no serum to column 12.

15

20

3. Add 25ul of sugar solution to each row in decreasing concentrations down rows. No sugar solution is added to the final row.

25

4. Incubate at 4°C overnight and then at 37°C for 30 min.

5. Add 50ul of 0.5% pig RBC to each well; vortex and incubate at room temperature for 2 hours. Determine agglutination visually.

30

00504900-160697

II. RESULTS

Human serum caused the agglutination of pig RBC's at a titre of between 1/32-1/64, which is consistent with the presence of high levels of naturally occurring xenoantibody (NXAb) in human serum. To examine the specificity of the NXAb response, sugar inhibition studies were performed. Sugars such as melibiose, stachyose, galactose and fucose which have terminal galactose residues in the $\alpha 1-6$ configuration were found to inhibit agglutination in the μM to mM range. Sugars with other structures, such as lactose and sucrose, were only inhibitory when very high concentrations were used. At these high concentrations, the observed effects are most probably non-specific, due, for example, to changes in osmolarity. Results are summarized below:

Pig RBC Hemagglutination by Human Serum: Sugar Inhibition

	<u>Sugar</u>	<u>Linkage</u>	<u>Inhibitory Concentration</u>
	Melibiose	Gal $\alpha 1-6\text{Glc}$	$5 \times 10^{-4}\text{M}$
	Stachyose	Gal $\alpha 1-6\text{Gal}$	$2 \times 10^{-3}\text{M}$
20	Galactose		$2 \times 10^{-3}\text{M}$
	Fucose	6-Deoxy- α -L-Gal	$1 \times 10^{-3}\text{M}$
	Lactose	Gal $\beta 1-4$ -Glc	$> 10^{-1}\text{M}$
	Sucrose	α -D-Glc- β -D-Fruc	$> 10^{-1}\text{M}$

EXAMPLE 4

25 Inhibition of Human Serum-Induced Lysis of Porcine Cells by Sugars

The ability of human serum to cause the lysis of porcine cells was examined using both pig epithelial (PK₁) and aortic endothelial (PAE's) cells, the isolation and culture of which is described in Example 2. Cell lysis was determined using either the ⁵¹Chromium release assay as described by Cerottini and Brunner, Nature New Biol. 237:272, 1972 or the Cytotox LDH release assay according to the manufacturer's instructions (Promega, USA).

I. METHODS

A. ⁵¹CR Release Assay

1. Preparation of Cells:

a) Trypsinize a confluent flask of cells.

5 On average, approximately 3×10^6 PAE's and approximately 3×10^7 PK₁ cells are obtained per 10 ml flask. About 1×10^5 cells are required for each well in the ⁵¹CR Release Assay.

b) Wash cells 4 times in 10 ml RPMI (no FCS); spin 1200 rpm for 5 min.

c) Resuspend cells in 100 μ l RPMI (with 10% heat-inactivated FCS; see below).

2. Labelling Cells with ⁵¹CR:

a) Combine in a 10 ml tube: Cells in 195 μ l RPMI/10% FCS (heat inactivated); 5 μ l ⁵¹CR (120 μ Ci).

b) Incubate at 37°C for 2 hr.

c) Add 2 ml RPMI/10% FCS (heat inactivated).

d) Centrifuge cells through a layer of FCS (heat inactivated) to remove excess label.

e) Gently overlay the labelled cells onto a 4 ml cushion of FCS using a Pasteur pipette.

f) Centrifuge at 700g for 5 min. at 4°C.

g) Remove supernatant taking care not to disturb the cell pellet.

h) Resuspend pellet in RPMI/10% FCS (heat inactivated) at about 3×10^7 cells/ml.

3. Assay Conditions:

a) For PAE's, rabbit complement was used as the complement source, since the ⁵¹CR-release assay was not sufficiently sensitive to detect lysis when human complement, a less "active" source, was used. In contrast, with the LDH assay, which is significantly more sensitive, normal human serum (NHS) was used as the source of complement.

b) To each test well of a 96-well V bottom plate, add:

- 100 μ l labelled cells
- 10-50 μ l NHS (heat inactivated) (5-25% of final)
- Complement:

PAE's: 50 μ l absorbed rabbit complement (25% final)
PK₁: 10-40 μ l NHS (5-25% of

- 10 final)
- 50 μ l antibody (total anti-GAL (IgG + IgM, anti-GAL IgG, anti-GAL antibody-depleted serum, or anti-GAL antibody-depleted IgG)

- c) Adjust volume to 200 μ l with
- 15 RPMI/10% FCS (heat inactivated) if required
- d) Incubate plates at 37°C for 3 hr.
- e) Centrifuge plates at 1000 rpm for 5 min to pellet cells

- f) Remove 100 μ l of supernatant from
- 20 each well and transfer to a gamma counter tube

g) Add 3 ml scintillation fluid and measure ⁵¹CR release using a gamma counter (Packard Instrument Company, Illinois, USA)

- (To determine maximum release, add 100
- 25 μ l 8% Triton X-100 made up in RPMI/10% FCS (heat inactivated) to 100 μ l labelled cells)

(Note: Each reaction is set up in quadruplicate)

4. Calculation of % Lysis:

30

$$\% \text{ Lysis} = \frac{\text{Experimental cpm} - \text{Spontaneous Release cpm}}{\text{Max. Release cpm} - \text{Spontaneous Release cpm}} \times 100$$

5. Sugar Inhibition of Complement-Induced Cell Cytotoxicity:

35 In a 96-well test plate, mix the following:

- 50 μ l labelled cells
 - 50 μ l complement (PAE's: pig spleen cell complement; PK₁'s: NHS)
- absorbed

- 10⁻¹ to 10⁻³ M) - x μ l sugar (final concentration of sugar:
- y μ l NHS (heat inactivated) - final
concentration 5-20%)
5 - make volume to 200 μ l with RPMI

Plate Layout:

	<u>Plate 1</u>		<u>Plate 2</u>	
	5%	10%	15%	20%
Rows:	1-4	5-8	1-4	5-8
10 Columns:	1. Spontaneous Release 2. Maximum Release 3. Melibiose 4. Lactose			

B. LDH Release Assay

- 15 1. General Procedures:
a) Prepare cells as for ⁵¹CR Release assay, and labeled with LDH as per the manufacturer's instructions (Cytotox non-radioactive LDH release assay, Promega, USA)
- 20 b) To each well of a 96-well plate add (each reaction set up in quadruplicate):
- 25 μ l labeled cells
- 5-20 μ l NHS
25 - x μ l sugar (final concentration of sugar: 10⁻¹ to 10⁻³ M)
- RPMI/10% FCS (heat inactivated), to total volume of 100 μ l
- 30 c) Incubate plates at 37°C for 3 hr.
d) Centrifuge plates at 1500 rpm for 5 min.
e) Remove 50 μ l supernatant from each well (taking care not to remove any cells) and transfer to ELISA plate containing 50 μ l substrate mix (prepared according to manufacturer's instructions)
- 35 f) Cover tray and incubate in the dark at room temperature for 30 min.

- g) Add 50 μ l stop solution to each well using multichannel pipette
- h) Read absorbance at 492 nm.

2. Controls:

- 5 a) Spontaneous release (no antibody or complement)
 - 25 μ l labeled cells
 - 75 μ l RPMI/10% FCS (heat inactivated)
- b) Maximum release
 - 10 - 25 μ l labeled cells
 - 50 μ l 16% Triton X-100
 - 25 μ l RPMI/10% FCS (heat inactivated)

3. Calculation of % Lysis:

$$\% \text{ Lysis} = \frac{\text{Experimental release} - (\text{Spontaneous release cpm} + \text{sugar cpm})}{\text{Maximum release} - (\text{Spontaneous release cpm} + \text{sugar cpm})} \times 100$$

Maximum release - (Spontaneous release cpm + sugar cpm)

4. Experimental Design:

Plate 1

- 20 Columns: 1. spontaneous release Rows: 1-4: cells + no sugar
- 2. maximum release 5-8: no cells + no sugar
- 3. 5% serum
- 4. 10% serum
- 5. 25% serum
- 6. RF10 alone

25 Plate 2 melibiose

Plate 3 galactose

Plate 4 lactose

Plate 5 sucrose

Plates 6-9 same as plates 2-5 but no cells added

30 Columns: 1-2 Sugar Conc.

- | | | | |
|-------|------------------------|-----------|-----------|
| 1-2 | 1 x 10 ⁻¹ M | Rows: 1-2 | 0% serum |
| 3-4 | 5 x 10 ⁻² M | 3-4 | 5% serum |
| 5-6 | 1 x 10 ⁻² M | 5-6 | 10% serum |
| 7-8 | 5 x 10 ⁻³ M | 7-8 | 25% serum |
| 9-10 | 2 x 10 ⁻³ M | | |
| 11-12 | 1 x 10 ⁻³ M | | |

35

5. Preparation of Pig Spleen-Absorbed Rabbit Complement:

- a) Cut pig spleen (obtained from local abattoir) into small pieces and prepare a single-cell suspension by passage through a fine metal sieve
- 5 b) Pellet cells by centrifugation at 700g, 7 min. at 4°C
- c) Resuspend cell pellet in RPMI/10% FCS and repeat centrifugation
- d) Resuspend in RPMI/10% FCS/10%
- 10 dimethylsulfoxide (DMSO)
- e) Count cells and store frozen aliquots (3×10^9 cells/aliquot)
 - use one aliquot for each absorption
- f) For absorption, thaw and centrifuge at 600g, 5
- 15 min. at 4°C and remove the supernatant containing the DMSO
- g) Wash two times with RPMI/10% FCS (10 ml)
- h) Resuspend the cell pellet in rabbit complement; mix (rotary wheel) 2 hr. at 4°C
- 20 i) Centrifuge 600g, 5 min. at 4°C and remove the supernatant containing the rabbit complement; store at 4°C

II. RESULTS

Comparable results were obtained with both cell types (PAE's and PK₁'s) using both lysis assays. The results of a typical lysis experiment are represented in Figure 2, in which the lysis of PAE's by human serum and by purified anti-GAL antibodies was determined using the ⁵¹CR release assay. Comparable results were also obtained

30 with PK₁ cells using the ⁵¹CR release assay and with both cell lines using the LDH release assay. The results of these assays can be summarized as follows:

1. Xenoantibodies (NXAb) in human serum in the presence of complement are capable of lysing porcine

cells. Lysis increases with increasing concentrations of serum.

2. Pre-absorption of NHS with pig spleen cells (which removes the NXAb): No lysis.
- 5 3. Use of heat-inactivated complement: No lysis.
4. Use of NHS depleted of anti-GAL antibodies: No lysis.
5. Use of purified total anti-GAL antibodies
10 (IgG + IgM): Lysis.
6. Use of purified anti-GAL IgG: No lysis.
7. Use of purified total anti-GAL antibodies (IgG + IgM) and dithiothreitol (DTT): No lysis. (DTT is a reducing agent that disrupts the multimeric structure
15 of IgM antibodies without affecting IgG.)

Together these results demonstrate that the anti-GAL antibodies are responsible for the observed lysis. Purified anti-GAL IgG and DTT-treated total (IgG + IgM) anti-GAL antibodies failed to elicit lysis, indicating
20 that IgM, but not IgG, antibodies are causative agents in this system. Preliminary attempts to verify this observation using purified IgM prepared either in crude form by euglobulin fractionation or by α -IgM affinity chromatography were unsuccessful. The inventors believe
25 this reflects inactivation of the IgM during preparation, rather than a true reflection of the capacity of anti-GAL IgM to cause lysis of porcine cells. heat inactivation of the complement prevented lysis, indicating that lysis of porcine cells is a complement-dependent phenomenon.

30 The effect of adding the disaccharide sugars melibiose (Gal α 1 \rightarrow 6 Gal) and lactose (Gal β 1 \rightarrow 4 Glu) on the lysis of PAE's by human serum was assessed using the Cytotox non-radioactive LDH release assay. PAE's were incubated in the presence of 50% human serum as the

source of xenoantibody and complement, together with various concentrations of each sugar (1mM to 100mM). Under these conditions, melibiose, which has the Gal $\alpha 1 \rightarrow 6$ Gal configuration, but not lactose, which has the terminal Gal moiety by in a $\beta 1 \rightarrow 4$ configuration, protected the pig cells from lysis.

EXAMPLE 5

Inhibition of Human Serum-Induced Damage to Rat Hearts by Sugars

The Langendorf isolated perfused ex vivo heart model was used to further demonstrate the involvement of anti-GAL xenoantibodies in hyperacute rejection.

I. METHODS

A. Preparation and storage of Human Plasma

1. Centrifuge fresh human blood at 3000 rpm, 10 min., 4°C to remove red blood cells (RBC's)
2. Remove the plasma
3. Centrifuge the plasma at 10,000 rpm, 10 min. 4°C to remove any remaining cells; decant the plasma
4. Add 2.5 ml of 0.1M EDTA pH 7.30 for every 50 ml of plasma
5. Store 50 ml aliquots at -70°C
6. For heat-inactivated plasma, heat at 56°C for 60 min., then centrifuge at 2,500 rpm for 10 min.

B. Assessment of Complement Activity

Before being used in the ex vivo model, both heat inactivated and control plasma was tested for complement activity. Classical complement activity was determined by hemolysis using sensitized sheep RBC's as described by Harrison and Lachman, In: Weir et al. (eds.), Handbook of Experimental Immunology and Immunochemistry, 4th Ed., Blackwell scientific Publications (1986). Alternative complement pathway

activity was determined using the rabbit hemolytic assay as described by Serrais et al., J. Immunol. Meth. 140: 93-100 (1991). The assay was performed in buffer containing EGTA and $MgCl_2$. The EGTA chelates the Ca^{++} , thus inhibiting the classical pathway. The Mg^{++} is required for activation and assembly of CdbBb, the alternative pathway C3 convertase.

C. Preparation of Plasma for Heart Perfusions

Plasma prepared from different blood packs is thawed at 37°C, pooled and filtered (100 μm steel mesh, 8.0 μm and 4.5 μm Millipore filters, sequentially). $CaCl_2$ is added at 0.58 mg/ml plasma, and the plasma kept on ice until ready for perfusion.

D. Ex Vivo Isolated Perfused Rodent Heart Model

1. Anesthetize rats with Nembutal (1 μl sodium pentobarbitone (60 mg/ml)/g body weight) and mice with ether.

2. Surgically expose the heart and inject heparin (Porcine Mucous, 10,000 U/ml) into the femoral vein (rats: 0.3 ml injected).

3. Remove heart and place in ice-cold Krebs-Henseleit buffer containing heparin (0.2 ml/50 ml buffer).

Krebs-Henseleit buffer:

- 119 mM NaCl
- 25 mM $NaHCO_3$
- 4.6 mM KCl
- 1.2 mM $MgSO_4 \cdot 7H_2O$
- 1.3 mM $CaCl_2 \cdot 2H_2O$
- 1.2 mM KH_2PO_4
- 11 mM glucose
- 0.25% (v/v) BSA
- Adjust to pH 7.4; store at 4°C

4. Connect aorta to the canula of the Langendorff perfusion apparatus and tie firmly. The apparatus was assembled by the present inventors according to experimental requirements of the Langendorff heart model as described in Doring & Dehner, The Isolated Perfused

Heart According to Langendorf, Bionestechnik-Verlag
March GmbH, D7806, West Germany.

5. Perfuse with Krebs-Henseleit buffer (made
fresh each day), which is gassed continuously with
5 carbogen (95% O₂, 5% CO₂) at a pressure of 100 mmHg, at
37°C.

6. Attach a hook, connected to a transducer
(Physiograph MK-111-S, Narco Bio-Systems) to the apex of
the heart.

10 7. Perfuse heart for 20 min. with Krebs-
Henseleit buffer to enable heart to stabilize (reservoir
volume: 270 ml).

8. Add plasma (pre-warmed to 37°C) as follows:
15 - at 20 min. - add 10 ml plasma (= 5% plasma)
- at 25 min. - add 10 ml plasma (= 9 % plasma)
- at 30 min. - add 10 ml plasma (= 13 % plasma)

9. Monitor heart for a further 30 min. and
record heart flow and contraction rate.

E. Sugar perfusion

20 1. Stabilize heart in Krebs Henseleit
buffer for 30 min. as described above.

2. Add 2.5 ml of 1.08 M stock sugar
solution to reservoir; total volume = 270 ml; final sugar
concentration = 10mM.

25 3. Allow heart to restabilize for 10 min,
then add plasma (control or heat inactivated) as per the
schedule described above.

4. Record heart beat and flow rate.

F. Large-Scale Preparation of anti-GAL antibody-
30 Depleted Plasma

(all manipulations are performed at 4°C)

1. Start with 200 ml freshly prepared human
plasma; 100 ml is subject to depletion; 100 ml is used as
an untreated control from the sam patient drawn on the
35 same day; store at 4°C.

2. Filter the plasma sequentially through a 100 μm , 8 μm metal sieves and finally through a 0.45 μm Millipore filter; dilute to 1000 ml with PBS, pH 8.0.

3. Concentrate to 200 ml using an Amicon spiral wound cartridge (removes salt).

4. Equilibrate melibiose sepharose column (40 ml) with PBS, pH 8.0 (10 column volumes).

5. Passage the plasma through the melibiose sepharose column; collect the run-through and store at -70°C (=partially depleted plasma).

6. Wash column with PBS, pH 8.0 (10 column volumes) until the O.D. (280nm) of the eluate is approximately zero.

7. Combine the partially depleted plasma and the eluate from the wash; concentrate to 200 ml (Amicon spiral concentrator).

8. Elute the anti-GAL antibody fraction with 4M guanidinium HCl pH 6.4 (2 column volumes).

9. Regenerate the column with PBS (10 column volumes).

10. Repeat the entire process an additional two times, i.e., repassage plasma through the melibiose column, wash, elute the anti-GAL antibody fraction and regenerate column.

11. For the anti-GAL antibody-depleted fraction:

- combine the eluate from the melibiose sepharose column with run-through from the final wash
- adjust the volume to 5 liters with Krebs Henseleit buffer and add EDTA to 10 mM; adjust pH to 7.0

- concentrate back to original volume (Amicon spiral concentrator); aliquot (35 ml) and store at -70°C

12. For the anti-Gal antibody fraction:

- combine the eluted anti-GAL antibody fractions, dilute to 5 liters with Krebs Henseleit buffer and add EDTA to 10 mM

- concentrate back to 10 ml (Amicon spiral concentrator); aliquot (1 ml) and store at -70°C

13. The anti-GAL antibody-depleted fraction and the purified anti-GAL antibody fraction are tested for

a) Anti-GAL reactivity: Use as primary reagents to stain porcine cells (PK₁'s). Detect staining as described in Example 2, above. Analyze stained samples using a FACScan II (Becton Dickinson), according to the manufacturer's instructions.

b) Protein content: Determine using the colorimetric method of Bradford, Anal. Biochem. 72: 248-54 (1976), with purified human IgG as the standard.

c) Electrolyte concentration: On the day of the perfusion, the anti-GAL antibody depleted plasma is also tested to determine the calcium, magnesium and potassium levels using an electrolyte autoanalyser (Olympus); the levels of each are adjusted to normal as required.

II. RESULTS

Rat hearts were connected to the Langendorff apparatus and then stabilized by perfusion with Krebs Henseleit buffer for 10 min., and then a further 10 min. with the same buffer containing either melibiose or lactose (10mM). Human plasma was then added in stages as described above to a final concentration of 13 % and the effect of the added sugar on cardiac function was assessed. The parameters measured were heart rate, amplitude (strength) of contraction and output (Figure 3).

In the presence of human serum alone (lower trace), the heart essentially stopped beating within minutes. The same result was obtained if lactose was added. In the presence of melibiose (upper trace) or
5 anti-GAL antibody-depleted plasma, however, the heart was able to maintain a strong beat. When the purified anti-GAL antibody was added back to the anti-GAL antibody-depleted plasma, the heart again stopped beating within minutes.

10

EXAMPLE 6

Characterization of the Porcine α -1,3-GalT Gene

cDNA's encoding porcine α -1,3-GalT were generated by Polymerase Chain Reaction (PCR) technology. Total RNA of pig liver was isolated by homogenizing liver slices in
15 7M guanidinium thiocyanate, as described by Chomczynski & Sacchi, Anal. Biochem 162, 156-159 (1987); Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd Edition), Cold Spring Harbor Laboratory Press (1989). Sixteen μ g of the RNA, together with 1 μ g oligo dT primer,
20 were heat denatured for 5 minutes at 65°C prior to being transcribed into cDNA using avian myeloblastosis virus (AMV) reverse transcriptase in a 100 μ l reaction carried out at 37°C for 90 minutes. Three μ l of the cDNA synthesis reaction was used in the subsequent PCR
25 amplifications. General procedures used for generation of cDNA are provided in Sambrook et al (1989), supra.

Primers for PCR were synthesized using phosphoramidite technology, on an Applied Biosystems DNA synthesizer. The sequence of the PCR primers was based
30 on identifying conserved regions within the published sequences for murine and bovine α -1,3-GalT genes. Joiazze et al., J. Biol. Chem 264: 14290-97 (1989); Joiazze et al., Biol. Chem 267: 5534-5541 (1992). All primers were synthesized with EcoR1 linkers at the 5' end

for ease of cloning. In the following listing of the primers used in the present study, nucleotide positions varying between bovine and murine sequences are single-underlined; nucleotide positions varying between bovine and human sequences are double-underlined:

Exon 2 primer (forward): 5'-
GTGAATTCAGCCCTGCCTCCTTCTGCAG-3'

(SEQ ID NO: 1)

10 Designation: GTE2F -- 28-mer
 - 1 difference b/w bovine & murine
 - no sequence available for human exon 2

Exon 4 primer (forward): 5'-
GTGAATTCAGGAGAAAATAATGAATGTC-3'

(SEQ ID NO: 2)

15 Designation: GTE4F -- 28-mer
 - no differences b/w bovine, murine & human

Exon 9 primer (reverse): 5'-
GTGAATTCGGGATCTGCCTTGTACCACC-3'

(SEQ ID NO: 3)

20 Designation: GTE9R -- 28-mer
 - 3 differences b/w bovine & murine
 - 1 difference b/w bovine & human

3'-UTR primer (reverse): 5'GTGAATTCGAAATCACTGGGAATTTACA-
3'

25 (SEQ ID NO: 4)

 Designation: GT3UR -- 28-mer
 - no differences b/w bovine & murine
 - no differences b/w bovine & human

30 Exon 9 primer (forward): 5'-
AGGAATTCAGCATGATGCGCATGAAGAC-3'

(SEQ ID NO: 5)

 Designation: GTE9F -- 28-mer

- no differences b/w bovine & murine
- 3 differences b/w bovine & human

PolyA primer (reverse): 5'-TTGAATTCTTTTTTTTTTTTV*N**-3'
(SEQ ID NO: 6) * V = A or C or G; ** N = A or C or G
5 or T (primer includes all nucleotide variants for V and N)

Designation: APATR -- 23-mer

The PCR conditions used to generate porcine α -1,3-GalT cDNA fragments were as

10 follows:

- 1) For GTE2F + GTE9R and GTE4F + GTE9R: heat to 94°C (60 seconds); then proceed with 35 reiterations (cycles) of the following three steps: (1) 94°C, 40 seconds, (2) 57°C, 50 seconds, and (3) 72°C, 80 seconds.
- 15 2) For GTE9F + GT3UR: heat to 94°C (120 seconds); then proceed with 35 cycles of: (1) 94°C, 40 seconds, (2) 48°C, 45 seconds, and (3) 72°C, 60 seconds.

The PCR fragments were subcloned into EcoR1-restricted pBluescript II KS+ (Stratagene, Cat, # 2
20 12206) and the DNA sequence was determined using the chain termination method. The DNA sequence was assembled and analyzed using DNASIS-Mac v2.01 (Hitachi)

The nucleotide sequence of porcine α -1,3-GalT (SEQ ID NO: 7) and the derived amino acid sequence (SEQ
25 ID NO: 10) of the enzyme are shown in Figures 4 and 5. A single large open reading frame extends from the initiating methionine at nucleotide 91 to a stop codon located at nucleotide 1204. The sequence surrounding the putative initiating methionine conforms to the consensus
30 eukaryotic initiation sequence. Kozak, Cell 44, 283-92 (1986).

The porcine cDNA sequence is compared to the corresponding murine (SEQ ID NO: 9) and bovine (SEQ ID NO: 8) sequences in Figure 4. The locations of introns
35 within the murine gene are also shown. Joizazze et al., J. Biol. Chem 267: 5534 (1992). This alignment

demonstrates that exon 3, located within the 5' untranslated region of the mouse gene, is not found in either the porcine or bovine cDNAs. The overall sequence identities between the coding sequences are as follows:

5 a) pig compared to mouse:- 75.02% (exon 3 not considered)

 b) pig compared to bovine:- 85.15%

 The amino acid sequences of the porcine (SEQ ID NO: 10), murine (SEQ ID NO: 12) and bovine (SEQ ID NO: 11) α -1,3-GalT enzymes are depicted in Figure 5. The locations of introns are also shown, based on their positions within the mouse gene (Joziassse et al., 1992). This alignment illustrates that the overall amino acid homologies are:

15 a) pig compared to mouse: 71.98%

 b) pig compared to bovine: 82.87%

 c) bovine compared to mouse: 73.72%

EXAMPLE 7

Identification of Potential Sites to Interrupt the α -1-3-GalT Gene

20 The present inventors' choice of a site for interrupting the α -1,3-GalT gene has been influenced by several characteristics of the gene and its expression. In particular, several mRNAs for α -1,3-GalT have been detected in the mouse. Joziassse et al., J. Biol. Chem. 267: 5534 (1992). These mRNAs are products of alternative splicing events in which exons 5 and/or 6 may be deleted. Hence, these exons are not appropriate interruption sites in the mouse, since a transcript encoding a functional α -1,3-GalT enzyme presumably could be formed when exons 5 or 6 are spliced out. Moreover, the present inventors have isolated two different classes of α -1,3-GalT cDNA clones from the pig - one that includes exon 5 and one with exon 5 deleted. It is possible that mRNA's with and without exon 6 are also

formed by alternative splicing in the pig. Thus, for initial experiments the present inventors have not chosen these exons as sites for interruption.

Insertion of an interrupting-DNA fragment into
5 exon 4 (which encodes the cytoplasmic NH₂-terminal domain and the membrane-anchoring domain; see Figure 5) would disturb production of a transcript encoding an active α -1,3-GalT. Hence this exon is an appropriate site to disrupt the α -1,3-GalT gene. Similarly, exons 7 and 8,
10 which encode the NH₂-terminal region of the catalytic domain, are suitable disruption sites. Insertion of a interrupting DNA fragment within these exons would prevent the synthesis of an active catalytic domain.

A preferred site for interrupting the mouse gene
15 is located at a Sall site found within exon 9 of the mouse α -1,3-GalT gene, at codons 221 + 222 (see Figure 5). This site is positioned 150 amino acids from the COOH-terminus, within the catalytic domain. The mouse gene within the present inventors' constructs for
20 homologous recombination is interrupted at this Sall site. The amino acids encoded by nucleotides at this Sall site are conserved in the pig and bovine sequences, although the Sall site itself is not. Construction of a Sall site at this position in the pig gene (e.g., by in
25 vitro mutagenesis) provides a useful construct to inactivate the gene.

EXAMPLE 8

Choice of a DNA Fragment to Interrupt the α -1,3-GalT Gene

The present inventors have used both the neomycin
30 resistance (neo^R) gene and the hygromycin resistance gene (hyg^R) to interrupt the α -1,3-GalT gene. In one set of "knockout" constructs the neo^R and hyg^R genes are linked to the murine phosphoglycerate kinase (PGK) promoter (Adra et al., Gene 60: 65-74 (1987) and are both bordered

by polylinker sequences that include restriction sites for EcoRV and ClaI.

In another construct, expression of the neo^R gene is directed by an altered polyoma virus promoter (PMC1; Thomas and Cappechi, cell 51: 503-12 (1987)). In this construct the present inventors have addressed the problem of including an antibiotic resistance gene within the genome of transplant organs. That is, in some circumstances it may not be desirable to have genes conferring resistance to antibiotics present in the organ to be transplanted. The FLP/FRT recombinase system of yeast has been used to eliminate the neo^R gene from the sequence that interrupts the α -1,3-GalT gene.

In a construct of the present invention, the neo^R gene is bordered at both the 5' and 3' ends by FRT DNA elements. In addition, stop codons for each of three reading frames have been inserted 3' to the neo^R gene, and these stop codons, together with a single FRT sequence, will remain within the α -1,3-GalT gene after the neo^R gene has been excised by FLP. Targeted cells carrying a genomic copy of the neo gene flanked by direct repeats of the FRT could be supplied with FLP recombinase in two ways:

1) Introduction into cells of partially purified FLP protein:

FLP protein (0.1 - 10 μ g) is introduced ("transfected") into approximately 10^7 cells using standard electroporation conditions. The cells are plated out into gelatinized tissue culture dishes in appropriate medium, at a sufficient dilution to result in individual colonies. Approximately 200 of these colonies are then picked for further analysis.

2) Transfection with plasmids containing the FLP gene:

A plasmid containing the FLP gene under control of a promoter able to drive FLP expression, e.g., the human interferon-inducible 6-16 promoter, is constructed according to standard methods. Porter et al., EMBO J. 7: 85 (1988). Approximately 10 μ g of FLP expression plasmid is transfected into approximately 10^7 cells using standard electroporation conditions. With a plasmid containing the human 6-16 promoter, interferon is added at approximately 500 units/ml, in order to induce expression of FLP. The cells are then treated as in (1), above.

The procedure to knock out the α -1,3-GalT gene in ES cells using an FRT-containing construct is:

- a) electroporate the complete construct into ES cells
- b) select neo^R cells, and identify those ES cells having an interrupted α -1,3-GalT gene
- c) delete the neo^R gene using FLP recombinase, as described above; cells are tested for the excision event as follows:

First, samples of each selected cell line are tested for the absence of the neo^R gene by treatment with the chemical G418. The cells will die in the presence of approximately 200 μ g/ml G418 unless the neo^R gene is still present in the genome. Cell lines that are G418 sensitive are then tested further to confirm that excision of neo^R has occurred. This is done by Southern analysis or PCR analysis, both described in Sambrook et al. (1989). For Southern analysis, genomic DNA is isolated from the cells, digested with an appropriate restriction enzyme, subjected to agarose gel electrophoresis, and the digested DNA transferred to a membrane. The DNA is hybridized with a labeled probe, the label is detected (e.g., with X-ray film or color development), and the pattern of bands indicates whether

or not an excision event had occurred in the cell line. For PCR analysis, genomic DNA is isolated from the cells and subjected to PCR reaction with suitable oligonucleotide primers.

- 5 d) following confirmation of neo^R excision, the manipulated ES cells or PGC's are used to generate chimeric animals.

EXAMPLE 9

Preparation of DNA Constructs to Interrupt the α -1,3-GalT

10 Gene in Mice

Gene targeting (homologous recombination) is more efficient if the cloned cDNA fragments used for targeting are isolated from the cell line which is used for the gene knockout (i.e., the DNA is "isogeneic").

- 15 Accordingly, DNA was isolated from the E14 ES cell line (Hooper et al., Nature 326: 292-95 (1987)) and used to construct a mouse genomic library. The DNA was digested partially with the restriction enzyme Sau 3A, and fragments 12 kb - 20 kb in size were isolated by glycerol
20 gradient fractionation. The size-fractionated DNA was ligated into the Bam H1 site of λ EMBL3 (Sambrook et al. 1989, *supra*), and packaged *in vitro* to form lambda phage particles. The lambda library was plated by infection of E. coli strain PMC103 host cells (Doherty et al., Gene
25 124: 29-35 (1993)) at a density of 4×10^4 phage per plate. A bovine cDNA clone, about 900 bp in length and containing a portion of the α -1,3-GalT gene corresponding to exons 7 - 9, was used to probe a total of 5.6×10^5 independent recombinant phage. Four overlapping clones
30 containing α -1,3-GalT gene sequences were isolated and purified. The Sall restriction sites within these clones were mapped (Figure 6), and the 4.0kb, 5.5kb, 11kb and 12kb Sall fragments from two of the clones (λ 3 and λ 5) were subcloned into pBlueScript KS+ (Stratagene) or pUBS

(pUC19 carrying the pBlueScript KS+ polylinker) to facilitate further detailed mapping of restriction sites.

These four subclones (designated p α GT-S4.0, p α GT-S5.5, p α GT-S11 and p α GT-S13) were mapped for restriction sites with restriction enzymes BamHI, EcoRI, HindIII, XbaI, XhoI, KpnI, SacI, SacII, EcoRV, PstI, SmaI, NotI and BglII. p α GT-S4.0 and p α GT-S5.5 were also checked for PvuI, PvuII, NdeI and SphI restriction sites. Detailed restriction maps of the 4 subclones were drawn from these data (Figures 7-12).

On the basis of these maps a knockout strategy was conceived. Basically the strategy is to insert a resistance gene (either neo^R or hyg^R) into the SalI site which lies within Exon 9. The knockout construct carries the 4.0 and 5.5kb SalI fragments from p α GT-S4.0 and p α GT-S5.5 which flank the Exon 9 SalI site (Figure 13). Screening for homologous recombination events then can be carried out using a DNA fragment representing the genomic region but lying outside the DNA included in the knockout construct, i.e., outside the 9.5kb covered by p α GT-S4.0 and p α GT-S5.5. A 0.7kb EcoRI/XmnI fragment from p α GT-S11 is used to screen Southern blots of BglII digested ES cell DNA for homologous recombinant events. An 8.3kb band should appear on these Southern blots when the uninterrupted α 1,3-GalT gene is probed with this EcoRI/XmnI fragment (Figure 14). Insertion of the neo^R gene after a homologous recombination event will give rise to a 6.4kb band, due to the presence of a BglII site just flanking the Exon 9 SalI site within the knockout construct. Thus the presence of the 6.4kb band is diagnostic for a homologous recombination event.

To carry out this strategy, the present inventors prepared a series of knockout constructs. The generation of one such construct is outlined in detail in Figure 15. The vector p α GT-S5.5, which carries the 5.5kb fragment

immediately 3' to the Exon 9 SalI site, was chosen as the starting vector. p α GT-S5.5 was digested with EcoRV and ClaI, generating a vector with a blunt end and a ClaI compatible end. A 1.3kb fragment carrying the PMC1 promoter-driven neo^R gene flanked by FRT sites was excised from plasmid pNeo2FRT (previously constructed by the present inventors) by digesting with BamHI, filling in the restriction site and then digesting with ClaI to generate a fragment with one blunt end and one ClaI compatible end. The nucleotide sequence of this 1.3kb fragment is provided in Figure 16 (SEQ ID NO: 13). This fragment was then ligated into the ClaI/EcoRV digested p α GT-S5.5, the ligation mix transformed and colonies screened for recombinants. One colony was recovered that contained the Neo^R fragment inserted into the EcoRV/ClaI of p α GT-S5.5, based on the restriction pattern after digestion with diagnostic restriction enzymes ClaI, EcoRV, XbaI and EcoRI. This construct was designated PNeo α GT6.8.

pNeo α GT6.8 was digested with SmaI, generating a vector with blunt ends. The 4.0kb SalI fragment was excised from p α GT-S4.0 and the ends filled. This fragment was then ligated into the SmaI digested p α GT-S5.5, the ligation mix transformed and colonies screened for recombinants. Four colonies were recovered which contained the 4.0kb SalI fragment inserted into the SmaI sites of pNeo α GT6.8 with the 5' portion of Exon 9 lying near the 3' portion of the exon in the nearby SalI 5.5kb fragment. The identity and orientation of the insert was confirmed by the restriction pattern after digestion with diagnostic restriction enzymes XbaI, EcoRI, HindIII, BamHI, EcoRV and others. This construct was designated pNeo α GT10.8.

pNeo α GT10.8 was digested with ClaI, generating a vector with ClaI compatible ends. Two complementary

oligomers were synthesized that, when annealed, generated a linker containing translation termination codons in all three reading frames and a BglII site. The linker has ClaI compatible ends. The linker was ligated into the
5 ClaI digested pNeoαGT10.8, the ligation mix transformed and colonies screened for recombinants. Many colonies were recovered that contained the linker inserted into the ClaI sites within pNeoαGT10.8 based on the restriction pattern after digestion with diagnostic
10 restriction enzymes BglII, Cla and BglII/NotI. This construct has been sequenced to confirm the identity, copy number and orientation of the insert. This construct is called pNeoαGT10.8B (Figure 17).

EXAMPLE 10

15 ES Cells - General Materials and Methods Working Conditions

Procedures for the isolation and culturing of all cell lines (embryonic stem, primordial germ and fetal fibroblast cell lines) require aseptic conditions to
20 prevent growth of contaminating organisms:

1. All laboratory bench tops and equipment are wiped down with 70% ethanol prior to use.
2. All surgical instruments are autoclaved prior to use.
- 25 3. Water for media preparation and cleaning of glassware is of high quality (e.g., Milli-Q water, prepared by passage through a Milli-Q ultrapure water system (Millipore)).
4. Glassware is either dry-heat sterilized or
30 autoclaved following extensive cleaning in Milli-Q water before use.
5. All tissue culture work is carried out under laminar flow conditions (Hepa filtered horizontal laminar flow workstation).

6. All media are filter sterilized (22 μ m disposable filter) prior to use.

7. Antibiotics are used to minimize the risk of bacterial contamination (Penicillin, Streptomycin and Gentamicin for bacteria; Nystatin for fungi).

Media/Solution Preparation

DULBECCOS MODIFIED EAGLE MEDIUM (DMEM)

10.0g DMEM powder- Gibco (the low-glucose or high-glucose formulation, with or without pyruvate, may be used; L-glutamine is included)
1.0 liter Milli-Q-Water
3.7g NaHCO₃
Stir slowly until dissolved
15 Adjust pH ~ 7.2
Filter sterilize (following filter sterilization pH rises to 7.4)
Keep at 4°C.

STO CELL MEDIUM

20 83.0 ml DMEM
15.0 ml 15% fetal bovine serum (FBS); batch tested before use
1.0 ml Pen/Strep 1:100
1.0 ml Glutamine 1:100 (if needed) (see note below)
25 Filter sterilize and keep at 4°C.

Note: Replenish complete medium (DMEM medium) (STO or ES) with glutamine.

*This step is only required if medium is older than 1 week - 10 days, as the glutamine breaks down after this time.

ES CELL MEDIUM WITH OR WITHOUT LIF

up to 100.0 ml DMEM
15.0 ml 15% FBS (batch tested before use; see below)
35 1.0 ml (from 0.01M stock) β -mercaptoethanol (0.1 mM final concentration)
1.0 ml Pen Strep. 1:100
0 - 1.0 ml Glutamine 1:100 (if needed)
1.0 ml Nystatin 1:100

- 0 - 2.5 ml Recombinant murine LIF (from 4×10^4
U/ml; 1000U/ml stock); activity-tested
using LIF Assay (see below)
0.4 ml Gentamicin
5 1.0 ml Nucleotides
1.0 ml Non-essential amino acids

PENICILLIN/STREPTOMYCIN ANTIBIOTIC SOLUTION (1:100)
- Commonwealth Serum Laboratories, Australia;
Catalogue No. 05081901

- 10 Penicillin G - 5000 U/ml
Streptomycin Sulphate - 5000 μ g/ml.

MITOMYCIN-C SOLUTION

- 2.0 mg Mitomycin-C (Sigma Chemical Co. ("Sigma"));
Catalogue No. M0503)
15 200.0 ml STO Cell Medium

Filter sterilize, divide into 20x 10 ml aliquot's and
store at -20°C .

PHOSPHATE BUFFERED SALINE (PBS)

- For 100 ml Milli-Q Water: (Ca^{++} and Mg^{++} - containing)
20 (Ca^{++} and Mg^{++} - free)
NaCl 0.89 0.80
KCl 0.02 0.02
KH₂PO₄ 0.02 0.02
Na₂HPO₄ 12H₂O 0.289 1.115
25 CaCl₂ - 2H₂O 0.014 -
MgCl₂ - 6H₂O 0.01 -
Na pyruvate 0.0036 -
D-glucose 0.1 g -

- Adjust to pH 7.4 and filter sterilize
30 (Ca^{++} and Mg^{++} - free PBS is purchased from ICN Cell
Biology and Tissue Culture, Cat. No. 18-604-54)

TRYPSIN/VERSENE (TV) WORKING SOLUTION (TV x 1)

- In PBS (Ca^{++} and Mg^{++} - free):
0.25% (w/v) trypsin (lyophilized)
35 0.04% (w/v) EDTA or EGTA

or:

To 1 liter of milli-Q water add the following:

	Trypsin powder (Porcine, Difco)	2.5 g
	EDTA or EGTA	0.4 g
	NaCl	7.0 g
5	Na ₂ HPO ₄ ·12H ₂ O	0.3 g
	KH ₂ PO ₄	0.24 g
	KCl	0.37 g
	D-Glucose	1.0 g
	Tris	3.0 g
10	Phenol red	1.0 ml

Adjust to pH 7.6, filter sterilize, aliquot and store frozen.

EGTA: Ethylene-glycol-bis(β -amino-ethyl ether)N,N,N',N'-
-tetra-acetic acid [Ethylene-bis(oxy-
15 ethylenenitrilo)]tetraacetic acid

EDTA: Ethylenediaminetetraacetic Acid

Use either EDTA or EGTA. EGTA is preferred as it is less damaging to the ES/PGC cells.

GELATIN WORKING SOLUTION

20 0.1% gelatin in Milli-Q Water

Dissolve gelatin by heating to 60°C.
Filter sterilize when still warm.

To gelatinize tissue culture plates:

1. Cover dish with solution, leave 30 minutes
- 25 2. Aspirate gelatin and let dish air-dry.

NUCLEOSIDE STOCK SOLUTION

	Milli-Q Water	100 ml
	Adenosine (Sigma)	80 mg
	Guanosine (Sigma)	85 mg
30	Cytidine (Sigma)	73 mg
	Uridine (Sigma)	73 mg
	Thymidine (Sigma)	24 mg

1. Dissolve by warming to 37°C.
2. Filter sterilize and aliquot while warm.
- 35 3. Store at 4°C or -20°C.

0054900-1244

4. Thawing of nucleotides for use in ES cell media
 - (a) nucleotides come out of solution upon thawing;
 - (b) Warm to 37°C to resolubilize before use.

5 NON-ESSENTIAL AMINO ACIDS (1:100)

- Commonwealth Serum Laboratories; Catalogue No. 09751301

100x concentrate for minimum essential medium (Eagle):
(1.0 ml is added to 100 ml ES Cell Medium)

mg/10 ml milli-Q H₂O

10	Glycine	7.5
	L-Alanine	8.9
	L-Asparagine · H ₂ O	15.0
	L-Aspartic Acid	13.3
	L-Glutamic Acid	14.7
15	L-Proline	11.5
	L-Serine	10.5

WHITTEN'S CULTURE MEDIUM

	KCl	0.0356
	KH ₂ PO ₄	0.0162
20	MgSO ₄ · 7H ₂ O	0.0294
	NaCl	0.4
	NaHCO ₃	0.2106
	Glucose	0.1
	Na Pyruvate	0.0036
25	Ca Lactate 5H ₂ O	0.0527
	Na Lactate	0.2416 ml
	Milli-Q-H ₂ O	100 ml

The solution is adjusted to a final milliosmolarity of 250-280 by addition of H₂O or NaCl.

- 30 Filter sterilize and store at 4°C for two weeks.

Working solution:

10 ml	Whitten's medium
1.5g	BSA fraction V (Miles Pentex,
Diagnostic division,	Kankakee, Il., USA;
35 Code No. 81-001-4)	

Filter Sterilize and equilibrate in 5%O₂:5%CO₂:90% N₂ at 39.5°C, 95% humidity.

FBS BATCH TRIALS

Batches of FBS vary in the ability to support growth of ES cells, and in the ability to maintain the undifferentiated state of such cells. The following procedure is used to identify suitable batches of FBS. Use ES cells from between 2 & 20 passages:

Day 1

Split ES colonies and plate into dishes without feeder cells but with LIF. Incubate for 3 days.

Day 4 Trypsinise to detach colonies and cells. Count cells and dispense into gelatinized 6cm dishes containing ES Cell Medium and LIF (no serum added) as follows:

Dish Number		No. Cells	Batch FBS		Control Serum (Batch Tested)
Non-Inactivated Serum			A	B	
20	1	2	250	5 ml	-
	3	4	250	-	5 ml
	5	6	250	-	5 ml
	7	8	2000	5 ml	-
	9	10	2000	-	5 ml
25	11	12	2000	-	5 ml
Inactivated Serum, as control (56°C for 15 min.)					
	13	14	250	5 ml	-
	15	16	250	-	5 ml
30	17	18	250	-	5 ml
	19	20	2000	5 ml	-
	21	22	2000	-	5 ml
	23	24	2000	-	5 ml

There are duplicate plates for each treatment.

Incubate low density dishes for 5 days
Incubate high density dishes for 3 days

Day 7 Fix high density cells and stain with hematoxylin.

Day 9 Fix low density cells and stain for alkaline phosphatase.

LIF ASSAY

This procedure is used to assay the potency of Leukaemic Inhibitory Factor (LIF).

- 5 Day 1 Split one 10 cm dish of confluent STO cells into five dishes. Incubate for 2 - 3 days in STO medium.
- Day 3/4 When cells are confluent, replace medium with DMEM + 10% FBS. Incubate for 3 days.
- 10 Day 6/7 Collect conditioned medium (CM) and store at 4°C.

*Prepare low density ES cell cultures as described above.

Dish	No. Cells	C.M.	Medium	1000 U/ml LIF	Medium w/o LIF	Presumed LIF Content
15	1,2,3	250	0.1 ml	4.9 ml	-	200 U/ml
	4,5,6	250	0.25 ml	4.75 ml	-	500 U/ml
	7,8,9	250	0.5 ml	4.5 ml	-	1000 U/ml
	10,11,12	250	1.0 ml	4.0 ml	-	2000 U/ml
	13,14,15	250	-	-	5 ml	-
20	16,17,18	250	-	-	-	5 ml

There are triplicate plates for each treatment.

Fix and stain for alkaline phosphatase.

Preparation of Fibroblast Feeder Cell Layers

- 25 Embryonic pluripotential cells are cultured in vitro on a layer of fetal fibroblast cells. The fibroblast cells provide a wide range of factors necessary for the growth of pluripotential embryonic cells (e.g. growth factors, cytokines, factors that are essential for maintenance of ES cell pluripotency).

30 ISOLATION OF PORCINE FETAL FIBROBLASTS:

1. Remove developing porcine fetuses (preferably between days 16-30 of development) from uterus by aseptic dissection.
2. Remove skin layer from fetus.

3. Dissect out soft tissue avoiding developing viscera. The white (fibroblast containing) tissue is found just under the skin layer.
4. Wash dissected tissue in PBS (Ca^{++} and Mg^{++} free).
- 5 Centrifuge at 1000 rpm for 5 min.
5. Remove supernatant.
6. Incubate tissue in Trypsin/Versene Working Solution for 20 min.
7. Dissociate cells by vigorously pipetting.
- 10 Centrifuge at 1000 rpm for 5 min.
8. Remove supernatant.
9. Resuspend cells in STO Cell Medium. Allow large cell-clumps to settle.
10. Plate out cells within supernatant (i.e., large cell clumps are not included) onto gelatinized tissue culture plates. Incubate cells in an atmosphere of 5% CO_2 , 95% air (37.5°C, 95% humidity) until a confluent layer of fibroblast cells appears (~4-5 days).
- 15
- 20 11. Passage of cells may be continued to increase cell numbers, or cells may be frozen or inactivated for further use.

CULTURE OF FETAL FIBROBLAST FEEDER LAYERS FROM FROZEN STOCKS:

- 25 Several different types of mouse feeder (STO cells) and porcine and bovine fetal fibroblasts can be used to form feeder layers. These include:
- 30 (1) Bradley/Baylor mouse STO feeder cells that have been modified to express human LIF (gift from Allan Bradley, Institute for Molecular Genetics, Baylor College of Medicine, Texas Medical Center, Houston, Texas, USA)
 - (2) Robertson/Columbia mouse STO feeder cells that have been modified to express murine LIF (gift from Elizabeth Robertson, Columbia University, New York, USA)
 - 35 (3) Several porcine fetal fibroblast lines
 - (4) Several bovine fetal fibroblast lines

(the fibroblast lines of (3) and (4) were derived by the present inventors using the procedures described above)

The procedure for producing feeder layers is as follows:

- 5 1. Rinse one 10 cm tissue culture (tissue cure) dish with gelatin/Milli-Q water solution for 30 min. Aspirate gelatin solution and let dish air-dry.
3. Add 10 ml of STO cell medium to 15 ml centrifuge tube.
- 10 4. Remove feeder layer cells frozen in freezing media from liquid N₂ container.
5. Thaw cells by warming vial in hands or in 37°C water bath.
6. Transfer STO cells to medium in centrifuge tube.
- 15 7. Spin at 1000 rpm for 5 min.
8. Resuspend cells in 10 ml medium and transfer to gelatin-treated tissue culture dish.
9. Incubate at 37°C for 3 days.

SPLITTING OF FEEDER LAYER STO CELL/FETAL FIBROBLASTS:

- 20 This procedure is used to expand the number of cells from a single confluent plate/dish; cells are detached from the confluent plate and transferred to fresh plates at sub-confluent densities.
1. Gelatinize five 10 cm tissue culture dishes.
 - 25 2. Examine incubated STO cells under microscope and check for confluence.
 3. If STO feeder monolayer is confluent (cells cover bottom of dish, or nearly so), wash gently with PBS (Ca⁺⁺ and Mg⁺⁺ - free) for 1 min.
 - 30 4. Aspirate PBS and add 1 ml Trypsin/Versene Working Solution for 1 min (or until cells start to detach). Check under microscope.
 5. Detach cells by vigorously pipetting, add 1.0 ml STO Cell medium (i.e., a ratio of 1:1 STO Cell

- medium:Trypsin/Versene Working Solution) to neutralize trypsin, and transfer to a centrifuge tube containing 10-15 ml STO Cell medium. Wash cells remaining on dish with some of STO cell medium from the tube. Centrifuge at 1000 rpm for 5 min., aspirate supernatant, resuspend pellet in 1 ml STO Cell medium. Resuspend cells to make single cell suspension. Make up to 50 ml with STO Cell medium.
- 5
6. Dispense 10 ml into each of the five tissue culture dishes and incubate until confluent (~ 3 days).
- 10

INACTIVATION OF FEEDER LAYERS:

The present inventors use two alternative methods for inactivating feeder layers, which stops the cells from dividing:

15 (1) Mitomycin treatment:

1. Check dishes for confluence of STO cells/fetal fibroblasts.
2. Thaw mitomycin-C solution and use undiluted.
3. Aspirate STO cell medium from feeder cell plate.
- 20 4. Add 10 ml aliquot of mitomycin-C to plate and incubate at 37°C for 1-3 hours.
5. Aspirate mitomycin-C, wash cells in 1x PBS (without Ca^{++} or Mg^{++}) for 1 min.
6. Aspirate PBS and add 1 ml trypsin solution for 1 min.
- 25 7. Detach cells by vigorously pipetting and transfer to STO cell medium in centrifuge tube.
8. Centrifuge at 1000rpm for 5 min.
9. Resuspend cell pellet in 1 ml ES Cell Medium.
- 30 10. Plate out in dishes in preparation for addition of ES cells.

(2) Gamma Irradiation:

1. Check dishes for confluence of STO cells/fetal fibroblast.

2. Trypsinise cells into single cell suspension.
3. Irradiate cells (3000 rads) in STO cell medium.
4. Centrifuge at 1000 rpm for 5 min.
5. Resuspend pellet in 1 ml ES Cell Medium.
- 5 6. Transfer cells to gelatinized tissue culture dishes with ES Cell Medium and place in incubator at 37°C until the cells adhere to the dish. NOTE: If cells are not confluent, count using hemocytometer and seed at 5×10^4 cells in 10 1 ml medium per well of Nunc 4-well plate. One 10 cm dish of inactivated cells can be split into:
Ten 4-well plates (Nunc tissue culture plates),
or Eight 3.5 cm tissue culture dishes, or
15 Three 6 cm tissue culture dishes, or
Two 20 cm tissue culture dishes.

Demonstration of Totipotency

A. Blastocyst Injection

The ability of embryonic cell lines to form germline
20 chimeric animals is a conclusive test for their totipotency. This can be accomplished by blastocyst injection experiments, using techniques for various mammalian species substantially the same as those established for the mouse. See Example 14, below. See
25 also, e.g., Bradley, Production and Analysis of Chimeric Mice, In: Teratocarcinomas and Embryonic Stem Cells: A Practical Approach (E.J. Robertson, ed.), IRL Press, Oxford, pp. 113-52 (1987). However, for porcine manipulations the holding pipette must be somewhat larger
30 as porcine embryos are larger than mouse embryos.

B. Co-Culture of ES Cells/PGC's and Morula Embryos

Embryos at the morula stage of development are surgically collected from superovulated animals. For

porcine embryos, for example, the zona pellucida is then disrupted using Acid Tyrodes solution and ES cells/PGC's are cultured in the presence of the zona pellucida-disrupted morulae. ES/PGC cells adhere to the exposed
5 morula cells and, following overnight culture in Whitten's medium, the embryos are transferred to synchronized recipients. Preferably, the zona pellucida-disrupted morula is completely free of the zona pellucida. However, this need not be the case as long as
10 the ES cells/PGC's can gain direct access to at least some of the morula cells.

C. Morula Injection

ES cells and PGC's can be injected into a morula embryo prior to formation of the blastocyst cavity. The
15 technique is similar to blastocyst injection. ES cells or PGC's are drawn into an injection pipette, which is inserted beneath the zona pellucida. Then, the cells are expelled so that they are in contact with the cells of the morula embryo. The injected morula is then cultured
20 overnight in Whitten's medium (porcine) or other appropriate medium to allow blastocyst formation.

D. Nuclear Transfer and Embryo Cloning

ES cells and PGC's can be fused to enucleated zygotes that have been derived by in vitro maturation, in
25 vitro culture, in vitro fertilization or collected surgically. Following successful fusion the embryos can be transferred to synchronized recipients. *In vitro* or *in vivo*-collected porcine oocytes, for example, are manipulated in Whitten's medium supplemented with 1.5%
30 BSA Fraction V and 7 μ g/ml cytochalasin B (Sigma). A bevelled micropipette is used to remove the metaphase plate from the oocyte. A single ES cell or PGC (after trypsin treatment to form a single-cell suspension) is

inserted through the zona using a bevelled micropipette, such that the cell comes in contact with the oocyte plasma membrane. Fusion is achieved in a 28 V/cm AC field for 5 sec. followed by an 80 V/cm DC pulse of 100 μ sec. duration. Subsequent to observed fusion, embryos are incubated at 39° C in 5% CO₂, 5% O₂, 90% N₂ in microdrops of Whitten's medium supplemented with 1.5% BSA, until transfer to a synchronized recipient.

EXAMPLE 11

10 Murine ES Cell Culture

ES cells are able to differentiate spontaneously into many different cell types, and culture conditions which prevent this differentiation are critical for the continuous passage of these cells in an undifferentiated form, capable of contribution to chimeric mice.

I. CULTURE CONDITIONS

ES cells are grown in polystyrene cell culture dishes treated with 0.1% gelatin (made up in PBS or Milli-Q water) for 10 minutes. A feeder layer of mitotically inactivated fibroblasts provides a source of cytokines. The fibroblasts are either primary mouse embryo fibroblasts (PMEFs), or STO fibroblasts, an immortal line. The medium used is DMEM supplemented with glucose, amino acids and nucleosides. Robertson, Embryo-Derived Stem Cell Lines. In: Teratocarcinomas and Embryonic Stem Cells: A Practical Approach (E.J. Robertson, ed.), IRL Press, Oxford (1987). To this medium is added LIF (final concentration of 10³U/ml Esgro, AMRAD). FBS is added to 15%. The batch of FBS is chosen on the basis of its ability to support ES cell growth with low levels of differentiation (i.e, only rare individual cells undergo differentiation. The ES cells are grown in an atmosphere of 5-10% CO₂, at 37°C

II. ROUTINE PASSAGE

ES cells must be passaged frequently to prevent the colonies from growing too large and differentiating. This is achieved by splitting the cells at a ratio of 1:10 to 1:40, every two to four days.

5

EXAMPLE 12

Genetic Manipulation of Cells

The general procedures set out in this Example provide guidelines that are readily adaptable to individual experimental situations that might employ, for example, different cell lines or equipment supplied by different manufacturers. This Example also provides specific procedures used and results obtained in generating a set of mouse ES cell lines in which the α 1-3 galactosyltransferase gene was disrupted by homologous recombination. The general procedures provided in this Example are adapted for mouse ES cells. However, the procedures are substantially similar for porcine ES cells.

I. INTRODUCTION OF DNA INTO ES CELLS BY ELECTROPORATION

20 A. Coat required number of plates with 0.1% gelatin (in PBS or Milli-Q water). (Usually 2 X 6 well plates and 8 well plate)

B. Thaw 10^7 embryonic fibroblasts into DMEES (equivalent to ES Cell Medium); inactivate by irradiating
25 at 3000 Rad.

C. Count irradiated cells, spin down and resuspend in DMEES to 10^6 cells/ml.

D. Aspirate gelatin from plates and plate cells at: 7×10^5 cells/well (6 well plate) in 2.5ml medium; 7
30 $\times 10^4$ cells/well (24 well plate) in 1 ml medium.
Incubate at 37°C, 5-10% CO₂ for 3 - 4 hr.

E. Wash ES cells in 5 ml (250 ml flask) PBS-EGTA and let sit at room temperature for 4 min.

F. Remove PBS, add 5 ml trypsin (CSL) and leave at room temperature for 2 - 4 min. Wash down cells, add 10 ml DMEES and count. Approximately 5×10^6 to 2×10^7 ES cells are needed for experiments.

5 G. Centrifuge cells and resuspend in 10 ml PBS. Centrifuge again and resuspend in 540 μ l PBS. Dilute 50 μ l into 10 ml DMEES and culture to determine plating efficiency.

H. Add 5 - 10 μ g DNA to cells in 10 μ l PBS (total 10 volume, 500 μ l) and transfer to sterile electroporation cuvette (e.g. Biorad).

I. Electroporate at 0.22 kV, 500 μ FD (time constant should be ~ 8.4). This is achieved using a Biorad Gene Pulser unit (Biorad Catalogue No. 1652078) 15 with capacitance extender (Biorad Catalogue No. 1652087), or similar device.

J. Resuspend in 10 ml DMEES with constant pipetting to break up clumps of DNA from lysed cells.

K. Centrifuge cells and resuspend in 5ml DMEES.

20 L. Take 50 μ l, add 50 μ l trypan blue solution and count for viability.

M. Culture by dilution plating to determine plating efficiency.

II. SELECTION CONDITIONS

25 ES cells that do not express a neomycin resistance gene are selectively killed by treatment with G418 at 200-500 μ g per ml of medium. Antibiotic-containing medium is changed daily. A population of cells that has not been electroporated also is treated in order to see 30 how genuinely sensitive cells respond to the G418 treatment. After 6 to 10 days, cells resistant to the antibiotic will be evident as healthy colonies. These cells will have been transformed by the targeting construct and can be screened for homologous

recombination (i.e., screened for gene targeting versus random integration).

Resistant colonies are picked from the selection dish with a mouth pipette and dispersed into a single cell suspension. Half of these cells are frozen away while the other half is expanded and used to determine whether or not homologous recombination has occurred. If the colonies are small, it is sometimes preferable to expand the whole colony in a 24 well dish, and then to freeze half while further expanding the other half for genetic analysis.

III. PICKING ES CELL COLONIES FOR GENETIC ANALYSIS AFTER SELECTION

A. Method 1: Freezing Half Colonies

- 15 1. The day before colony picking:
 - 20 a) Coat required number of plates with 0.1% gelatin (in PBS). Two plates per 24 colonies to be picked: one plate is for freezing and one plate is for clone expansion. Start with 20 X 24 well plates.
 - 25 b) Count irradiated fibroblasts, spin down and resuspend in DMEES.
 - 25 c) Aspirate gelatin from 10 plates and plate $\sim 10^5$ (can use as few as 5×10^4) cells/well in 1ml DMEES. Incubate at 37°C , 10% CO_2 overnight (or a minimum of 1 h).
 - 30 d) Aspirate the gelatin from the other 10 plates.
2. On the day of colony picking:
 - 35 a) Change medium on ES cells before and regularly during picking (to remove floating cells).
 - 35 b) Pull plugged pasteur pipettes. Use a fresh pipette after each 24 colonies. The desired tip is about half a colony in diameter, with the constriction over 1-2cm. The tip

should be perpendicular and neat.
Note: after drawing the pipette, rub the glass at the desired break point with freshly drawn glass, then bend.)

- 5 c) Label multi-tip reservoirs for:
1 PBS-EGTA
2 Trypsin-Versene
3 DMEES
10 4 2 X Freezing mix(20% DMSO in FCS)
- d) Using multipipettor, dispense 50 μ l PBS-EGTA into 24 wells of 96 well plate.
- 15 e) At microscope: Connect finely drawn pasteur pipette to mouth pipette tube. Dislodge colony from plate and transfer (in minimum volume) to one well of a 96 well plate. Expel contents of pipette; the bubbles
20 serve as a location guide. Pick 24 colonies or as many as possible in <10-15 min (preferably a multiple of 6).
- 25 f) Back in hood: Add 100 μ l trypsin to each well using multipipettor) and leave at RT for 2 min.
- 30 g) Pipette up and down 10- 15X to disperse cells, then add 100 μ l DMEES. (This should be done within 4-6 min after trypsin addition).
- 35 i) Divide cell suspension between freezing and expansion plates using 12 channel pipette with every second tip fitted. Transfer 125 μ l to gelatinized 24 well plate (to freeze); the remaining ~125 μ l is transferred to a 24 well plate with feeder layer (for DNA). The plates are labelled and carefully aligned to
40 ensure that one clone goes into the same well of each tray.
- j) Add 125 μ l 2 X freeze mix to each well on freezing plate, mix well by swirling.

- 5
- k) Seal in ziplock bag or plastic wrap and place in -70°C freezer in an equilibrated styrofoam box. Interleave the plates with styrofoam sheet.
 - l) Incubate expansion plates until there are sufficient cells for genotype analysis.

10 A. Method 2: Freezing after expansion to 24 wells.

1. The day before colony picking:

- 15
- a) Coat required number of plates with 0.1% gelatin (in PBS). Start with 10 X 24 well plates.
 - b) Count irradiated fibroblasts, spin down and resuspend in DMEES.
 - c) Aspirate gelatin from the plates and plate $\sim 10^5$ cells/well in 1ml DMEES. Incubate at 37°C, 10% CO₂ overnight (or a minimum of 1 h).
- 20

2. On the day of colony picking:

- 25
- a) Pick colonies as described for half colonies (method 1, above) but instead of dividing the cell suspension between freezing and expansion plates, the entire cell suspension goes into the expansion plate.
 - b) After 3-4 days (with daily medium changes) the cells will have grown sufficiently to be frozen. Working one plate at a time (with practice two can be handled), aspirate medium from each well. Flood with PBS/EGTA for 4 minutes. Meanwhile, set up pipette tips to fit alternate channels of a twelve channel multipipettor. Aspirate PBS.
 - c) Add 100 μ l trypsin (using multipipettor and alternate channels) and leave at room temp. for 2 min.
- 30
- 35
- 40

- 5 d) Pipette up and down 10- 15X to disperse cells of first row, change tips, then add 100 μ l DMEES. Repeat for each row. (This should be done within 6 min of trypsin addition).
- 10 e) Using 12 channel pipette with every second tip fitted, transfer 125 μ l to gelatinized 24 well plate (to freeze). The remaining cells will be expanded for DNA. It is crucial that the plates are labelled and carefully aligned to ensure that the freezing tray matches the expansion tray.
- 15 f) Add 125 μ l 2 X freeze mix to each well on freezing plate; mix well by swirling.
- 20 g) Seal in ziplock bag or plastic wrap and place in -70°C freezer in an equilibrated styrofoam box. Interleave plates with styrofoam sheets.
- 25 h) Add 1ml of DMEES to the expansion tray. (There will be sufficient feeder cells to give good plating efficiency). Incubate for 3-4 days until there are sufficient cells for genotype analysis.

IV. THAWING OF ES CELL CLONES FROZEN IN 24-WELL PLATES

Cells that have been identified to have the desired genetic alteration are recovered from a duplicate plate frozen at -70°C. The plate is taken to the laminar flow hood and removed from the plastic bag. Each well is filled with warm medium, and feeder cells are added to the well(s) of interest. The plate is placed in a 37°C incubator for 60 min., then the medium is replaced. Colonies will appear after two or three days. These colonies are expanded for establishment of new frozen stocks, and tested for 1) karyotype analysis; 2) confirmation of the desired genetic alteration; 3) mycoplasma infection; and 4) ability to form chimeras.

EXAMPLE 13

Production Of Mouse ES Cell Knockouts Using
The pNEO α GT10.8B Construct

I. TRANSFORMATION

5 A total of 1×10^7 E14 ES cells was electroporated with $5 \mu\text{l}$ of $1 \mu\text{g}/\mu\text{l}$ pNeo α GT10.8B DNA (linearized by XhoI digestion) (see Example 9 and Figure 17). Electroporation was carried out in $600 \mu\text{l}$ in a wide cuvette at $25 \mu\text{F}$, 350V for 0.5msec . Cells were recovered in 6ml ES complete
10 medium and plated into 6 x 100mm petri dishes, each containing a feeder layer of Neo^R STO cells.

Cells were cultured in ES complete medium for 3 days and then medium containing $200\text{--}350 \mu\text{g}/\text{ml}$ G418 was substituted. This medium was changed every second day.
15 After 9 days, individual Neo^R colonies were sufficiently large to be identified and recovered. Colonies were picked in $20 \mu\text{l}$ PBS and $20 \mu\text{l}$ of trypsin solution were added. Forty μl of 60% BRL conditioned medium in ES complete medium were then added. Aliquots of $40 \mu\text{l}$ were
20 transferred to single wells of each of two 24-well plates. One plate contained a feeder layer of STO cells in $100 \mu\text{l}$ ES complete medium. $140 \mu\text{l}$ of 2x DMSO freezing mix was added to this plate, which was stored at -80°C . Each of the wells of the second 24-well plate contained
25 1ml of 60% BRL conditioned medium in ES complete medium. This plate was incubated at 37°C until the colonies were confluent.

II. CONFIRMATION OF HOMOLOGOUS RECOMBINATION

Medium was aspirated off confluent colonies and
30 $400 \mu\text{l}$ lysis buffer (10mM Tris pH 7.8, 100mM NaCl, 1mM EDTA, 1% SDS, and $500 \mu\text{g}/\text{ml}$ Proteinase K) added. The cells were lysed at 37°C overnight, extracted with $400 \mu\text{l}$ 1:1 phenol/chloroform and transferred to Eppendorf tubes containing 1ml 95% ethanol and 0.2M NaAc. DNA was

pelleted by centrifuging at 13,000 rpm in an Eppendorf centrifuge, the pellet washed twice with 80% ethanol and redissolved in 30 μ l water.

Southern analysis (see, e.g., Sambrook et al.,
5 supra) was used to identify ES cell clones where homologous recombination had occurred at the 3' end of the construct. Aliquots of 15 μ l of DNA were digested with 20 units of the restriction enzyme BglII according to the manufacturer's recommendations. After incubation
10 at 37°C overnight, the DNA was electrophoresed through a 0.8% agarose gel (in a Tris acetate, EDTA buffer) at 1-2V/cm overnight, using 750ng of HindIII-digested lambda DNA as markers. The DNA was transferred to a Zetaprobe nylon membrane using a Hybaid vacublotter at a vacuum of
15 80cm Hg for 1 hour.

The membrane was prehybridised in a Hybaid hybridization bottle in 10ml of the following hybridization mix for 3 hours at 65°C:

20 0.25M Na₂HPO₄ pH 7.2
 7% SDS
 1mM EDTA
 100 μ g/ml salmon sperm DNA
 10% PEG

Radioactively labeled probe DNA was prepared using a
25 BRESATEC gigaprime oligo labeling kit (Cat. No. GPK-1) according to the manufacturer's recommendations. Approximately 50ng of a 0.7kb EcoRI/XmnI DNA fragment from beyond the 3' terminus of the construct pNeo α GT10.8B (see Example 9 and Figure 17) were labeled with ³²P-dATP
30 to a specific activity of 5x10⁸ cpm/ μ g. The denatured probe was added to the prehybridising membrane in the Hybaid bottle and incubated overnight at 65°C.

The membrane was removed from the Hybaid bottle, rinsed with 0.5xSSC, 0.1% SDS prewarmed to 65°C, and then
35 washed 2-3 times with 0.1xSSC, 0.1% SDS at 65°C for 30 min each wash. Excess moisture was then blotted from the

membrane, the membrane wrapped in plastic wrap and exposed to a phospho-imager screen for 16 hours up to 3 days. The image was visualized on an Imagequant phospho-imager.

5 Results are shown in Figure 18, which is a Southern blot of DNA from 15 ES cell lines probed with the diagnostic 0.7kb EcoRI/XmnI DNA fragment described above and in Example 9. The 6.4kb band, diagnostic for a homologous recombination event in the α 1-3
10 galactosyltransferase gene (α 1-3 Gal T) (see Example 9), is seen in 6 of the 15 ES cell lines examined. All of the 6 knockout cell lines appeared to be heterozygous for the inactivated allele since the 8.3kb band, diagnostic for the uninterrupted α -1,3-Gal T gene (see Example 9),
15 was also present in all six lanes.

Two cell lines, designated hereinafter "8D1" and "7C2," were chosen for further analysis. Cell lines 8D1 and 7C2 were identified by Southern analysis to contain an α -1,3-Gal T allele where homologous recombination had
20 occurred at the 3' boundary of the construct.

Long range PCR was then used to determine whether or not homologous recombination had occurred at the 5' boundary of the construct within these cell lines. Two sets of primers were used in separate PCR experiments:

25 1) Wild-type primers:-

MGT-KOex8F and MGT-KOR1 span the intron between exons 8 & 9, and amplify a 5.5 kb fragment from the wild-type α -1,3-GalT gene (Figure 19)

SEQUENCES:

30 MGT-KOex8F

5'TGCTGGAAAAGTACTACGCCACACAGAAACTCA-3'

(SEQ ID NO: 14)

(Nucleotides 1014-1046 in Figure 4)

MGT-KOR1

35 5'AGCCAGAGTAATAGTGTCAAGTTTCCATCACAA-3'

(SEQ ID NO: 15)

(Nucleotides 1779-1811 in Figure 4)

2) Knockout primers:-

MGT-KOex8F and MGT-KONeoR span exon 8 to the Neo^R gene cassette in the "knock-out" allele and amplify a 5.5 kb fragment from the knocked out allele (Figure 19)

SEQUENCE:

MGT-KONeoR

5'-GCCACACGCGTCACCTTAATATGCCAAGTGGAC-3'

10 (SEQ ID NO: 16)

(Nucleotides 323-355; Figure 16)

Each reaction contained ~100 ng genomic DNA as template in a reaction volume of 50 μ l and contained 25mM Tris HCl (pH9.1), 16mM (NH₄)₂SO₄, 250 μ M dNTPs, 3.5 mM MgCl₂, 100 ng each primer, 2 units Taq polymerase and 0.025 units Pfu polymerase. The reactions were heated at 94°C for 1 min, then 45 cycles of 94°C for 15 sec, 68°C for 6 min, followed by a single step of 72°C for 10 min. Genomic DNAs from putative "knock-out" ES cell lines from CBA/C mice (homozygous for the wild-type α -1,3-Gal T allele) were amplified in separate reactions using each set of primers. A 10 μ l aliquot of each PCR was analyzed by Southern blotting (Sambrook et al., 1989).

The results are illustrated in Figure 20:

25 Knockout primers:-

A 5.5 kb fragment that hybridized to the 1.3 kb Neo^R gene cassette (Figure 16) was generated from 7C2 DNA (Figure 20; lane 4) and 8D1 DNA (not shown). This band was not generated from CBA/cDNA (Figure 20; lane 3).

Wild-type primers:-

A 5.5 kb fragment that hybridized to the α -1,3-Gal T gene probe (isolated by Sal I digestion of p α GT-S4.0) was generated from 7C2 and CBA/cDNA's (Figure

20; lanes 1 and 2 respectively) and 8D1 DNA (not shown). This product did not hybridize to the Neo^R gene probe.

These results demonstrate that homologous recombination had occurred at the 5' boundary of the construct in cell lines 8D1 & 7C2.

EXAMPLE 14

Generation of Animals Carrying an ES Cell Genome

The procedures provided in this Example are adapted for mouse ES cells. However, the general strategy is substantially the same for porcine ES cells and PGC's.

I. PREPARATION OF ES CELLS FOR INJECTION

ES cells are split into wells of a 24-well dish at cell densities of 1:2, 1:4, 1:8 and 1:16, relative to the initial density, two and three days before injection. The most vigorous and least differentiated cultures are chosen on the basis of morphology.

II. EMBRYO INJECTION AND PRODUCTION OF CHIMERIC MICE

Mouse embryos are collected from either superovulated or naturally mated female mice, approximately 3.5 days after mating. After overnight culture in M16 medium (Bradley, Production and Analysis of Chimaeras. In Teratocarcinomas and Embryonic Stem Cells a Practical Approach (E.J. Robertson, ed.) IRL Press, Oxford, pp. 113-52 (1987)), those that have cavitated to form blastocysts are microinjected with about 12 to 20 ES cells. This microsurgical procedure is performed with instruments drawn from capillary glass, and injection is controlled with micrometer syringe-based hydraulic devices. A differential interference contrast-equipped inverted microscope is used to view the procedure.

After injection, blastocysts are transferred to the uterus of pseudopregnant female mice. Chimeric mice are identified by coat color contribution by the ES cells. Chimeric mice show agouti coat colour derived from the host blastocyst, and chinchilla contributed by the ES cells.

Chimeric mice were generated from ES cells carrying the interrupted a-1,3-Gal T allele (including 8D1, 7C2 cells) by injection into C57B1/6J x CBA F2 blastocysts. The ability of individual chimaeric mice to transmit the ES cell characteristics through the germ-line was estimated by glucose phosphate isomerase (Gpi) analysis of sperm (Bradley, supra, (1987)); Mann et al., J. Reprod & Fert. 99, 505-512 (1993). Glucose phosphate isomerase catalyses the interconversion of glucose-6-phosphate to fructose-6-phosphate. Mice have a single structural Gpi locus with two main alleles Gpi 1A and Gpi 1B. Gpi 1A codes for protein which appears as a slow cathodically migrating band during electrophoresis and occurs in strains such as BALB/c and C129. (The ES cells used here were derived from strain 129 mice). Gpi 1B determines an enzyme that moves faster than Gpi 1A and occurs in the wild and in strains such as C57 and CBA (used here to derive host blastocysts).

Heterozygotes have the two parental bands plus an intermediate band which indicates the dimeric structure of the enzyme. Multiple electrophoretic forms occasionally observed are due to oxidation of sulphydryl groups and not due to tissue-specific expression. In chimaeric mice, the ratio of Gpi 1A (strain 129-derived) to Gpi 1B (derived from the host blastocyst) indicates the proportion of cells with the ES cell genotype within different tissues. The appearance of Gpi 1A (derived from the ES cells) in the sperm suggests that the mouse is able to transmit the ES cell genotype through the germ-line.

III. GENERATION OF MICE HOMOZYGOUS FOR THE GENETIC CHANGE INTRODUCED INTO THE ES CELLS.

Chimeric mice with sperm derived from ES cells were mated to BALB/c mice. Offspring with the 129/Ola X BALB/c genotype (i.e. heterozygous for the ES cell genotype) are grey. Half of these grey mice were expected to carry the interrupted allele. Mice heterozygous for the interrupted allele were identified by PCR analysis of genomic DNA obtained from blood.

10 To generate mice homozygous for the inactivated α -1,3-Gal T gene, the heterozygous mice were mated to each other. One quarter of the offspring were expected to be homozygous for the interrupted gene. Homozygotes were identified by PCR analysis of genomic DNA obtained from blood. The PCR
15 strategy was based on the insertion of a Neo^R gene in the Sal I site of exon 9 of the α -1,3-Gal T gene (Figure 13). Wild-type primers:-

E9F: 5'TCAGCATGATGCGCATGAAGAC 3'
(SEQ ID NO: 17)

20 (homologous to sequence about 40 to 60 bp 5' to the Sal I site of exon 9, corresponding to nucleotides 1257-1278; Figure 4)

E9R2: 5'TGGCCGCGTGGTAGTAAAAA 3'
(SEQ ID NO: 18)

25 (homologous to a region about 175 to 195 bp 3' to the Sal I site of exon 9, corresponding to nucleotides 1511-1492; Figure 4)

The expected fragment size generated from the wild-type allele is 255 bp (Figure 21). These primers also can
30 potentially generate a 1596 bp PCR fragment from the interrupted allele. In practice this fragment was not generated when both the wild-type and interrupted alleles

were present, probably because the smaller 255 bp product is amplified preferentially.

Knock-out primers:-

NeoF1: 5' TCTTGACGAGTTCTTCTGAG 3'

5 (SEQ ID NO: 19)

(corresponding to nucleotides 1170-1189; Figure 16)

E9R2: (the same primer described above to detect the wild-type allele)

The expected fragment size is 364 bp (Figure 21).

10 Mice were grown to weaning age and bled from the tail. Sodium Heparin was added to about 10 U/ml. PCR amplification was conducted on 1 μ l of heparinised blood (~10⁴ nucleated cells) in a 50 μ l reaction volume containing 100 mM Tris-Acetate pH 8.8, 3.5 mM MgCl₂, 0.2mM dNTPs, and 15 2 units Tth DNA polymerase. Each reaction contained both the wild-type and knock-out primers at a concentration of 2ng/ μ l for each primer. To ensure that Tth polymerase was not inhibited by heparinized blood, each reaction was performed in duplicate.

20 One of the reactions was spiked with two DNA samples:
i) 10 fg (~600 molecules) of linearized KO plasmid pNeo α GT10.8B.

ii) 1 fg (~1000 molecules) of a 983 bp RT-PCR product that includes Exon 9.

25 The other reaction was not spiked. Thus, two separate PCR reactions were set up for each blood sample. In addition, control PCR reactions with no genomic DNA template and with or without spikes were conducted. Each reaction mix was heated at 94°C for 3 min., then incubated for 40 cycles at 30 94°C for 40 sec., 53°C for 40 sec., and 72°C for 40 sec. Aliquots of 5 μ l of each reaction mix were electrophoresed on a 3% agarose gel, and DNA fragments were visualized on a UV light box after staining with ethidium bromide. HpaII-digested pUC19 plasmid DNA was used for markers.

Results of the PCR analysis for three mice, and a "no DNA" control, are shown in Figure 22. For mouse #42, the KO primers generated a 364 bp band in the + spike reaction only. The wild-type primers generated a 255 bp band in the + spike and - spike reactions. These results demonstrate that mouse #42 is homozygous for the wild-type allele. For mouse #43, the wild-type primers generated a 255 bp band in the + spike reaction only. The KO primers generated a 364 bp band in the + spike and - spike reactions. These results demonstrate that mouse #43 is homozygous for the interrupted allele. For mouse #44, the KO primers generated a 364 bp band in the + spike and - spike reactions. The wild-type primers generated a 255 bp band in the + spike and - spike reactions. These results demonstrate that mouse #44 is heterozygous for the interrupted allele. In the control PCR reactions, no product was evident when template was not included. PCR products of 364 bp and 255 bp were evident when pNeoαGT10.8B and Exon 9 RT-PCR DNA were the only templates included in the control reactions.

EXAMPLE 15

Characterization of Homozygous Knockout Mice

I. ABSENCE OF Gal T mRNA IN Gal T KNOCKOUT MICE

A. RNA Isolation

Total RNA was extracted using the RNeasyTM kit (BIOTECHX Laboratories, Inc., 6023 South Loop East, Houston, Texas 77033, USA.), supplied by Bresatec. This extraction procedure is based on the method described by Chomczynski et al., Anal. Biochem. 162: 156-159 (1987), and involves homogenization in a guanidinium/phenol solution, a chloroform extraction, 2 isopropanol precipitations, and 75% EtOH washes. The RNA was stored as an EtOH precipitate at -20°C and quantitated by measuring absorption at

wavelength 260 nm in water. The integrity and quantitation was confirmed by electrophoresis in agarose/formaldehyde gels. Sambrook et al. Molecular Cloning. A Laboratory Manual. Second Edition. (1989)

5 B. RT-PCR

First strand cDNA synthesis involved:

- annealing 2 μ g of total RNA from kidney, heart or liver with 120ng oligo dT primer (Gibco BRL, M-MLV Reverse Transcriptase Kit) at 65°C for 5 minutes in 5 μ l of 10 mM Tris-HCl, 1mM EDTA (pH8).
- reverse transcription at 37°C for 1-2 hours in a final reaction volume of 20 μ l utilizing the M-MLV Reverse Transcriptase Kit (Gibco BRL). Each reaction contained 5mM DTT, 0.1 μ g/ μ l BSA, 1mM dNTPS, 40 U of human placental RNase Inhibitor (Bresatec), 200U of M-MLV Reverse Transcriptase and the associated RTase buffer at 1X concentration.

15 C. PCR Analysis of cDNA

20 α -1,3-Gal T cDNA was detected by PCR amplification of oligo dT-primed cDNA template. Failure to generate this PCR fragment, in conjunction with the control PCR results, indicated that α -1,3-Gal T mRNA was absent from the RNA preparation. To demonstrate that the α -1,3-Gal T primers supported amplification of the α -1,3-Gal T template, each reaction was assembled in duplicate, and one of the reactions was spiked with 0.1 fg (~100 molecules) of a 983 bp mouse α -1,3-Gal T cDNA product (generated by primers 7F and mGT-3UR, spanning exon 7 to the 3' untranslated region). As a second control to demonstrate that cDNA synthesis had occurred, a ferrochelatase PCR fragment was generated from the cDNA template.

25 1. Primers:

30 Primers to detect α -1,3-Gal T cDNA:

7F: 5'-TGGAGATCGCATTGAAGAGC 3'
(SEQ ID NO: 20)
(corresponding to nucleotides 889-911
within exon 7 (Figure 4))

5 9R2: 5'-TGGCCGCGTGGTAGTAAAAA 3'
(SEQ ID NO: 21)
(corresponding to nucleotides 1492-1511
within exon 9 (Figure 4))

10 Primers 7F and 9R2 were expected to generate a
fragment of ~619 bp (Figure 23) from the cDNA
template. These primers will not generate a fragment
from genomic DNA possibly present in the cDNA
preparation, since the primers span two large introns.

15 mGT-3UR: 5'-GGGTTTTGGTTTTGATTGTT 3'
(SEQ ID NO: 22)
(corresponding to nucleotides 1866-1888
within the 3' untranslated region;
Figure 4).

20 This primer was used with primer 7F to generate the
DNA fragment used in the control spike PCRs.

Primers to detect mouse ferrochelatase cDNA (EcoRI
linkers, underlined):

25 FC-F: 5'-CTGAATTCATGTTAAACATGGGAGGCCCC 3'
(SEQ ID NO: 23)
(corresponding to nucleotides 215-235,
Taketani et al., J. Biol.Chem. 265:
19377-80 (1990)).

30 gFC-R: 5'-CTGAATTCTGCCCACTCCCTGCCGATG 3'
(SEQ ID NO: 24)
(corresponding to nucleotides 888-908,
Taketani et al., J. Biol.Chem. 265:
19377-80 (1990)).

These primers were expected to generate a 709 bp fragment (Figure 23). These primers will not generate a fragment from genomic DNA possibly present in the cDNA preparation, since the primers span five introns.

5 Reaction volumes were 50 μ l, consisting of 4 μ l of the first strand cDNA synthesis reaction, 100 ng of each primer, 2 mM $MgCl_2$, 0.3 mM dNTPS, 2U of Taq-Polymerase (Bresatec) and Taq reaction buffer (Bresatec) at 1X concentration. Reactions were heated at 94°C for 2 min, 10 then 29 cycles of 94°C for 15 sec, 58°C for 30 sec and 72°C for 1 min followed by single steps of 72°C for 4 min and 4°C for 5 min. A 10 μ l aliquot of each PCR was electrophoresed on a 2% agarose gel and DNA fragments were visualized on a UV light box after staining the gel with 15 ethidium bromide.

Figure 24 shows the PCR fragments generated from RNA isolated from kidney (K), heart (H) and liver (L) of a wild-type mouse, and mice heterozygous or homozygous for the interrupted α -1,3-Gal T allele. Figure 24(i) shows 20 that the 709 bp ferrochelatase fragment was generated from each of the cDNA preparations, indicating that cDNA template was produced from the reverse transcription reaction, and was available for the α -1,3-Gal T gene primers. The 619 bp α -1,3-Gal T fragment was present in 25 each of the reactions spiked with the 983 bp α -1,3-Gal T cDNA product (Figure 24(ii)), indicating that amplification of the α -1,3-Gal T cDNA (spike) template had occurred.

In the reactions that were not spiked (Figure 24 (iii)), the 619 bp α -1,3-Gal T fragment was detected in 30 cDNAs synthesized from the wild-type and heterozygous RNAs. This indicates that α -1,3-Gal T mRNA is present in the kidney, heart and liver of the wild-type and heterozygous mice. The 619 bp fragment was not detected in the unspiked homozygous KO reactions, indicating that α -1,3-Gal T mRNA 35 is not synthesized in the homozygous KO mice.

II. TEST FOR EXPRESSION OF THE GAL EPI TOPE IN HOMOZYGOUS
KNOCKOUT MICE USING ANTI-GAL ANTIBODIES WITH
FLUORESCENCE-ACTIVATED CELL SORTING (FACS)

A. Solutions

5 Solutions 1 to 5 are 10x isotonic.

1. 1.68M NaCl (948.21g/l) Dry salts overnight in
hot oven before weighing

2. 1.68M KCl (125g/l) Dry salts overnight in hot
oven before weighing

10 3. 1.12M CaCl₂ (165g/l CaCl₂·2H₂O) Dry salts
overnight in hot oven before weighing

4. 1.68M MgSO₄ (414g/l MgSO₄·7H₂O) Do not dry in hot
oven

5. Potassium phosphate buffer pH 7.2:

15 a) 1.68M KH₂PO₄ (229 g/L)

b) 1.12M K₂HPO₄ (226 g/L K₂HPO₄·3H₂O or 195
g/l K₂HPO₄)

Potassium phosphate buffer is prepared by
mixing together equal volumes of solutions a) and b). To
20 pH the buffer, remove a small sample, dilute 1:50 and
read on pH meter.

6. Hepes buffer 1M (CSL, Melbourne Australia)

7. KDS BSS:

Add stock solutions in the following order to
25 double-distilled water (DDW):

	Stock	Ratio of Solutions
	DDW	1210
	NaCl	121
	KCL	3
30	CaCl ₂	3
	MgSO ₄	1
	Potassium phosphate buffer	2
	Hepes	20

Filter sterlise, store at 4°C

8. KDS/BSS/2%HSA/0.02% azide:

	KDS/BSS	244.5ml
	Human serum albumin	5ml
	(CSL, Melbourne, Australia)	
5	10% Na azide in MT-PBS	0.5ml

9. FITC dilution: Dilute 7.5ul FITC-IgG to 600ul with KDS/BSS

10. Red cell lysis buffer:

0.168M NH_4Cl in double distilled water

10 11. 4% paraformaldehyde (PFA)

Solutions:

	A.	$\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$	22.6 g/L
	B.	NaOH	25.2 g/L
15	C.	40% paraformaldehyde:	
		1) 4 g paraformaldehyde (BDH, Kilsyth, Australia, #29447) dissolved in 10ml double distilled water. Heat 70°C 2 hours on stirrer in fume hood and a few drops of 2M NaOH are added until the solution becomes clear.	
20		2) 0.54 g glucose is then added.	
		3) Store RT in light proof bottle.	
	D.	Add together 83 ml of A + 17 ml of B.	
25	E.	Final 4% PFA fixative solution: 90 ml of D + 10 ml of C. pH 7.4 - 7.6; adjust pH with 1M HCl.	

12. Hanks Balanced Salt Solution (Ca and Mg free) (HBBS):

	KCL	400mg
30	KH_2PO_4	60mg
	NaCl	8g
	NaHCO_3	350mg
	$\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$	68mg
	Glucose	1g
35	H_2O	to 1 liter

adjust to pH 7.0; filter sterilize

13. Sheep antihuman IgG and IgM fluorescein isothiocyanate (FITC) F(ab)2 fragments (Silenus, Hawthorn, Australia):

B. Methods

1. Eye bleed mice, collect 300-400ul into pre-chilled Ependorf tube, store on ice, add EDTA 20mg/ml to give final concentration of 2mg/ml.
- 5 2. Transfer blood (including appropriate human controls) to 10ml plain tube and add 10ml red cell lysis buffer (0.168M NH_4Cl) pre-warmed to 42°C; incubate for several minutes or until cells have lysed.
3. Pellet cells by centrifugation (800 x g, 7 min,
10 4°C).
4. Resuspend cells in 10ml KDS/BSS/2% HSA/0.02%
NaN₃
5. Pellet cells as above; repeat steps 4 & 5.
6. Resuspend cells in 1000ul KDS/BSS/2% HSA/0.1%
15 NaN₃; transfer aliquots to V bottom FACS tubes.
7. Pellet cells as above.
8. Resuspend cells in 100ul KDS/BSS/2% HSA/0.1%
NaN₃
9. Add 50ul of purified anti-GAL antibody (see
20 Example 1, above), normal human serum (NHS) or HBBS/2%
HSA/0.1% NaN₃ and incubate 45 min.
10. Add 2ml KDS/BSS/2% HSA/0.02% NaN₃; centrifuge
cells as above.
11. Add 50ul of a 1:80 dilution of sheep antihuman
25 IgG or IgM FITC F(ab)2 fragment (Silenus).
12. Add 2ml KDS/BSS/2% HSA/0.02% NaN₃; centrifuge
cells as above.
13. Resuspend cells in 300ul KDS/BSS/2% HSA/0.02%
NaN₃.
- 30 14. Transfer samples to plastic round-bottom FACS
tubes and add 3 ul of propidium iodide (100ug/ml);
samples are now ready for analysis; keep on ice.
15. Analyse on Beckman FACS scan using peripheral
blood lymphocyte settings.

C. Results

The results of these experiments are given below:

		median channel fluorescence (log scale)	peak channel fluorescence (log scale)
5	MOUSE 129 (Normal) PBL + FITC anti- IgG alone (neg. control)	9	9
	MOUSE 19 PBL (wild type) GAL IgG	197	286
10	MOUSE 21 PBL (Gal KO) GAL IgG	22	15
15	MOUSE 129 (Normal) PBL + FITC anti- IgM alone (neg. control)	7	1
	MOUSE 19 PBL (wild type) GAL IgM	185	167
20	MOUSE 21 PBL (Gal KO) GAL IgM	34	18
25	MOUSE 129 PBL (normal) PBL + FITC IgG alone (neg. control)	8	9
	MOUSE 129 PBL (normal) GAL IgG	120	328
30	MOUSE 9 PBL (Gal KO) GAL IgG	10	9

The results of human anti-Gal binding to human peripheral blood lymphocytes (negative control) are not shown but were negative. These experiments demonstrate that human anti-Gal (IgG and IgM) antibodies bind to peripheral blood cells of the homozygous $\alpha 1,3$ galactosyltransferase knockout mice (mouse 21 and mouse 9) very weakly if at all. This confirms the expected lack of the galactose $\alpha 1,3$ galactose (GAL) epitope in

such mice. In contrast, peripheral blood cells of normal mice (mouse 129 and mouse 19) of the same strain display clear binding of anti-Gal antibodies.

III. TEST FOR EXPRESSION OF THE GAL EPI TOPE IN HOMOZYGOUS
5 KNOCKOUT MICE USING IB₄ LECTIN WITH FACS

IB₄ Lectin has an exclusive affinity for terminal α-D-galactosyl residues, and is demonstrated below to be useful for characterizing the knockout mice.

A. Solutions

- 10 1. 4% paraformaldehyde (see above)
2. Mouse Tonicity PBS (MT-PBS)
Na₂HPO₄ 2.27g
NaH₂PO₄·2H₂O 0.62g
NaCl 8.7g
15 Make up to 1 liter with DDW
3. Dead Cell Removal Buffer (DCRB):
-4.5 g Sorbitol
-7.6 g Glucose monohydrate, (6.93 g if
anhydrous)
20 -12.5 ml KDS/BSS
-Make up to 100 ml with DDW
-Filter, store at 4°C
-Open only under sterile conditions
4. KDS/BSS (Mouse Tonicity, Hepes Buffered
25 Balanced Salt Solution pH 7.2) (see above)
5. Red cell lysis buffer (see above)
6. KDS/BSS/2%HSA/0.02%azide (see above)
7. Hanks Balanced Salt Solution (Ca and Mg
free) (see above)

30 B. Methods

1. Remove spleen, hold with curved forceps and collect splenocytes by injecting with a 27 gauge needle bent at 90°C, injecting (2.5 ml syringe) 100-200

ul buffer into the spleen two or three times. Using the flat surface of the bent needle massage cells out of holes made in spleen. Repeat injections and removal of cells until no cells remain in capsule.

5 2. Transfer splenocytes to 10ml tube and centrifuge to pellet cells (500xg, 7 min, 4°C).

 3. Remove supernatant and add 3ml red cell lysis buffer pre-warmed to 42°C; incubate for several minutes or until cells have lysed. Underlay with 1ml
10 HIFCS (heat inactivated fetal calf serum) and stand on ice 5 minutes. Top to 10ml with KDS BSS/10% HIFCS.

 4. Centrifuge as above.

 5. Resuspend cells in 3ml dead cell removal buffer; mix well with pipette.

15 6. Pass through a glass pipette plugged with cotton wool and collect cells into a 10ml tube. Don't force cells through, allow to drain under gravity.

 7. Underlay cells with 1 ml BSS/10% HIFCS.

 8. Centrifuge as above.

20 9. Remove supernatant.

 10. Centrifuge as above; repeat steps 4 & 5.

 11. Add 0.5 ml cold 4% paraformaldehyde (PFA).

 12. Incubate on ice for 5 min with intermittent mixing.

25 13. Add 2 ml ice cold HBBS and centrifuge as above.

 14. Repeat washings with 2ml and then 1ml HBBS.

 15. Resuspend cells in 100ul KDS/BSS/2%
30 HSA/0.1% NaN₃; transfer to V bottom FACS tubes.

 16. Add FITC IB4 lectin (Sigma, Cat. No. L 2895), 50ul at 20ug/ml, or 50ul HBBS; incubate on ice for 30 min.

 17. Add 2ml KDS/BSS/2% HSA/0.1% NaN₃; spin
35 cells as above.

18. Resuspend cells in 300ul KDS/BSS/2%
HSA/0.1% NaN₃.

19. Transfer samples to plastic round-bottom
FACS tubes; samples are now ready for analysis; keep on
5 ice.

20. Analyse on FACS scanner using peripheral
blood lymphocyte setting.

C. Samples

- 10
1. Mouse 129 splenocytes alone
 2. Mouse 129 splenocytes + IB₄ lectin
 3. human PBL alone
 4. Human PBL + IB₄ lectin

D. Results

Results of these experiments are given below:

	mean fluorescence channel (log scale)	median fluorescence channel (log scale)	peak fluorescence channel (log scale)
15			
splenocytes alone (autofluorescence)	1	1	1
mouse 19 (wild type) splenocytes	252	58	16
20			
mouse 21 (KO mouse) splenocytes	3	2	1

The results demonstrate that IB₄ lectin binds
spleen cells of the homozygous α 1,3 galactosyltransferase
25 gene targeted (Gal KO) mouse (mouse 21) very weakly if at
all. This confirms the expected lack of the galactose
 α 1,3 galactose (GAL) epitope in such mice. In contrast,
peripheral blood cells of a normal mouse (mouse 19) of
the same strain binds IB₄ lectin strongly.

IV. IMMUNOHISTOLOGICAL ASSESSMENT OF MOUSE TISSUES FOR THE PRESENCE OF THE GAL EPI TOPE USING ANTI-GAL ANTIBODIES.

A. Reagents

- 5 1. TBS: Tris Buffered Saline
- NaCl 8g
- KCl 0.2g
- Tris base 3g
- dissolve in 800ml distilled water. Adjust pH
- 10 to 8.0 with 1 M HCl. Adjust volume to 1L. Sterilise by autoclaving. Store at RT.
2. Blocking buffer:
- TBS + 2% bovine serum albumin (BSA) + 10% rabbit serum:
- 15 3. Peroxidase conjugates:
- DAKO (Denmark) peroxidase (POD) conjugated to rabbit anti-human IgG (fragment) and DAKO (Denmark) peroxidase (POD) conjugated to rabbit anti-human IgM (fragment).
- 20 Conjugates were both separately pre-absorbed on 10% mouse liver powder at 4°C overnight, then centrifuged at 18,000xg for 10 minutes in a Biofuge and then at 30 psi for 30 min in a Beckman airfuge. Conjugated antisera were diluted 1/50 in 2% blocking buffer (TBS + 2% BSA +
- 25 2% rabbit serum) with 16% normal mouse serum.
4. Mouse liver powder preparation:
- As modified from Antibodies, a Laboratory Manual Ed Harber and David Lane, Cold Spring Harbour Laboratories (1988) p663:
- 30 a) Prepare a fine suspension of mouse liver in mouse tonicity phosphate buffered saline (MT-PBS). Mash liver through a sieve with a 5 ml plunger. Discard any fibrous tissue. One gram of tissue should be resuspended in approximately 1 ml MT-PBS.

b) Transfer the tissue/saline suspension to ice for 5 min.

c) Add 8 ml of acetone (-20°C) (Univar 6, Ajax Chemicals) for 10 minutes. Mix vigorously.

5 Incubate on ice for 30 minutes with occasional vigorous mixing.

d) Collect the precipitate by centrifugation at 10,000g (9,000 rpm in Sorvall RC-5B refrigerated superspeed centrifuge). Spin for 10 minutes.

10 e) Resuspend the pellet with fresh acetone (-20°C) and mix vigorously. Allow to sit on ice for 10 minutes.

f) Centrifuge at 10,000g for 10 minutes. Transfer the pellet to a clean piece of filter paper.

15 Spread the precipitate and allow to air-dry at room temperature.

g) After the pellet is dry, transfer it to an airtight container. Remove any large pieces that will not break into a fine powder. Dessicate and store at 4°C . Yield as approximately 10-20% of the original wet weight. To use acetone powders, add to a final concentration of 1%. Incubate for 30 min at 4°C . Spin at 10,000g for 10 minutes. (13,000 rpm in Biofuge)

5. DAB/ H_2O_2 /Imidazole:

25 Peroxidase substrate: 3,3'-Diaminobenzidine tetrahydrochloride (DAB) (Sigma, Missouri)

- 1 tablet DAB (take out of fridge 10 min before use)

- 1 tablet urea H_2O_2 (Sigma, Missouri)

30 - add to 15 ml tris HCL, pH 7.6 + 0.01M imidazole (0.0102g), (Sigma, Missouri)

- make up immediately before use

6. Tris HCL:

1.211g Tris in 200ml double distilled water pH

7.6

7. Animal serum sources:

5

Mouse and rabbit sera were obtained in-house
(St. Vincent's Hospital, Dept, of Clinical Immunology).

Sheep serum was obtained from the University of
Melbourne Veterinary Clinic and Hospital, Werribee,
Australia.

10

8. Harris Haematoxylin:

Haematoxylin C.I. 75290 (BDII, Poole, U.K.
#34037) 10g

Absolute ethanol 200ml

Potassium alum 200g

15

double distilled water 2000ml

glacial acetic acid 80ml

Preparation:

1. Dissolve haematoxylin in absolute ethanol

2. Heat to dissolve alum in double distilled

20 water

3. Mix solution 1 and 2

4. Immediately before use add 80 ml 1% sodium
iodate and 80 ml glacial acetic acid

9. Scott's Tap Water:

25

Sodium hydrogen carbonate 14 g

MgSO₄ 80 g

Tap water 4 litres

B. Methods

30

1. Cut 4 um sections of the relevant tissue on
cryostat

2. Tissue should be free of cracks

3. Air dry slides for 30 min
4. Apply 10% blocking buffer at room temp in humidified chamber, 60 min
5. Remove blocking antibody with tissue made to fine point
6. Apply 1st antibody, anti-GAL, or 2% blocking buffer as control, 50ul, ensure no air bubbles and incubate at room temp in humidified chamber for 30 min
7. Wash off with Tris buffered saline (TBS) 3 times 2 minutes washes
8. Apply second antibody 1:50 peroxidase (POD) conjugated rabbit anti-human IgG and IgM (DAKO, Denmark); incubate 30 min at room temp in humidified chamber
9. Wash off with Tris buffered saline (TBS) 3 times 3 minute washes
10. Wash off with TBS as above
11. Incubate DAB/H₂O₂/imidazole for 10 minutes
12. Wash in water
13. Stain with haemotoxylin C - 10 seconds
14. Wash in water
15. Place in Scotts tap water for 15 seconds
16. Wash in water
17. Wash in absolute alcohol (x3) (Univar 214, Ajax chemicals)
18. Wash in absolute xylene (x3) (Univar 577, Ajax chemicals)
19. Coverslip using automatic coverslip machine (Tissue Tek)

Controls:

1. Buffer only + POD conjugated rabbit anti-human IgM (negative)

2. Buffer only + POD conjugated rabbit anti-human IgG (negative)
3. Human kidney (negative)
4. Pig renal cortex (positive)

5 Samples:

1. Mouse 129 SV (control) kidney
2. mouse 9 (Gal Knockout) kidney
3. mouse 21 (Gal Knockout) kidney

C. Results

10 KIDNEY

	GLOMERULI	ENDOTHELIUM	comments
MOUSE 129 anti-IgM	POSITIVE	POSITIVE	
MOUSE 9 anti-IgM	NEGATIVE	NEGATIVE	weak adventitial staining
15 MOUSE 21 anti-IgM	NEGATIVE	NEGATIVE	weak adventitial staining
MOUSE 129 anti-IgG	POSITIVE	POSITIVE	
20 MOUSE 9 anti-IgG	NEGATIVE	NEGATIVE	
MOUSE 21 anti-IgG	NEGATIVE	NEGATIVE	
POD conjugated antibody alone	ALL NEGATIVE	ALL NEGATIVE	

25 These results indicate that human anti-Gal IgG and
IgM antibodies do not bind kidney tissue of the $\alpha 1,3$
galactosyltransferase gene targeted (Gal KO) mice (mouse
21 and mouse 9). This confirms that lack of the
galactose $\alpha 1,3$ galactose (GAL) epitope in the gene
30 targeted (KO) mice. In contrast, these antibodies react
strongly with the endothelium of blood vessels and the
glomeruli of a normal mouse of the same strain (129).

V. IMMUNOHISTOLOGICAL EXAMINATION OF MOUSE TISSUES
USING IB₄ LECTIN

A. Reagents

1. Blocking buffer: TBS + 2% BSA + 10% sheep
5 serum
2. FITC IB₄ (Sigma, Missouri, USA #L-2895)
1 mg diluted in 1 ml HBBS to give stock
solution, then dilute to final volume of 20
ug/ml in TBS + 2% BSA + 2% sheep serum
- 10 3. Peroxidase anti-FITC

Boehringer anti-fluorescein POD Fab fragments;
dilute 1/300 in 2% blocking buffer
4. DAB/H₂O₂/Imidazole - see above
5. Tris HCL - see above
- 15 6. Animal serum sources - see above
7. Harris Haematoxylin - see above
8. Scott's Tap Water - see above
- B. Methods
- 20 1. Preparation of Sections; same as Section 4B,
steps 1-7 above.
2. Apply 50 µl FITC conjugated IB₄ (Sigma # 1-
2894)
20 µg/ml, incubate in a humidified chamber
for 30 minutes.
- 25 3. Wash with TBS, 3 minutes (x3).
4. Apply 50 µl per oxidase conjugated anti - FITC
Fab fragments (Boehringer Mannheim), diluted 1-3--with
TBS + 2% BSA + 2% sheep serum. Incubate for 30 minutes in
humidified chamber.
- 30 5. Wash with TBS, 3 minutes (x3).
6. Processing for microscopy - same as Section IVB
steps 14-22.

Controls

1. Buffer only + POD anti-FITC (negative)
2. Human kidney (negative)
3. Pig renal cortex (positive)

5 **Samples 1st Experiment**

1. Mouse 129 SV normal mouse heart liver kidney lung
2. mouse 6 wild type heart liver kidney lung
3. mouse 7 heterozygote KO heart liver kidney lung
4. mouse 9 homozygous KO heart liver kidney lung

10 **Samples 2nd Experiment**

1. mouse 19 wild type heart liver kidney lung
2. mouse 20 heterozygote KO heart liver kidney lung
3. mouse 21 homozygous KO heart liver kidney lung

C. Results

15 **Kidney**

20

25

	GLOMERULI	ENDOTHELIUM
HUMAN	NEGATIVE	NEGATIVE
PIG	POSITIVE	POSITIVE
129 MOUSE	POSITIVE	POSITIVE
MOUSE 6	POSITIVE	POSITIVE
MOUSE 7	POSITIVE	POSITIVE
MOUSE 9	NEGATIVE	NEGATIVE
MOUSE 19	POSITIVE	POSITIVE
MOUSE 20	POSITIVE	POSITIVE
MOUSE 21	NEGATIVE	NEGATIVE
anti-FITC alone	ALL NEGATIVE	ALL NEGATIVE

Liver

5

	ENDOTHELIUM	BILE DUCT
129 MOUSE	POSITIVE	POSITIVE
MOUSE 6	POSITIVE	POSITIVE
MOUSE 7	POSITIVE	POSITIVE
MOUSE 9	NEGATIVE	NEGATIVE
MOUSE 19	POSITIVE	POSITIVE
MOUSE 20	POSITIVE	POSITIVE
MOUSE 21	NEGATIVE	NEGATIVE
anti-FITC alone	ALL NEGATIVE	ALL NEGATIVE

10

Heart

15

	ENDOTHELIUM	PERINUCLEAR	ENDO- MYOCARDIUM
129 MOUSE	POSITIVE	POSITIVE	POSITIVE
MOUSE 6	POSITIVE	POSITIVE	POSITIVE
MOUSE 7	POSITIVE	POSITIVE	POSITIVE
MOUSE 9	NEGATIVE	NEGATIVE	NEGATIVE
MOUSE 19	POSITIVE	POSITIVE	POSITIVE
MOUSE 20	POSITIVE	POSITIVE	POSITIVE
MOUSE 21	NEGATIVE	NEGATIVE	NEGATIVE
anti-FITC alone	ALL NEGATIVE	ALL NEGATIVE	ALL NEGATIVE

Lung

	ENDOTHELIUM	BRONCHI	PARENCHYMA
129 MOUSE	POSITIVE	POSITIVE	POSITIVE
MOUSE 6	POSITIVE	POSITIVE	POSITIVE
MOUSE 7	POSITIVE	POSITIVE	POSITIVE
MOUSE 9	NEGATIVE	NEGATIVE	NEGATIVE
MOUSE 19	POSITIVE	POSITIVE	POSITIVE
MOUSE 20	POSITIVE	POSITIVE	POSITIVE
MOUSE 21	NEGATIVE	NEGATIVE	NEGATIVE
anti-FITC alone	ALL NEGATIVE	ALL NEGATIVE	ALL NEGATIVE

10 These results indicate that IB₄ lectin does not bind
kidney, heart, liver or lung tissue of the α 1,3
galactosyltransferase gene targeted (Gal KO) homozygous
mice (mouse 21 and mouse 9). This confirms the lack of
the galactose α 1,3 galactose (GAL) epitope in the gene
15 targeted (KO) mice. In contrast these antibodies react
strongly with the tissues of a normal mouse and
heterozygous KO mice (mouse 129, mouse 6, mouse 7, mouse
19, mouse 20) of the same strain.

20 VI. RESISTANCE OF SPLEEN CELLS FROM KNOCKOUT MICE TO
LYSIS BY HUMAN SERUM

Lysis of spleen cells by human serum was tested
through use of a ⁵¹ chromium release assay. See in general
Example 4, above.

25 A. Preparation of Mouse Splenocytes - Shortman,
K.J. et al, Immunological Methods. 1:273-287 (1972).:
-Dissect out spleen, avoid damaging outer membranes and
carefully remove mesentery tissue and fat.
-Place in petri dish, with 1 ml RPMI 1640 (Gibco BRL)
/10% Heat-inactivated foetal calf serum (HI-FCS). (Heat-
30 inactivation = 40 Min at 56°C).

-Gently tease out cells into petri dish, collect and centrifuge 500xg, 5 min, 4°C

-Remove RPMI/10% HIFCS, gently resuspend cells in 3 ml 0.9% NH₄Cl (0.168M), using a Pasteur pipette. (Use
5 Pasteur pipettes or wide-bore pipettes for all re suspension and transfer procedures)

-Transfer to 10 ml tube, underlay with 1 ml HIFCS, stand on ice, 5 min.

10 -Transfer supernatant to clean tube, centrifuge 500xg, 7 min, 4°C

-Discard supernatant, re-suspend cells in 3 ml dead cell removal buffer, mix well with pipette.

15 -Pass through cotton wool plug in glass pipette (under gravity, do not force through), collect cells into 10 ml tube.

-Underlay cells with 1 ml HI-FCS.

-Centrifuge 500xg, 7 min, 4°C

-Remove supernatant, re-suspend cells in 50 µl RPMI, 10% HI-FCS. Store cells on ice.

20 B. Preparation of Serum:

Human - Collect whole blood from a pool of normal donors; allow to stand at room temp. for 2 hours.

25 Wring the clot with an 'Orange stick'; spin Remove and pool serum. Store half at -70°C in 3 ml aliquot's (normal human serum); heat-inactivate the other half, see below.

Fetal calf serum - purchased from Gibco BRL, and stored at -20°C.

30 C. Cell Counting:

1. Add 5 µl cells to 95.0 µl RPMI, 10% HI-FCS

5

4. Cell viability should be approx. 90-100 %

D. ⁵¹Chromium Labelling:

15

Incubate at 37°C for time shown above with gentle agitation every 15 min.

E. Washing

30

-Resuspend cells in 1ml RPMI/2% HI FCS

-Pellet cell suspension through another 4 ml HI FCS

-Resuspend cell pellet in 1ml RPMI/2% HI FCS, store on ice.

F. Release Assay:

-Perform assay in 96-well microtitre plate (ICN-FLOW).

-Assay should be set up in quadruplicate.

5 -Assay is performed in a total volume of 180 μ l.

Assay:

	NHS	*HI-NHS	16% SDS	CELLS	RPMI/2% HIFCS
MAX Release	-	90 μ l	22.5 μ l	25 μ l	42.5 μ l
Spont.Release	-	90		25	65 μ l
10 5% NHS	9 μ l	81		25	65
10% NHS	18	72		25	65
20% NHS	36	54		25	65
30% NHS	54	36		25	65
40% NHS	72	18		25	65
15 50% NHS	90	-		25	65

*HI = heat inactivated

-All volumes indicated are in μ l

-Reaction components are added to the plate in the order: RPMI, Serum and 51 Cr-labelled cells.

20 -Cover plate with plate-sealer

-Incubate, 4 hours, 37°C.

-Spin plate, 1500 rpm, 5 min.

-Remove plate-scaler, remove 80 μ l from each wall, count released chromium on gamma counter.

25 -Calculate specific lysis for each well according to the formula:

$$\% \text{ Specific Lysis} = \frac{(\text{Test cpm} - \text{Spontaneous release cpm}) \times 100}{(\text{Maximal release cpm} - \text{Spontaneous release cpm})}$$

30 Calculate mean and standard deviation for each experimental point. Graph % Human serum (X axis) against % Specific lysis (Y axis) for each type of cell (wild type, heterozygote KO and homozygous KO)

35 The results of these experiments are depicted in Figure 25. The results indicate that spleen cells from a homozygous knockout mouse are relatively resistant to lysis by human serum, in comparison to spleen cells derived from mice heterozygous for the interrupted allele or from wild-type mice.

EXAMPLE 16

Generation of Knockout Animals Through Microinjection of Eggs

Transgenic animals are generated routinely by microinjection of DNA into the pronuclei of fertilised eggs. Generally this technology results in the random integration of the transgene in the genome. However, conventional transgenic technology has resulted in homologous recombination between the injected transgene and the endogenous gene. See, for example, Brinster et al., Proc. Nat. Acad. Sci. USA 86: 1087-91 (1989). Described below are procedures for inactivating the α -1,3-Gal T gene in pigs through microinjection of eggs with gene targeting constructs.

I. GENE TARGETING CONSTRUCTS

The frequency of homologous recombination in embryos is improved if the gene targeting constructs are prepared with isogenic DNA. Therefore the "knock out" constructs are prepared from DNA isolated from the boar used to fertilize the oocytes used for microinjection. DNA is isolated from the tail or ear tissue, and genomic fragments from both α -1,3-Gal T alleles of the boar, encompassing exons 8 & 9 are cloned using long range PCR or conventional genomic library technologies. Clones for each of the α -1,3-Gal T alleles are identified using restriction fragment length polymorphism identification and DNA sequencing. Constructs to target both alleles are made by interrupting the coding sequence of exon 9, either by deletion or by inserting a heterologous DNA fragment. The constructs contain at least 8 kb of homologous DNA to promote efficient homologous recombination.

Various approaches can be used to detect gene targeting events, depending on the strategies used in designing the knockout constructs. Several such

approaches, and the corresponding strategies for construction of constructs, are provided below:

a) PCR of Genomic DNA:

5 Homologous DNA on one side of the interrupting DNA fragment is constructed to be less than 1 kb, allowing PCR amplification of a short diagnostic fragment. (Amplification of small fragments generally is relatively efficient).

b) Reverse Transcription/PCR:

10 A deletion of about 100 bp within exon 9 is made, allowing synthesis of a shortened α -1,3-Gal T mRNA in correctly targeted cells. The shortened mRNA is detected by RT/PCR, using primers that amplify a fragment extending from
15 exon 8 and encompassing the deletion site.

c) Green Fluorescent Protein (GFP) gene expression:

20 GFP is a protein from the bioluminescent jelly fish *Aequorea victoria*. It absorbs blue light (395 nm) and fluoresces to emit green light (509 nm). GFP is a useful marker for gene expression. Chafie et al., Green Fluorescent Protein as a Marker for Gene Expression. Science 263: 802-5 (1994). The α -1,3-Gal T
25 gene is interrupted within exon 9 by in-frame insertion of the GFP coding region. Expression of the GFP gene (with resulting fluorescence at 509 nm) is driven by the α -1,3-Gal T gene promoter in correctly targeted cells.

30 II. GENERATING EMBRYOS FOR MICROINJECTION

Fertilized embryos are generated as described by Nottle et al., (1993). Proc Aust Soc for Reproductive Biol 26, 33. The protocol involves:

- a) Sperm from the boar providing DNA for the targeting construct is collected and stored frozen in liquid N₂.

- b) Superovulation of donor gilts:

5 Gilts are mated at the second oestrus, and aborted between days 25-40 days of gestation to synchronise the subsequent oestrus cycles.

10 Abortion is achieved by intramuscular injection of 1 mg cloprostenol (a prostaglandin F2 α analogue), followed by a second 0.5 mg injection 24 hours later. Gilts are superovulated by injection of 1000 i.u. equine chorionic gonadotrophin (eCG) or pregnant mare serum gonadotrophin at the time of the second

15 cloprostenol injection, and a subsequent injection 72 hours later of 500 i.u. human chorionic gonadotrophin (hCG).

- c) Fertilization:

20 Superovulated gilts are artificially inseminated 20-30 hours after the hCG injection, followed by a second insemination 2-4 hours later, with semen from the boar that provided DNA for the targeting construct.

- d) Embryo collection:

25 Embryos are collected surgically 50-56 hours after hCG injection prior to fusion of the pronuclei. Oviducts are flushed with 15-20 ml phosphate saline buffer containing 1% fetal calf serum. One-cell embryos are recovered by

30 searching oviductal flushings using low magnification microscopy.

III. MICROINJECTION OF EMBRYOS

Embryos are centrifuged at 12000 x g for 8 min to stratify the cytoplasm and allow the pronuclei to

be visualised, and held in Dulbecco's Minimal Essential Medium with 25 mM Hepes and 5 mg/ml bovine serum albumin. Pronuclei are injected, using differential interference contrast optics, with 4-10 picolitres of DNA (10 ng/ μ l) in PBS. Gene targeting with isogenic DNA is maximized by coinjecting both allelic constructs derived from the boar into the male pronucleus.

IV. TRANSFER OF INJECTED EMBRYOS TO RECIPIENT GILTS

The oestrus cycles of recipient gilts are synchronized with those of donors. The recipients are mated and aborted using the protocol described above, and injected with 500 i.u. eCG. Injected embryos are transferred surgically (20-40 per oviduct) to recipients on the same day that they are collected from donor gilts.

V. SCREENING FOR HOMOLOGOUS RECOMBINATION

Homologous recombinants can be detected by analysis of tissue from the born piglets. Screening procedures involve PCR technology, the precise strategy depending on the design of the gene targeting construct. Because many α -1,3-Gal T mRNA molecules are synthesized from a single α -1,3-Gal T gene in expressing cells, the RT/PCR approach can be more sensitive than PCR amplification of genomic DNA. The RT/PCR screening strategy relies on successful transcription of the interrupted gene and relative stability of the shortened mRNA.

Alternatively, constructs that promote expression of heterologous genes (eg: GFP) in correctly targeted cells allow embryos to be screened at the blastocyst stage for marker gene expression (i.e.: GFP expression can be detected by measuring fluorescence within blastocysts at 509 nm). The microinjected embryos are cultured *in vitro*

until blastocyst development, screened for fluorescence, and fluorescing embryos transferred into recipients.

EXAMPLE 17

A Novel Variant of Leukemia Inhibitory Factor (LIF)

5 Previous reports have demonstrated the existence of two forms of murine LIF. The original form (from the D transcript) was expressed and commercialized by AMRAD Corporation Ltd (Kew Victoria, Australia). The protein product derived from this transcript (hereinafter "D-LIF") is sold commercially by AMRAD as "ESGRO™". Another form of LIF (hereinafter "M-LIF"), derived from an alternative transcript, is described in US Patent Application No. 07/994,099 and in Rathjen et al., Cell 62: 1105-14 (1990). The present inventors have now found a third transcript of LIF (hereinafter "T-LIF") which is found in ES cells and in human teratocarcinoma-derived cell lines such as the GCT 27 teratocarcinoma-derived cell lines described by Pera et al., Differentiation 42: 10 (1989).

20 The T-LIF protein is found intracellularly in contrast to the other two forms of LIF which are both extracellular. The transcript was cloned using the RACE PCR technique (see below) from murine ES cells and human GCT 27 teratocarcinoma-derived cell lines, and sequenced using standard methods. The presence of the T-LIF transcript was confirmed by PCR analysis of ES cell mRNA and RNA'ase protection on GCT 27 RNA. The transcript comprises a novel first exon, located in the first intron of the LIF gene, spliced to the known exon 2 and exon 3 sequences. The mouse nucleotide sequence (SEQ ID NO: 25) and deduced amino acid sequence (SEQ ID NO: 26) are set out in Figure 26. The human nucleotide sequence (SEQ ID NO: 31) and deduced amino acid sequence (SEQ ID NO: 32) are set out in Figure 27.

When expressed in a COS cell expression system, the murine T-LIF transcript produces a 17 kD protein that is unglycosylated (D-LIF is glycosylated in the Golgi during the secretion process) (Figure 28). Translation of T-LIF initiates at the first in-frame initiation codon (ATG) in exon 2 to produce a protein of 158 amino acids. The protein is 45 amino acids shorter than the unprocessed D-LIF protein and 22 amino acids shorter than the mature D-LIF product generated by cleavage of the signal sequence. Because the T-LIF protein does not contain a signal sequence, it does not leave the cell and is unglycosylated. The T form of LIF is efficacious in preventing the differentiation of ES cells in culture.

METHODS

RACE cDNA CLONING

Cytoplasmic RNA (10 μ g) from CP1 murine ES cells (Bradley et al., Nature 309: 255-56 (1984) was reverse transcribed from the oligonucleotide 5'ACACGGTACTTGTGCA-3' (SEQ ID NO: 27), which hybridizes to residues 500-484 of the murine LIF cDNA. The RNA was added to 20 pmol of primer and 2 μ l of 10x annealing buffer (500mM Tris-HCl (pH 8.0), 60mM MgCl₂, 400mM KCl) in a total volume of 16 μ l, heated to 85°C for 5 min, and cooled slowly to room temperature. The elongation reaction was carried out as described by Frohman et al. (Proc. Natl. Acad. Sci. USA 85: 8998-9002 (1988)). Excess oligonucleotide was removed by gel filtration through a 2ml Sephacryl S-400 (Pharmacia) column equilibrated with 0.05 x TE (TE = 10mM Tris-HCl pH 7.6, 1.0mM EDTA). Fractions of 50 μ l corresponding to the cDNA radioactive peak were pooled, concentrated by vacuum centrifugation, and resuspended in 23 μ l of H₂O. To tail the 3'-end of the cDNA with dG residues, 3 μ l of 10mM dGTP and 6 μ l of 5 x tailing buffer (Bethesda Research Laboratories) were added and the

mixture was incubated at 37°C for 60 min. and then at 70°C for 15 min. After ethanol precipitation, the cDNA template was resuspended in 500µl H₂O.

5 PCR was carried out using a mouse LIF specific
oligonucleotide, 5'-TTCTGGTCCCGGGTGATATTGGTCA-3'
(residues 389-365) (SEQ ID NO: 28), and an anchor
oligonucleotide, 5'-CCATGGCCTCGAGGGCCCCCCCCCCCCCCC-3' (SEQ
ID NO: 29). PCR was carried out in a final volume of
50µl containing 7µl of the cDNA template and 34pmol of
10 each oligonucleotide. Reaction conditions were as
recommended by Perkin-Elmer Cetus, with a final
concentration of 1.5mM MgCl₂. DNA was denatured prior to
the addition of Taq polymerase (Perkin-Elmer Cetus) by
heating the reaction mixture to 94°C for 5 min. Each PCR
15 cycle (35 in total) consisted of denaturation for 2 min
at 94°C, annealing for 2 min at 55°C, and elongation for
3 min at 72°C. After the final elongation (30 min at
72°C), samples were ethanol precipitated, digested with
SmaI and XhoI and analyzed by agarose gel
20 electrophoresis. DNA was purified from agarose gels
using Geneclean and cloned into SalI- and SmaI- digested
TST7 19U (Stratagene). Suitable recombinant plasmids
were purified by the rapid boiling method.

Double-stranded sequencing was performed with
25 Sequenase version 2.0 (USB) according to the
manufacturers recommendations.

BIOLOGICAL ASSAY FOR LIF ACTIVITY

An undifferentiated, murine ES cell culture (MBL5;
Pease et al., Dev. Biol. 141: 344-52 (1990), between
30 passages 15 and 30) is trypsinized and made into a single
cell suspension. The cells are pelleted by
centrifugation and resuspended in complete ES Cell Medium
without LIF (DMEM (without Hepes), 10% FCS, 1mM βME, 1mM
glutamine). The cells are then seeded into 24-well

microtitre plates at 5×10^2 cells/16 mm well containing 1 ml of ES Cell Medium without LIF.

5 The complete T-LIF open reading frame was reconstructed from the PCR product and inserted into the COS cell expression vector pXMT2 as described by Rathjen et al., Cell 62: 1105-14 (1990). The plasmid used for transfection of COS cells is shown in Figure 29. The COS cells were transfected by electroporation. Supernatants from COS cells expressing T-LIF were added to the above
10 ES cells in various dilutions (1/5, 1/10, 1/50, 1/100, 1/50, 1/1000) and incubated for 4 days in an incubator with 10% CO₂. Controls used supernatants from COS cells expressing D-LIF (pDR1, Rathjen et al., Cell 62: 1105-14 (1990)).

15 LIF activity is assessed as present if cells morphologically resemble ES-cells after 4 days and are distinct from the controls incubated without any form of LIF. The ES-cells are also stained for alkaline phosphatase as undifferentiated ES-cells are positive for
20 this marker.

Even though T-LIF is produced intracellularly, sufficient numbers of cells lyse to give significant amounts of LIF activity in the culture supernatants. If the COS cells expressing T-LIF are lysed, more LIF
25 activity is released.

PCR DETECTION OF T-LIF TRANSCRIPT

PCR was carried out on ES cell cDNA (prepared as described above except that the cDNA was not tailed with dG). PCR conditions were as described above except that
30 2mM MgCl₂ was used in the reactions. The oligonucleotides 5'-CACCTTTCGCTTTCCT-3' (SEQ. ID NO. 30) and 5'-TTCTGGTCCCGGGTGATATTGGTCA-3' (SEQ. ID. NO 28) were used at 80 picograms/reaction. Products of the PCR reaction were ethanol precipitated as described above,

separated electrophoretically on a 2% agarose gel and transferred to a nylon membrane for detection using Southern hybridization (Figure 30). The probe was the full length D-LIF transcript isolated from pDR1 (Rathjen et al., Cell 62: 1105-14 (1990). The control experiment is designed to detect all LIF transcripts using internal primers 5'-TTCTGGTCCCGGGTGATATTGGTCA-3' (SEQ. ID. NO 28) and 5'-CTGTTGGTTCTGCACTGGA-3' (SEQ. ID. NO. 33).

The foregoing detailed description has been provided for a better understanding of the invention only and no unnecessary limitation should be understood therefrom as some modifications will be apparent to those skilled in the art without deviating from the spirit and scope of the appended claims.

What is claimed is:

1 1. A purified and isolated nucleic acid molecule
2 comprising a nucleic acid sequence selected from the
3 group consisting of (1) the porcine nucleic acid sequence
4 depicted in Figure 4 (SEQ ID NO: 7), (2) a sequence
5 corresponding to the sequence of (1) within the scope of
6 the degeneracy of the genetic code, (3) a sequence that
7 encodes a porcine polypeptide having α -1,3
8 galactosyltransferase activity and that hybridizes under
9 standard high stringency conditions with a sequence
10 complementary to the sequence of (1) or (2), and (4) a
11 sequence complementary to the sequence of (1), (2) or
12 (3).

1 2. A host cell that is transformed with the
2 nucleic acid molecule of claim 1.

1 3. A porcine α -1,3 galactosyltransferase encoded
2 by the nucleic acid molecule of claim 2.

1 4. A DNA construct useful for inactivating the
2 porcine α -1,3 galactosyltransferase gene by insertion of
3 a desired DNA sequence into an insertion site of said
4 gene, comprising said desired DNA sequence flanked by
5 first and second homology sequences, said first and
6 second homology sequences being, respectively,
7 sufficiently homologous to first and second genomic
8 sequences flanking said insertion site to allow for
9 homologous recombination of said DNA construct with said
10 porcine α -1,3 galactosyltransferase gene when said DNA
11 construct is introduced into a porcine cell having said
12 α -1,3 galactosyltransferase gene.

1 5. The DNA construct of claim 4, wherein said
2 insertion site is within exon 4, exon 7, exon 8 or exon 9
3 of the porcine α -1,3 galactosyltransferase gene.

1 6. The DNA construct of claim 4, wherein said
2 desired DNA sequence is selected from the group
3 consisting of the neo^R gene, the hyg^R gene and the
4 thymidine kinase gene.

1 7. The DNA construct of claim 6, wherein said
2 desired DNA sequence is bordered at the 5' and 3' ends by
3 FRT DNA elements, and wherein stop codons for each of the
4 three reading frames have been inserted 3' to the desired
5 DNA sequence.

1 8. A DNA construct useful for inactivating the
2 murine α -1,3 galactosyltransferase gene by insertion of a
3 desired DNA sequence into an insertion site of said gene,
4 comprising said desired DNA sequence flanked by first and
5 second homology sequences, said first and second homology
6 sequences being, respectively, sufficiently homologous to
7 first and second genomic sequences flanking said
8 insertion site to allow for homologous recombination of
9 said DNA construct with said murine α -1,3
10 galactosyltransferase gene when said DNA construct is
11 introduced into a murine cell having said α -1,3
12 galactosyltransferase gene.

1 9. The DNA construct of claim 8, wherein said
2 insertion site is within exon 4, exon 7, exon 8 or exon 9
3 of the murine α -1,3 galactosyltransferase gene.

1 10. The DNA construct of claim 8, wherein said
2 desired DNA sequence is selected from the group
3 consisting of the neo^R gene, the hyg^R gene and the
4 thymidine kinase gene.

1 11. The DNA construct of claim 10, wherein said
2 desired DNA sequence is bordered at the 5' and 3' ends by
3 FRT DNA elements, and wherein stop codons for each of the
4 three reading frames have been inserted 3' to the desired
5 DNA sequence.

1 12. A method for generating a mammalian totipotent
2 cell having at least one inactivated α -1,3
3 galactosyltransferase allele, said totipotent cell
4 derived from a mammalian species having a functional α -
5 1,3 galactosyltransferase gene, comprising:

6 (a) providing a plurality of cells characterized as
7 totipotent cells of said mammalian species;

8 (b) introducing into said totipotent cells a nucleic
9 acid construct effective for inactivating said α -1,3
10 galactosyltransferase gene by insertion of a desired DNA
11 sequence into an insertion site of said gene through
12 homologous recombination; and

13 (c) identifying a totipotent cell having at least
14 one inactivated α -1,3 galactosyltransferase allele.

1 13. The method of claim 12 in which said totipotent
2 cell is a murine ES cell.

1 14. The method of claim 12 in which said totipotent
2 cell is a murine egg.

1 15. The method of claim 12 in which said totipotent
2 cell is a porcine ES cell.

1 16. The method of claim 12 in which said totipotent
2 cell is a porcine PGC.

1 17. The method of claim 12 in which said totipotent
2 cell is a porcine egg.

1 18. A method for generating a mammal lacking a
2 functional α -1,3 galactosyltransferase gene, said mammal
3 belonging to a species having a functional α -1,3
4 galactosyltransferase gene, comprising:

5 (a) providing a mammalian totipotent cell having at
6 least one inactivated α -1,3 galactosyltransferase allele,
7 said totipotent cell derived from a mammalian species
8 having a functional α -1,3 galactosyltransferase gene;

9 (b) manipulating said totipotent cell such that
10 mitotic descendants of said cell constitute all or part
11 of a developing embryo;

12 (c) recovering a neonate derived from said embryo;
13 and

14 (d) raising and breeding said neonate to obtain a
15 mammal homozygous for said inactivated α -1,3
16 galactosyltransferase allele.

1 19. The method of claim 18, wherein said totipotent
2 cell is a murine ES cell and said manipulating comprises
3 injecting said ES cell into the blastocyst cavity of a
4 murine blastocyst and implanting said injected blastocyst
5 into a murine recipient female.

1 20. The method of claim 18, wherein said totipotent
2 cell is a murine egg, and said manipulating comprises
3 implanting said egg into a murine recipient female.

1 21. The method of claim 18, wherein said totipotent
2 cell is a porcine ES cell and said manipulating comprises
3 injecting said ES cell into the blastocyst cavity of a
4 porcine blastocyst and implanting said injected
5 blastocyst into a porcine recipient female.

1 22. The method of claim 18, wherein said totipotent
2 cell is a porcine ES cell and said manipulating comprises
3 injecting said ES cell into a porcine morula.

1 23. The method of claim 18, wherein said totipotent
2 cell is a porcine ES cell and said manipulating comprises
3 co-culture of said ES cell with a zona pellucida-
4 disrupted porcine morula.

1 24. The method of claim 18, wherein said totipotent
2 cell is a porcine ES cell and said manipulating comprises
3 fusing said ES cell with an enucleated porcine zygote.

1 25. The method of claim 18, wherein said totipotent
2 cell is a porcine egg, and said manipulating comprises
3 implanting said egg into a porcine recipient female.

1 26. A mammal lacking a functional α -1,3
2 galactosyltransferase gene, said mammal belonging to a
3 species having a functional α -1,3 galactosyltransferase
4 gene, said mammal produced by the method of claim 18.

1 27. The mammal of claim 26, wherein said mammal is
2 a mouse.

1 28. The mammal of claim 26, wherein said mammal is
2 a pig.

1 29. A non-naturally occurring mammal lacking a
2 functional α -1,3 galactosyltransferase gene, said mammal
3 belonging to a species having a functional α -1,3
4 galactosyltransferase gene.

1 30. The mammal of claim 29, wherein said mammal is
2 a mouse.

1 31. The mammal of claim 29, wherein said mammal is
2 a pig.

1 32. A purified and isolated nucleic acid molecule
2 comprising a nucleic acid sequence selected from the
3 group consisting of (1) the nucleic acid sequence
4 depicted in Figure 26 (SEQ ID NO: 25), (2) a sequence
5 corresponding to the sequence of (1) within the scope of
6 the degeneracy of the genetic code, (3) a sequence that
7 encodes murine T-LIF and that hybridizes under standard
8 high stringency conditions with a sequence complementary
9 to the sequence of (1) or (2), and (4) a sequence
10 complementary to the sequence of (1), (2) or (3).

1 33. A host cell that is transformed with the
2 nucleic acid molecule of claim 32.

1 34. A murine T-LIF polypeptide encoded by the
2 nucleic acid molecule of claim 32.

1 35. A purified and isolated nucleic acid molecule
2 comprising a nucleic acid sequence selected from the
3 group consisting of (1) the nucleic acid sequence
4 depicted in Figure 27 (SEQ ID NO: 31), (2) a sequence
5 corresponding to the sequence of (1) within the scope of
6 the degeneracy of the genetic code, (3) a sequence that
7 encodes human T-LIF and that hybridizes under standard
8 high stringency conditions with a sequence complementary
9 to the sequence of (1) or (2), and (4) a sequence
10 complementary to the sequence of (1), (2) or (3).

1 36. A host cell that is transformed with the
2 nucleic acid molecule of claim 35.

1 37. A human T-LIF polypeptide encoded by the
2 nucleic acid molecule of claim 35.

1 38. A method for eliminating or reducing hyperacute
2 rejection of non-primate mammalian cells, tissues and
3 organs by human serum, comprising adding, to said human
4 serum, a physiologically acceptable amount of galactose
5 or a saccharide in which the terminal carbohydrate is an
6 α galactose linked at position 1, prior to exposure of
7 said human serum to said non-primate cells, wherein said
8 amount of galactose or saccharide is sufficient to reduce
9 or eliminate said hyperacute rejection.

1 39. The method of claim 38, wherein said saccharide
2 is selected from the group consisting of melibiose,
3 galactose α 1-3 galactose and stachyose.

1 40. A method for eliminating or reducing hyperacute
2 rejection of non-primate mammalian cells, tissues and
3 organs by human serum, comprising substantially depleting
4 said serum of immunoglobulin.

1 41. A method for eliminating or reducing hyperacute
2 rejection of non-primate mammalian cells, tissues and
3 organs by human serum, comprising substantially depleting
4 said serum of IgM antibodies.

1 42. A method for eliminating or reducing hyperacute
2 rejection of non-primate mammalian cells by human serum,
3 comprising substantially depleting said serum of anti-GAL
4 IgM and IgG antibodies.

1 43. A method for eliminating or reducing hyperacute
2 rejection of non-primate mammalian cells by human serum,
3 comprising substantially depleting said serum of anti-GAL
4 IgM antibodies.

1 44. Affinity-treated human serum substantially free
2 of anti-GAL antibodies.

1 45. Affinity-treated human serum substantially free
2 of anti-GAL IgM antibodies.

ABSTRACT OF THE DISCLOSURE

Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme α -1,3 galactosyltransferase. The porcine gene encoding α -1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating ("knocking out") the α -1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the α -1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture.

Fig. 1




FIGURE 2







FIGURE 3





Baseline




10mM Melibiose



5 % plasma



13% plasma



1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

—

Fig 4 (cont) 4-2

					Exon 3 Exon 4		
PGTCD	601	-----	-----	-----	-----CAGAAAA	650	
BOVGSTA	601	-----	-----	-----	-----CAGAAAA	650	
MUSGLYTNS	601	CAAGTCAGAA	ACAACTCTTC	CATCCTCAAC	ATCTCCATCA	CAGCAGAAAA	650
		START					
PGTCD	651	TAATCAATCT	CAAAGCAAGA	GTGCTTCTGT	CAATGCTGCT	TGTCTCAACT	700
BOVGSTA	651	TAATCAATCT	CAAAGCAAAA	GTGATTCTGT	CAATGCTGCT	TGTCTCAACT	700
MUSGLYTNS	651	TAATCAATCT	CAAAGCAAAA	CTAATCCTGT	TCATCCTCAT	TGTCTCAACC	700
				Exon 4 Exon 5			
PGTCD	701	GTAATGCTTG	TGTTTTCCGA	ATACATCAAC	AGCCCAAGAG	GTTCTTTGTT	750
BOVGSTA	701	GTCATTGTTG	TGTTTTCCGA	ATATATCCAC	AGCCCAAGAG	GCTCTTTGTT	750
MUSGLYTNS	701	GTGCTTGTGG	TGTTTTCCGA	ATATGTCAAC	AGCCCAAGAG	GCTCTTTGTT	750
				Exon 5 Exon 6			
PGTCD	751	CTGGATATAC	CAGTCAAAAA	ACCCAGAACT	TGCGACCACT	GCTCAGAGCC	800
BOVGSTA	751	CTGGATAAAC	CCATCAAGAA	ACCCAGAACT	TGCTGGCAGC	AGCATTCAGA	800
MUSGLYTNS	751	CTGGATATAT	CACACAAAAA	TTCCAGAGCT	TGCTCAGAAC	AGATGCGAGA	800
				Exon 6 Exon 7			
PGTCD	801	GCTGCTGG--	-TTTCCGAGC	TGCTTTAAAC	ATGCGACTCA	CAGTTACCAC	850
BOVGSTA	801	AGGCTGCTG	GCTTCCGACA	TGCTTTAAAC	ATG-----	--GTTACCAT	850
MUSGLYTNS	801	AGGACTGGTG	GTTCCTAAGC	TGCTTTAAAC	ATGCGACCCA	CAGTTATCAA	850
PGTCD	851	CAACACAGAC	ACCTATACG	CAACGAAAG	GAACAAACAA	AACACACAA	900
BOVGSTA	851	CAACACATC	CACACATAA	CGAAGAAAG	GAACAAACAA	ACCAAGACCA	900
MUSGLYTNS	851	CAACACAGC	TACAGGAGC	GACAGAAAG	GCTAGAAATC	CACATCCCAT	900
				Exon 7 Exon 8			
PGTCD	901	CAGACGACG	CTTCCGCTAG	TGCACTGCTT	TAATCCTGAG	AAACGCCCCG	950
BOVGSTA	901	--AAGCAAG	CTTAAGCTAT	CGCACTGCTT	CAACCCATTT	AAACGCCCCG	950
MUSGLYTNS	901	---TGACAG	CCTCAGCTAT	CGCACTGCTT	CAATCCAAAG	AAACGCCCCG	950
PGTCD	951	AGGCTGTGAC	CATAACCAGA	TGCAAGGCTC	CAGTGGTATG	GGAAGGCACT	1000
BOVGSTA	951	AGGTTGTGAC	CATGACCAAG	TGCAAGGCTC	CAGTGGTATG	GGAAGGCACT	1000
MUSGLYTNS	951	ATGTTTTGAC	ACTGACCCCG	TGCAAGGCTC	CGATTGTGTC	GGAAGGCACT	1000
PGTCD	1001	TACAACAGAG	CCGTCTTACA	TAATTATAAT	GCCAAACACA	AAATTACCCT	1050
BOVGSTA	1001	TACAACAGAG	CCGTCTTACA	CAATTATTAT	GCCAAACACA	AAATTACCCT	1050
MUSGLYTNS	1001	TATGACACAG	CTCTGCTGGA	AACTACTTAC	GCCACACAGA	AATCTACTGT	1050
				Exon 8 Exon 9			
PGTCD	1051	CGGCTTGACC	GTTTTTGCTG	TGCGAAGATA	CATTGAGCAT	TACTTGGAGG	1100
BOVGSTA	1051	CGGCTTGACC	GTTTTTGCTG	TGCGAAGATA	CATTGAGCAT	TACTTGGAGG	1100
MUSGLYTNS	1051	CGGCTTGACA	GTCTTTGCTG	TGCGAAGATA	CATTGAGCAT	TACTTAGAAG	1100
PGTCD	1101	AGTTCTTAAT	ATCTCCAAAT	ACATACTTCA	TGCTTGGCCA	CAAAGTCATC	1150
BOVGSTA	1101	AGTTCTTAAC	GTCTGCTAAT	AAGCACTTCA	TGCTGGGCCA	CCCACTCATC	1150
MUSGLYTNS	1101	ACTTTCTGGA	GTCTGCTGAC	ATCTACTTCA	TGCTTGGCCA	TGCGGTGATA	1150
PGTCD	1151	TTTACATCA	TCCTGCATCA	TATCTCCAGC	ATCCCTTTCA	TAGAGCTGGC	1200
BOVGSTA	1151	TTTATATCA	TCCTAGATCA	TGCTCCAGC	ATCCCTTTCA	TAGAGTGGC	1200
MUSGLYTNS	1151	TTTACCTCA	TCATAGATCA	CACCTCCCGG	ATGCTGTGTC	TGCACCTGAA	1200
PGTCD	1201	TCCTCTGGC	TCCTTTAAAG	TGTTTCAGAT	CAAGTCCGAC	AAGAGCTGGC	1250
BOVGSTA	1201	TCCTCTGGC	TCCTTCMAAG	TGTTTAAAT	CAAGCTGAC	AAGAGCTGGC	1250
MUSGLYTNS	1201	CCCTCTACAT	TCCTTACAAAC	TCTTTGACAT	CAGCTCTGAC	AAGAGCTGGC	1250

Fig 7(cont) 4-3

PGTCD	1251	AACACATCAG	CATCATCCCC	ATGAAGACCA	TCCGGGACCA	CATCCTGGCC	1300
BOVGSTA	1251	AGGACATCAG	CATCATCCCC	ATGAAGACTA	TCCGGGACCA	CATTCTGGCC	1300
MUSGLYTNS	1251	AGGATATCAG	CATCATCCCC	ATGAAGACCA	TTGGGGACCA	CATCCTGGCC	1300

PGTCD	1301	CACATCCAGC	ACCAGCTGGA	CTTCTCTTTC	TCCATCCAGC	TGCATCAGGT	1350
BOVGSTA	1301	CACATCCAGC	ATCAGCTTGA	CTTCTCTTTC	TCCATCCAGC	TGCAGCAGGT	1350
MUSGLYTNS	1301	CACATCCAGC	ACCAGCTGGA	CTTCTCTTTC	TCCATCCAGC	TGCATCAGGT	1350

PGTCD	1351	CTTCCAAAAC	AACTTTGGGG	TCCAGACCTT	GGGGCAGTCC	CTCCCTCAGC	1400
BOVGSTA	1351	CTTCCAAAC	AACTTTGGGG	TCCAGACCTT	GGGGCAGTCC	CTCCCTCAGC	1400
MUSGLYTNS	1351	CTTTCAAAC	AACTTTGGGG	TCCAGACCTT	GGGGCAGTCC	CTCCCTCAGC	1400

PGTCD	1401	TACAGGCTTG	GTGGTACAA	GCAGATCCCT	ACGAGTTTAC	CTACGAGAGC	1450
BOVGSTA	1401	TACAGGCTTG	GTGGTACAA	GCAGATCCCT	ACGAGTTTAC	CTACGAGAGC	1450
MUSGLYTNS	1401	TACAGGCTTG	GTGGTACAA	GCAGATCCCT	ACGAGTTTAC	CTACGAGAGC	1450

PGTCD	1451	CGGAACTCT	CGGAGCCCTA	CATTCCCTTT	CGGAGCCCTG	ATTTTATTA	1500
BOVGSTA	1451	CGGAACTCT	CTGAGCCCTA	CATTCCCTTT	CGGAGCCCTG	ATTTTATTA	1500
MUSGLYTNS	1451	CGGAACTCT	CGGAGCCCTA	CATTCCCTTT	CGGAGCCCTG	ATTTTATTA	1500

PGTCD	1501	CCAGCCAGCC	ATTTTGGGG	GAACAGCCAC	TCAAGTTCTA	AACATCACTC	1550
BOVGSTA	1501	CCAGCCAGCC	ATTTTGGGG	GAACAGCCAC	TCAAGTTCTT	AACATCACTC	1550
MUSGLYTNS	1501	CCAGCCAGCC	ATTTTGGGG	GAACAGCCAC	TCAAGTTCTC	AACATCACTC	1550

PGTCD	1551	AGGAGTCTTT	CAAGGGAATC	CTCCAGGACA	AGGAAATGA	CATAGAGGCC	1600
BOVGSTA	1551	AGGAGTCTTT	CAAGGGAATC	CTCCAGGACA	AGGAAATGA	CATAGAGGCC	1600
MUSGLYTNS	1551	AGGAGTCTTT	CAAGGGAATC	CTCCAGGACA	AGGAAATGA	CATAGAGGCC	1600

PGTCD	1601	GACTGCCATC	ATCAAAGCCA	TCTAAACAAG	TATTTAATTC	TCAACAAACC	1650
BOVGSTA	1601	GACTGCCATC	ATCAAAGCCA	TCTAAACAAG	TATTTAATTC	TCAACAAACC	1650
MUSGLYTNS	1601	GACTGCCATC	ATCAAAGCCA	TCTAAACAAG	TATTTAATTC	TCAACAAACC	1650

PGTCD	1651	CACATAAATC	TTATCCCCAG	AATACTCTTG	GCATTATCAT	ATAGGCAATG	1700
BOVGSTA	1651	CACATAAATC	TTATCCCCAG	AATACTCTTG	GCATTATCAT	ATAGGCAATG	1700
MUSGLYTNS	1651	CACATAAATC	TTATCCCCAG	AATACTCTTG	GCATTATCAT	ATAGGCAATG	1700

PGTCD	1701	CTCTCCATAT	TAGCAATGTC	AAGATAGCTT	GGCAGAAAAA	AGACTATAAT	1750
BOVGSTA	1701	CTCTCCATAT	TAGCAATGTC	AAGATAGCTT	GGCAGAAAAA	AGACTATAAT	1750
MUSGLYTNS	1701	CTCTCCATAT	TAGCAATGTC	AAGATAGCTT	GGCAGAAAAA	AGACTATAAT	1750

PGTCD	1751	TTGCTTAGAA	ATAACATCTC	ACTTTAAATT	GTGCCAGCAG	TTTTCTGAAT	1800
BOVGSTA	1751	TTGCTTAGAA	ATAACATCTC	ACTT-----T	GTGCCAGTAC	TTTTCTGAAT	1800
MUSGLYTNS	1751	TTGCTTAGAA	ATAACATCTC	ACTTTAAATT	GTG-----	---ATGGAAAC	1800

PGTCD	1801	TTCAAACAGT	ATTACTCTCG	CTACTTCCTC	ACAGAACTAG	---CACTTAA	1850
BOVGSTA	1801	TTCAAACAGT	ATTACTCTCG	CTACTTCCTC	ACAGAACTAG	---CACTTAA	1850
MUSGLYTNS	1801	TTCAAACAGT	ATTACTCTCG	CTACTTCCTC	ACAGAACTAG	CAACACTTGA	1850

Fig. 4(cont) 4 - 4

PGTCD	1851	TTTTAACTTT	TAAAAAATA	CTAACAAA-	----TACCAA	CACAGTAA-G	1900
BOVGSTA	1851	TTTTAACTTA	AAAAAATA	CTAACAAA-	----GACCAA	CACAGCAA-A	1900
MUSCLYTNS	1851	TTTCAACTTT	TAAAGAA-A	CAATCAAAAC	CAAAACCCAC	TACCATGCCA	1900
PGTCD	1901	TACATATTAT	TCTTCCTTTC	AACTTTCAGC	CTTCTCAAAAT	GGCAGAAATCA	1950
BOVGSTA	1901	TACATATTAT	TTCTCCTTCT	AACTTTCAGC	CTTCTAAATAC	GGCAGAAATCA	1950
MUSCLYTNS	1901	AACACATCAT	TTCTCCT-CA	CACCTTCAGC	CT-CTAAATAT	CTCAGAAACA	1950
PGTCD	1951	CTCTGTGG--	--TAATCAGA	TGTAAATTCC	CAGTCATTTC	2000
BOVGSTA	1951	ACCTGTGG--	--TAATCAGA	TGTAAATTCC	CAGTCATTTC	TTACCTATTTC	2000
MUSCLYTNS	1951	GTCTATGGCA	AGTAATCAGG	TATAAATTCT	CAATCATTTTC	TTATATATTTC	2000
PGTCD	2001	2050
BOVGSTA	2001	TTGCTTCTCT	GGCCGGGCA	TGGATACACC	ATCATTTGAA	CC.....	2050
MUSCLYTNS	2001	TGCTCTTCTG	GAAGCTTCA	TTCTAGAAAT	CAAAATTAAAT	TTGACAAAGC	2050
PGTCD	2051	2100
BOVGSTA	2051	2100
MUSCLYTNS	2051	AAAACCAT	GGCCGAACT	TCTTCCAGT	CTCTCATACA	ATTCAACACT	2100
PGTCD	2101	2150
BOVGSTA	2101	2150
MUSCLYTNS	2101	GGCCAGCTTC	TGACAGAGC	ATTAGGGAC	ACTCTCCTT	GTCTCAGACT	2150
PGTCD	2151	2200
BOVGSTA	2151	2200
MUSCLYTNS	2151	TGGACGGCTC	CATCCCTTTC	GCTTCATTAT	CTTCTCTCTC	ATCAGCATTC	2200
PGTCD	2201	2250
BOVGSTA	2201	2250
MUSCLYTNS	2201	TAAAGCACC	CACAGAGCT	TTCCAGCCAC	ACACCTTCAA	TAAAGATCCC	2250
PGTCD	2251	2300
BOVGSTA	2251	2300
MUSCLYTNS	2251	AATCTCAGCA	TCAGTCTCTA	AAAGCTGATG	GCTCCAGCAG	GGCTGGCAGT	2300
PGTCD	2301	2350
BOVGSTA	2301	2350
MUSCLYTNS	2301	CCAGGGCCCA	CTAGGCTATT	GTTCCTCTCC	TCCGCAATAA	CCAGGCAGAC	2350
PGTCD	2351	2400
BOVGSTA	2351	2400
MUSCLYTNS	2351	AGTCCCAATA	CCTACTTTCC	TCCACATCT	TCACAGTCCA	GGAAATATCA	2400
PGTCD	2401	2450
BOVGSTA	2401	2450
MUSCLYTNS	2401	AGCCTCAGCA	CTTACAGGCA	CATAGGACTT	GGGTTTCTCT	ATTCAACTCA	2450
PGTCD	2451	2500
BOVGSTA	2451	2500
MUSCLYTNS	2451	GTTACAAACA	CACAGAGCTT	TCTTCAGCAT	GACTAACAGC	ACCAATTGAA	2500

00954900-120497

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2433	2434	2435	2436	2437	2438	2439	2440	2441	2442	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

PGTCD	2501	2550	
BOVGSTA	2501	2550	
MUSGLYTNS	2501	TCCAAAGCTGT	CTTCATTTTC	TTTTCCCCAA	ATTGTATTCA	TGCTGTTAGC	2550
PGTCD	2551	2600	
BOVGSTA	2551	2600	
MUSGLYTNS	2551	TTTGTGTGTT	CAGCCCTGTC	GAGAGCCGTCT	CAGTGTATCA	GGGAGCCACA	2600
PGTCD	2601	2650	
BOVGSTA	2601	2650	
MUSGLYTNS	2601	GTACCTCAGC	CCACTCAGCA	CCAGCAGCCT	ATTATATCAG	AACACAATCT	2650
PGTCD	2651	2700	
BOVGSTA	2651	2700	
MUSGLYTNS	2651	CTCATCATCA	GGTCCCTACT	ACAACCTGCT	CTGAACCTCC	CAGTTCCCTA	2700
PGTCD	2701	2750	
BOVGSTA	2701	2750	
MUSGLYTNS	2701	CCCCATCCTC	TTCCAGTCTG	GGCCCTCTTA	TCCAGCAGCT	CAGTCAACAC	2750
PGTCD	2751	2800	
BOVGSTA	2751	2800	
MUSGLYTNS	2751	AAAACCCCTT	GTACATCAGC	CTCATTTCCC	CTGCTCTAGT	ACTATCCAAQ	2800
PGTCD	2801	2850	
BOVGSTA	2801	2850	
MUSGLYTNS	2801	TGTGACAGCC	AQCCAGCCAG	ATGTACTGCA	CAACATAGCA	ACCCAGTTTA	2850
PGTCD	2851	2900	
BOVGSTA	2851	2900	
MUSGLYTNS	2851	TGGCATTCGG	AQCCGCAGTC	ACTACAAAGC	AGCTGCTCAA	GTTCTGTTC	2900
PGTCD	2901	2950	
BOVGSTA	2901	2950	
MUSGLYTNS	2901	CCCGCTCTCA	CAQCTCCAG	CAGCCCTCTT	ATAQCTGCTT	CTCAACCTAT	2950
PGTCD	2951	3000	
BOVGSTA	2951	3000	
MUSGLYTNS	2951	GGCTCCCCAC	CCCTTTCCCA	AGTGTAAAT	GACCTTTCA	CACTGTCCC	3000
PGTCD	3001	3050	
BOVGSTA	3001	3050	
MUSGLYTNS	3001	CTAAGACCTT	TAAAAACAT	AGATATTTCC	ACTCTGACTG	GTAACAOTAG	3050
PGTCD	3051	3100	
BOVGSTA	3051	3100	
MUSGLYTNS	3051	CAGAAATACA	CTTATCAAAT	AQCAAGGCAA	ATAATTTCTG	GGTTGCTGTC	3100

Fig 5

PBM Line-up (aa):

			Ex4 ↓ Ex5	Ex5 ↓ Ex6	
PCT(Frame 1)	1	HNKGRVVL	MLLVSTVMV	PWEYINSPEG	SLFWIYQSKN PEVG-GSAQR 50
BCT(Frame 1)	1	HNKCKVIL	MLVVSTVIW	PWEYIHSPEG	SLFWINPSRN PEVGGSSIQK 50
MCT(Frame 1)	1	HNKCKVILL	MLIVSTVVV	PWEYVNSPDG	SPLWIIYHTXI PEVGENRWQK 50
			Ex6 ↓ Ex7	Ex7 ↓ Ex8	
PCT(Frame 1)	51	GWNFPWFNN	GTHSYHEED	AIGNEKEQK	EDNRCELPLV DWFNPEKRP 100
BCT(Frame 1)	51	GWNLPWFNN	G---YHEED	DINEEKEQK	ED-ESXLKLS DWFNPFKRP 100
MCT(Frame 1)	51	DWNFPWFNN	GTHCYQEDV	EGRREK-GRN	GDRIEELQLW DWFNPKNRP 100
			Ex8 ↓ Ex9		
PCT(Frame 1)	101	AVTITRWKAP	VWECTYNRA	VLONYNAKQK	ITVCLTVFAV GRYIEHYLEZ 150
BCT(Frame 1)	101	VVTHTRWKAP	VWECTYNRA	VLONYYAKQK	ITVCLTVFAV GRYIEHYLEZ 150
MCT(Frame 1)	101	VLTVTPWKAP	IVWECTYDTA	LLEKYYATQK	LTVCLTVFAV GRYIEHYLED 150
PCT(Frame 1)	151	FLISANTYFH	VGHXYIFYIN	VDDISRMPLI	ELG?LASFKV FEIKSEKRWQ 200
BCT(Frame 1)	151	FLTSANKIIFH	VGHXPVIFYIN	VDDVSRMPLI	ELGPLASFKV FAIKPEKRWQ 200
MCT(Frame 1)	151	FLECAKHYFH	VGHXYIFYIN	IDDTSRMPVV	HLNPLHSLQV FEIRSEKRWQ 200
PCT(Frame 1)	201	DISMHRMKT	GEHILAHIQH	EVDFLFCMDV	DQVFQNNFGV ETLOQSVACL 250
BCT(Frame 1)	201	DISMHRMKT	GEHIVAHIQH	EVDFLFCMDV	DQVFQDKFGV ETLCQSVACL 250
MCT(Frame 1)	201	DISMHRMKT	GEHILAHIQH	EVDFLFCMDV	DQVFQDNFGV ETLCQLVACL 250
PCT(Frame 1)	251	QANWYKAPD	EFTYERRKES	AAIYPFGCGD	FYYHAAIFCG TPTQVLNITQ 300
BCT(Frame 1)	251	QANWYKADPH	DFTYERRKES	AAIYPFGCGD	FYYHAAIFCG TPTQVLNITQ 300
MCT(Frame 1)	251	QANWYKASPE	KFTYERRELS	AAIYPFGCGD	FYYHAAIFCG TPTHILNLTR 300
PCT(Frame 1)	301	ECFKGILQOK	ENDIEAEWHD	ESHLNKYLIL	NKPTKILSPE YCHDYHIGMS 350
BCT(Frame 1)	301	ECFKGILKDK	KNDIEAQWHD	ESHLNKYFL	NKPTKILSPE YCHDYHIGLP 350
MCT(Frame 1)	301	ECFKGILQOK	KNDIEAQWHD	ESHLNKYFLP	NKPTKILSPE YCHDYHIGLP 350
PCT(Frame 1)	351	VDIRIVKIAN	QKKEYNLVRN	NI*..... 400
BCT(Frame 1)	351	ADIXLVQLSH	QTKEYNVVRN	NV*..... 400
MCT(Frame 1)	351	SDIXSVKVAH	QTKEYNLVRN	NV*..... 400

0054500-120457

Fig. 6.





Fig. 7




No sites for: BglII, Nde, PvuI, Xho, Kpn, SacII, EcoRV, Sma, Cla, Apa, Not

pBS+KS:

.... SacI SacII Not Xba Spe Bam Sma Pst Eco RV Hind Cla Sal Xho Apa Kpn





A	ApaI
B	BamHI
C	ClaI
E	EcoRI
G	BglII
H	HindIII
K	KpnI
N	NotI
P	PstI
S	SalI
Sa	SacI
V	EcoRV
X	XbaI
Xh	XhoI

No sites for: Nde, PvuI, Xho, Kpn, SacII, Sma, Cla, Apa, Not


Unmapped sites for: Pst, PvuII

pUBS:

.... SacI SacII Not Xba Spe Bam Sma Pst Eco RV Hind Cla Sal Xho Apa Kpn



Fig. 9



08984900.120457

Fig. 9 (cont)

No sites for: Xho, Kpn, SacII, Sma, Cla, EcoRV, Apa, Not, PvuI, Nde

pUBS:

.... SacI SacII Not Xba Spe Bam Sma Pst Eco RV Hind Cla Sal Xho Apa Kpn



A	Apal
B	BamHI
C	ClaI
E	EcoRI
G	BglII
H	HindIII
K	KpnI
N	NotI
P	PstI
S	SalI
Sa	SacI
V	EcoRV
X	XbaI
Xh	XhoI

Fig. 10





Fig. 10 (cont)




No sites for: Xho, SacII, Sma, Not






pUBS:

.... SacI SacII Not Xba Spe Bam Sma Pst Eco RV Hind Cla Sal Xho Apa Kpn




A Apal
B BamHI
C ClaI
E EcoRI
G BglI
H HindIII
K KpnI
N NotI
P PstI
S SalI
Sa SacI
V EcoRV
X XbaI
Xh XhoI








-  α1,3 galactotransferase (αGT) non-coding DNA
-  Exon 9 of αGT
-  Neo resistance gene
-  Bacterial origin of replication
-  Amp resistance gene


264021-0054880

05964900-120497




-  α1,3 galactotransferase (αGT) non-coding DNA
-  Exon 9 of αGT
-  Neo resistance gene
-  Bacterial origin of replication
-  Amp resistance gene

ig. 13



region around Cla-Bgl linker



- A Apal
- B BamHI
- E EcoRI
- G BglI
- H HindIII
- K KpnI
- N NotI
- P PstI
- S SalI
- Sa SacI
- V EcoRV
- X XbaI
- Xh XhoI

- α1,3 galactotransferase (αGT) non-coding DNA
- Exon 9 of αGT
- Neo resistance gene
- FRT recombination site
- Cla-Bgl-Cla linker
- Stop codons

Fig. 14







Fig. 15





- α 1,3 galactotransferase (α GT) non-coding
- Exon 9 of α GT
- Neo resistance gene
- FRT recombination site
- Bacterial origin of replication
- Amp resistance gene

Fig. 16

10	20	30	40	50	60
GAGGGCTCCA	GGAAATTCGAT	GATCCCCCAG	CTTGAAGTTC	CTATTCCGAA	GTTCCTATTC
70	80	90	100	110	120
TCTAGAAAGT	ATAGGAACCTT	CAAGCTGGGC	TGCAGGAATT	CGATTCCGAGC	AGTGTGGTTT
130	140	150	160	170	180
TGCAAGAGGA	AGCAAAAAGC	CTCTCCACCC	AGGCCTCGAA	TGTTTCCACC	CAATGTCCAG
190	200	210	220	230	240
CAGTGTGGTT	TTGCAAGAGG	AAGCAAAAAG	CCTCTCCACC	CAGGCCTGGA	ATGTTTCCAC
250	260	270	280	290	300
CCAATGTGCA	GCAAACCCCG	CCCAGCGTCT	TGTCATTGGC	GAATTCCGAC	ACGCAGATGC
310	320	330	340	350	360
AGTCGGGGCG	GCGCGGTCCC	AGGTCCACTT	GGCATATTAA	GGTGACCGCT	GTGGCCTCGA
370	380	390	400	410	420
ACACCGAGCG	ACCCTGCAGC	CAATATGGGA	TCCGCCATTG	AACAAGATGG	ATTGCACCCA
430	440	450	460	470	480
GGTCTCCCG	CCGCTTGGGT	GGAGAGGCTA	TTCGGCTATG	ACTGGGCACA	ACAGACAATC
490	500	510	520	530	540
GGCTGCTCTG	ATGCCGCGGT	GTTCGGGCTG	TCAGCGCAGG	GGCGCCCGGT	TCTTTTGTG
550	560	570	580	590	600
AAGACCGACC	TGTCCGGTGC	CCTGAATGAA	CTCCAAGACG	AGGCAGCGCG	GCTATCGTGG
610	620	630	640	650	660
CTGGCCACGA	CGGGCGTTCC	TTGCCGAGCT	GTGCTCGACG	TTGTCACTGA	AGCGGGAAGG
670	680	690	700	710	720
GACTGGCTGC	TATTGGGCGA	AGTCCCGGGG	CAGGATCTCC	TGTCATCTCA	CCTTGCTCCT
730	740	750	760	770	780
GCCGAGAAAG	TATCCATCAT	GGCTGATGCA	ATGCCGGCGG	TGCATACGCT	TGATCCGGCT
790	800	810	820	830	840
ACCTGCCCCAT	TCGACCACCA	AGCGAAACAT	CGCATCGAGC	GAGCACGTAC	TCCGATGGAA
850	860	870	880	890	900
GCCGGTCTTG	TCGATCAGGA	TGATCTGGAC	GAAGAGCATC	AGGGGCTCGC	GCCAGCCGAA
910	920	930	940	950	960
CTGTTCCGCA	GGCTCAAGGC	GCCGATGCCC	GACGGCGAGG	ATCTCGTCTG	GACCCATGGC
970	980	990	1000	1010	1020
GATGCCTGCT	TGCCGAATAT	CATGGTGGAA	AATGGCCGCT	TTTCTGGATT	CATCGACTGT
1030	1040	1050	1060	1070	1080
GGCCGGCTGG	GTGTGGCGGA	CCGCTATCAG	GACATAGCGT	TGGCTACCCG	TGATATTGCT
1090	1100	1110	1120	1130	1140
GAAGAGCTTG	GCGGCGAATG	GGCTGACCGC	TTCCTCGTGC	TTTACGGTAT	CGCCGCTCCC
1150	1160	1170	1180	1190	1200
GATTCCGAGC	GCATCGCCTT	CTATCGCCTT	CTTGACGAGT	TCTTCTGAGG	GGATCGGCAA
1210	1220	1230	1240	1250	1260
TAAAAAGACA	GAATAAAGC	CACGGGTGTT	GGCGGTTTGT	TCCGATCATC	AAGCTTGAAG

264021-0054980

Fig. 16 (cont)

1270	1280	1290	1300	1310	1320
TTCCTATTCC	GAAGTTCCTA	TTCTCTAGAA	AGTATAGGAA	CTTCAAGCTT	ATCGATGAGT
1330	1340	1350	1360	1370	1380
AGATCTTGAT	CGATACCGTC

Linker sequences : 0-28

FRT : 29-104

Polyoma virus enhancer repeats : 105-249

Herpes Simplex Virus Tyrosine Kinase promoter : 250-385

Neomycin phosphotransferase coding region : 385-1188

Herpes Simplex Virus Tyrosine Kinase PolyA signal : 1189-1249

FRT : 1250-1310

Linker sequences : 1311-1340

2547021 00549530

Fig. 17






Fig. 18



06984500.120497

Fig. 17

Uninterrupted gene



Targeted gene






Fig.



1. CBAC template; wild type primers
2. 7C2 template; wild type primers
3. CBAC template; KO primers
4. 7C2 template; KO primers

Fig. 21

Uninterrupted gene



Targeted gene





Fig. 22


- spike + spike
42 43 44 — 42 43 44 —
pUC/HpaII




364bp
255bp

Fig. 23

Primer binding sites within mouse ferrochelatase cDNA




Primer binding sites within mouse α -1,3-GalT cDNA




i) Ferrochelatase, FC-F/R


M, Marker SPP-I
C, MQW control
K, KIDNEY
H, HEART
L, LIVER



ii) α -1,3-GT cDNA spike
+ 7F/9R2 primers




iii) α -1,3-GT 7F/9R2 primers



264037-0054830

Fig. 25



Mouse 19: Wild type; Mouse 20: Heterozygote Gal KO; Mouse 21: Homozygous Gal KO

Fig. 26

T- LIF SEQUENCE - Murine

CTGACACCTTTCGCTTTCCTCTTGCGTGTCCGCCTGCGACCTTCCCCACCCC
GGCCTCTTTCCTGGTTGCACCACTTCCTCTCATTCCAAAGGATTGTGCCCTTA
CTGCTGCTGGTTCTGCACTGGAACACGGGGCAGGGAGCCCTCTTCCCATCAC
CCCTGTAAATGCCACCTGTGCCATACGCCACCCATGCCACGGCAACCTC

Met Asn Gln Ile Lys Asn Gln Leu Ala Gln Leu Asn Gly
ATG AAC CAG ATC AAG AAT CAA CTG GCA CAG CTC AAT GGC

Ser Ala Asn Ala Leu Phe Ile Ser Tyr Tyr Thr Ala Gln Gly
AGC GCC AAT GCT CTC TTC ATT TCC TAT TAC ACA GCT CAA GGX

Glu Pro Phe Pro Asn Asn Val Glu Lys Leu Cys Ala Pro Asn
GAG CCG TTT CCC AAC AAC GTG GAA AAG CTA TGT GCG CCT AAC

Met Thr Asp Phe Pro Ser Phe His Gly Asn Gly Thr Glu Lys
ATG ACA GAC TTC CCA TCT TTC CAT GGC AAC GGG ACA GAG AAG

Thr Lys Leu Val Glu Leu Tyr Arg Met Val Ala Tyr Leu Ser
ACC AAG TTG GTG GAG CTG TAT CGG ATG GTC GCA TAC CTG AGC

Ala Ser Leu Thr Asn Ile Thr Arg Asp Gln Lys Val Leu Asn
GCC TCC CTG ACC AAT ATC ACC CGG GAC CAG AAG GTC CTG AAC

Pro Thr Ala Val Ser Leu Gln Val Lys Leu Asn Ala Thr Ile
CCC ACT GCC GTG AGC CTC CAG GTC AAG CTC AAT GCT ACT ATA

Asp Val Met Arg Gly Leu Leu Ser Asn Val Leu Cys Arg Leu
GAC GTC ATG AGG GGC CTC CTC AGC AAT GTG CTT TGC CGT CTG

Cys Asn Lys Tyr Arg Val Gly His Val Asp Val Pro Pro Val
TGC AAC AAG TAC CGT GTG GGC CAC GTG GAT GTG CCA CCT GTC

Pro Asp His Ser Asp Lys Glu Ala Phe Gln Arg Lys Lys Leu
CCC GAC CAC TCT GAC AAA GAA GCC TTC CAA AGG AAA AAG TTG

Gly Cys Gln Leu Leu Gly Thr Tyr Lys Gln Val Ile Ser Val
GGT TGC CAG CTT CTG GGG ACA TAC AAG CAA GTC ATA AGT GTG

Val Val Gln Ala Phe ***
GTG GTC CAG GCC TTC TAG AGAGGAGGTCTTGAATGTACCATGGACTG...

064900-10497

HUMAN T-LIF SEQUENCE

Met Asn Gln Ile .

5 10 15

20 25 30

35 40 45

[illegible]

65 70

75 80 85

90 95 100

105 110 115

120 125 130

Lys Asp Val Phe Gln Lys Lys Lys Leu Gly Cys Gln Leu Leu

27-2

135

140

GGG AAG TAT AAG CAG ATC ATC GCC GTG TTG GCC CAG GCC TTC 677

Gly Lys Tyr Lys Gln Ile Ile Ala Val Leu Ala Gln Ala Phe

145

150

155

TAG CAGGAGGTCT

722

(29)


[illegible]







← 8 kD

[illegible]

Fig. 29

(30)




-  SV40 origin of replication
-  Adenovirus promoter
-  LIF T coding region
-  Dihydrofolate reductase 3' end
-  Ampicillin resistance gene
-  Bacterial origin of replication

08964900-120497

Fig. 30

(31)



06964900-120492

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled MATERIALS AND METHODS FOR MANAGEMENT OF HYPERACUTE REJECTION IN HUMAN XENOTRANSPLANTATION, the specification of which

☐ is attached hereto.

☒ was filed on January 26, 1995 as Application Serial No. 08/378,617 and was amended on _____.

☐ was described and claimed in PCT International Application No. _____
filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Mark S. Ellinger, Reg. No. 34,812; William E. Booth, Reg. No. 28,933; Karl Bozicevic, Reg. No. 28,807; Barry E. Bretschneider, Reg. No. 28,055; Paul T. Clark, Reg. No. 30,162; Peter J. Devlin, Reg. No. 31,753; Willis M. Ertman, Reg. No. 18,658; David L. Feigenbaum, Reg. No. 30,378; Janis K. Fraser, Reg. No. 34,819; John W. Freeman, Reg. No. 29,066; Timothy A. French, Reg. No. 30,175; Alan H. Gordon, Reg. No. 26,168; Scott C. Harris, Reg. No. 32,030; Mark J. Hebert, Reg. No., 31,766; Gilbert H. Hennessey, Reg. No. 25,759; Charles Hieken, Reg. No. 18,411; Robert E. Hillman, Reg. No. 22,837; G. Roger Lee, Reg. No. 28,963; Steven E. Lipman, Reg. No. 30,011; Gregory A. Madera, Reg. No. 28,878; Ralph A. Mittelberger, Reg. No. 33,195; Ronald E. Myrick, Reg. No. 26,315; Robert C. Nabinger, Reg. No. 33,431; Frank P. Porcelli, Reg. No. 27,374; Eric L. Prah, Reg. No. 32,590; Alan D. Rosenthal, Reg. No. 27,833; Richard M. Sharkansky, Reg. No. 25,800; John M. Skenyon, Reg. No. 27,468; Michael O. Sutton, Reg. No. 26,675; Rene D. Tegtmeyer, Reg. No. 33,567; Hans R. Troesch, Reg. No. 36,950; John N. Williams, Reg. No. 18,948; Gary A. Walpert, Reg. No. 26,098; Dorothy P. Whelan, Reg. No. 33,814; Charles C. Winchester, Reg. No. 21,040; Thomas S. Borecki, Reg. No. 32,964 and Charles Mattenson, Reg. No. 30,660.

Address all telephone calls to Tom Borecki at telephone number (708)473-6695.

Address all correspondence to Tom Borecki, Baxter Healthcare Corporation, 1620 Waukegan Road, McGaw Park, IL 60085.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

COMBINED DECLARATION AND POWER OF ATTORNEY CONTINUED

Full Name of Inventor: Anthony J.F. d'Apice

Inventor's Signature: *Anthony J.F. d'Apice*

Date: 5 April 95

Residence Address: Balwyn, Victoria, Australia

Citizen of: Australia

Post Office Address: Balwyn, Victoria, Australia

Full Name of Inventor: Martin J. Pearse

Inventor's Signature: *M. Pearse*

Date: 5/4/95

Residence Address: Mordialloc Victoria 3195 AUSTRALIA

Citizen of: Australia

Post Office Address: 37 Chute Street, Mordialloc Victoria, 3195 AUSTRALIA

2025-04-05 10:00:00

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled MATERIALS AND METHODS FOR MANAGEMENT OF HYPERACUTE REJECTION IN HUMAN XENOTRANSPLANTATION, the specification of which

☐ is attached hereto.

☒ was filed on January 26, 1995 as Application Serial No. 08/378,617 and was amended on _____.

☐ was described and claimed in PCT International Application No. _____
filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Mark S. Ellinger, Reg. No. 34,812, William E. Booth, Reg. No. 28,933; Karl Bozicevic, Reg. No. 28,807; Barry E. Bretschneider, Reg. No. 28,055; Paul T. Clark, Reg. No. 30,162; Peter J. Devlin, Reg. No. 31,753; Willis M. Ertman, Reg. No. 18,658; David L. Feigenbaum, Reg. No. 30,378; Janis K. Fraser, Reg. No. 34,819; John W. Freeman, Reg. No. 29,066; Timothy A. French, Reg. No. 30,175; Alan H. Gordon, Reg. No. 26,168; Scott C. Harris, Reg. No. 32,030; Mark J. Hebert, Reg. No. 31,766; Gilbert H. Hennessey, Reg. No. 25,759; Charles Hieken, Reg. No. 18,411; Robert E. Hillman, Reg. No. 22,837; G. Roger Lee, Reg. No. 28,963; Steven E. Lipman, Reg. No. 30,011; Gregory A. Madera, Reg. No. 28,878; Ralph A. Mittelberger, Reg. No. 33,195; Ronald E. Myrick, Reg. No. 26,315; Robert C. Nabinger, Reg. No., 33,431; Frank P. Porcelli, Reg. No. 27,374; Eric L. Prahl, Reg. No. 32,590; Alan D. Rosenthal, Reg. No. 27,833; Richard M. Sharkansky, Reg. No. 25,800; John M. Skenyon, Reg. No. 27,468; Michael O. Sutton, Reg. No. 26,675; Rene D. Tegtmeier, Reg. No. 33,567; Hans R. Troesch, Reg. No. 36,950; John N. Williams, Reg. No. 18,948; Gary A. Walpert, Reg. No. 26,098; Dorothy P. Whelan, Reg. No. 33,814; Charles C. Winchester, Reg. No. 21,040; Thomas S. Borecki, Reg. No. 32,964 and Charles Mattenson, Reg. No. 30,660.


Address all telephone calls to Tom Borecki at telephone number (708)473-6695.

Address all correspondence to Tom Borecki, Baxter Healthcare Corporation, 1620 Waukegan Road, McGaw Park, IL 60085.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

COMBINED DECLARATION AND POWER OF ATTORNEY CONTINUED

Full Name of Inventor: Allan J. Robins

Inventor's Signature: 


Date: 22nd March 1995

Residence Address: Waterloo Corner, South Australia

Citizen of: Australia

Post Office Address: Lot 8, Darker Road, Waterloo Corner, South Australia 5100

Full Name of Inventor: Robert J. Crawford

Inventor's Signature: 

Date: 22 March 1995

Residence Address: West Lake Shores, South Australia

Citizen of: Australia

Post Office Address: 7 ^{a Rec} Mirani Court, West Lake Shores, South Australia 5020

Full Name of Inventor: Peter D. Rathjen

Inventor's Signature: 

Date: 24 / March / 1995

Residence Address: Blackwood, South Australia

Citizen of: Australia

Post Office Address: One Mimosa Avenue, Blackwood, South Australia 5051